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CHAPTER I 
 
INTRODUCTION 
 
Preface 
 The following introduction will attempt to provide the necessary foundational knowledge 
with which to interpret the original research described herein. It is not meant to be a 
comprehensive review of all mentioned topics. Rather, it attempts to highlight concepts that 
underlie our hypotheses and experimental design and inform interpretations of our data. 
Important details relevant to the interpretation of data, if not discussed here, are described 
within the introductions to each of the results sections.  
 The topics I have chosen to discuss here include the processing of dopamine (DA) in the 
brain and its role in the brain’s reward circuitry. I pay special attention to describing the DA 
transporter (DAT) and its regulation, as many of our studies focus on the transporter as a major 
player in regulating DA reward circuitries and the response to cocaine. From here, I present a 
high-level view of reward and addiction, focusing in more detail on psychostimulants and food 
reward as well as the overlap between food and drug reward. Finally, I discuss how hormones 
associated with regulating feeding behavior and metabolism have targets within the brain’s 
reward system and present evidence supporting the idea that these hormones may modulate 
reward for drugs of abuse.  
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Introduction to dopamine (DA) 
Neurotransmitter systems in the brain allow for chemically-mediated communication 
between neurons and encode diverse neuronal and behavioral responses. DA (3-
hydroxytyramine) is a neurotransmitter responsible for regulating movement, mood, cognition, 
and motivated behaviors. Dysfunctions in DA signaling have been implicated in Parkinson’s 
disease, major depressive disorder, schizophrenia, obesity, and addiction, among other 
disorders.1-5 DA is produced primarily in midbrain neurons whose cell bodies are located in the 
substantia nigra pars compacta (SN) and ventral tegmental area (VTA), while a smaller amount 
of DA is produced by the hypothalamus. This process involves, first, the conversion of tyrosine 
to L-DOPA by the enzyme tyrosine hydroxylase (TH) (Figure 1). This is the rate-limiting step in 
DA synthesis. L-DOPA is then converted to DA by aromatic L-amino acid decarboxylase 
(AADC). Of note, DA can be metabolized to norepinephrine (NE) by DA β-hydroxylase. 
Together, DA and NE make up a class of neurotransmitters called catecholamines.  
DA produced by the cells residing in the SN is released from terminals located in the 
forebrain dorsal striatum (DS). This pathway makes up the nigrostriatal circuit, and is primarily 
involved in the control of movement, but notably also plays roles in motivated feeding behavior 
and habit formation.6,7 DA produced by neurons originating in the VTA is released at terminals in 
both the ventral striatum, also known as the nucleus accumbens (NAc), as well as the prefrontal 
cortex (PFC). These projections are known as the mesolimbic and mesocortical systems, 
respectively. The final DA projection consists of the tuberoinfundibular system which projects 
from the hypothalamus to the pituitary and regulates prolactin secretion. A summary of the DA 
circuitry can be found in Figure 2 (tuberoinfudibular pathway not shown).   
DA is generated by enzymatic processes occurring in the cell’s distal terminals. Here, 
DA is taken up into vesicles by the vesicular monoamine transporter (VMAT), primarily the 
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VMAT2 isoform in brain (Figure 1). This transporter actively concentrates DA in the vesicle 
using energy harnessed from moving protons from the acidified vesicle to the more basic 
cytosol. Increasing evidence also suggests that the neurotransmitters glutamate8 and γ-
aminobutyric acid (GABA)9 may be co-released from midbrain DA-producing neurons. The 
functional implications of this finding are still being investigated, but this suggests that 
neurotransmission via DA neurons may possess more complex signaling modalities than 
previously believed.  
Following the accumulation of DA into vesicles, release of DA may occur with 
appropriate neuronal excitation. Neuronal depolarization following an action potential drives the 
activation of voltage-gated calcium channels in neuronal terminals. These channels allow for 
calcium ion influx into the terminals. Calcium ions, in turn, trigger the release of vesicles 
containing DA into the extracellular space.  
DA release is known to occur by either tonic or phasic stimulation. Under tonic 
stimulation, DA is continuously released at low levels. Tonic DA release sets the background 
level of DA in the brain, which is believed to be an important contributor to a number of traits 
and disorders, including reward sensitivity, impulsivity, schizophrenia, and depression.10-12 Tonic 
DA release is driven primarily by internal pacemaker currents.13 On the other hand, highly 
relevant external stimuli may drive trains of action potentials via stimulation by presynaptic 
afferents coming from cortical and subcortical areas.14-16 This results in phasic firing patterns 
which acutely elevate levels of synaptic DA. Phasic DA levels are responsible for immediate 
behavioral reactions to salient environmental stimuli.  
 
 
 
  4 
 
 
 
Figure 1. The DA synthesis and storage pathway. The rate-limiting step in DA synthesis is the 
conversion of tyrosine to L-DOPA using the enzyme TH. L-DOPA is subsequently converted to 
DA by the enzyme AADC. DA is packaged into vesicles by VMAT2. Adapted from 17. 
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Figure 2. Sagittal depiction of nigrostriatal, mesocortical, and mesolimbic pathways in the adult 
mouse brain. Projections from the SN (pars compacta) to the DS make up the nigrostriatal 
pathway (green). The mesolimbic pathway and mesocortical pathway (blue) consist of DAergic 
projections from the VTA to the NAc and medial frontal cortex, respectively. Tuberoinfundibular 
pathway not shown. Adapted from 18. 
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Introduction to DA receptors 
 DA signals through two classes of g protein-coupled receptors (GPCRs): D1-like DA 
receptors and D2-like DA receptors. D1-like receptors include the D1 and the D5 receptors, with 
D1 being the most abundant in the central nervous system (CNS). D1-like receptors are 
primarily Gs-coupled GPCRs, meaning that they activate stimulatory g proteins that allow for the 
upregulation of cyclic adenosine monophosphate (cAMP) signaling in the cell. D2-like receptors, 
on the other hand, include receptors D2, D3, and D4, and couple to the inhibitory g protein, Gi, 
and inhibit the formation of cAMP. D2 receptors are the most abundant of the D2-like DA 
receptors and can be found on the postsynaptic membrane as well as on presynaptic terminals. 
These presynaptic autoreceptors are a shorter isoform of the D2 receptor and act to provide 
feedback regarding extracellular DA levels and regulate DA production and release.  
 Importantly, because DA signals through metabotropic g protein cascades rather than 
ligand-gated ion channels, DA neurotransmission is slow and insufficient to drive postsynaptic 
neuronal firing on its own. Rather, DA is thought of as a modulatory neurotransmitter because it 
modulates inputs from fast ionotropic GABAergic and glutamatergic inputs.  
 
The DA transporter (DAT) 
Extracellular, synaptic DA levels and DA neurotransmission are regulated not only by 
vesicular release, but also by mechanisms meant to terminate the DA signal. DA is degraded by 
two enzymes: monoamine oxidase (MAO) and catechol-o-methyltransferase (COMT). MAO is 
located intracellularly within the presynaptic neuron, while COMT is found within the synaptic 
cleft. Despite the presence of degrading enzymes, the primary means for DA clearance at the 
synapse is by active reuptake through the DA transporter (DAT; SLC6A3). DAT protein is 
functionally expressed on the cell surface in the perisynaptic space where it primarily recycles 
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DA back into the presynaptic cytosol, although the DAT possesses some affinity for NE and 5-
HT as well. This process allows the cell to repackage DA into vesicles for later release and, 
importantly, regulates the duration of extracellular DA signaling.  
Recently, DAT from Drosophila melanogaster (dDAT) was crystallized in an outward-
open conformation bound to the tricyclic antidepressant, nortriptyline, providing greater insight 
into DAT three dimensional conformations and functional domains.19 The DAT is a twelve 
transmembrane domain protein belonging to the SLC6 family of Na+/Cl--dependent transporters. 
Its N- and C-termini both extend intracellularly and are important sites for regulating DAT 
function. Helical transmembrane domains 1 and 6 form the core of the transporter; residues in 
these domains interact with DAT substrates and ions and promote movement of the helical 
domains during the transport cycle.  
DA reuptake is an active process. This is made thermodynamically favorable by the co-
transport of Na+ and Cl- ions with their concentration gradient. The rate of reuptake by the 
transporter is approximately one molecule of DA per second per transporter,20 a process which 
is limited by the time to bind DA, 2 Na+ ions, and Cl- and then transition from an outward- to an 
inward-facing conformation. On a larger scale, the efficiency with which a DA signal is 
terminated is determined by the amount of functional DAT expressed on the plasma membrane. 
Several factors have been identified as prominent regulators of DA reuptake, including the 
expression of DAT at the cell surface, enzymatic modification of the DAT, protein-protein or 
protein-lipid interactions involving the DAT, and finally, the presence of DAT substrates or 
inhibitors.21 A summary of some of the mechanisms regulating DAT surface expression can be 
found in Figure 3 and these mechanisms are described in greater detail below.   
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DA uptake is regulated in part by DAT cell surface expression 
Of the possible mechanisms for DAT regulation, its surface expression and trafficking is 
of particular interest. The DAT traffics rapidly between the cell surface and intracellular recycling 
vesicles, allowing for the tight regulation of extracellular DA levels.22 This process is highly 
regulated; the DAT constitutively traffics to and from the cell surface and its surface expression 
is also responsive to DAT substrates and a number of intracellular signaling kinases.  
Newly synthesized DAT is generated in the endoplasmic reticulum. From here, the DAT 
moves on to Golgi vesicles where it gets glycosylated at several sites on the eventual 
extracellular face of the transporter.23,24 Glycosylation is an important feature of DAT processing 
that allows the DAT to be expressed at the cell surface, although it does not appear to regulate 
uptake once expressed.25 Following initial expression, the DAT is constitutively trafficked from 
the cell surface and may be recycled back to the membrane. Its surface half-life is 
approximately 13 minutes26,27 and the basal surface DAT endocytic rate is 3-5% per minute.22 
The constitutive internalization of the DAT is believed to be a clathrin- and dynamin-dependent 
phenomenon.28 The DAT is internalized into small-GTPase-expressing vesicles, including Rab-5 
and Rab-11,29,30 which mark a subset of recycling endosomes. DAT protein can be held within 
these vesicles to rapidly insert into the membrane as needed.  
Once at the plasma membrane, DAT expression can be stabilized or destabilized by a 
number of protein-protein interactions. These proteins include PICK1 (protein that interacts with 
C-kinase),31 Hic-5,32 α-synuclein,33 flotillin,34 and even DAT itself, allowing for the formation of 
DAT oligomers.25 PICK1, α-synuclein, and DAT oligomerization stabilize DAT at the cell surface, 
while Hic-5, a potential scaffolding protein, decreases DAT on the plasma membrane when 
overexpressed. Interestingly, flotillin is a protein which stabilizes the DAT within particular 
microdomains in the plasma membrane, but also appears to be necessary for PKC-induced  
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Figure 3. Factors affecting DAT trafficking and membrane expression. As described in the text, 
a number of factors regulate DAT trafficking and expression, including (A) constitutive 
trafficking, (B) DAT-substrate interactions, as with amphetamine, (C) interactions with cocaine‐
like inhibitors, (D) the phosphorylation state of DAT, (E) GPCR-induced intracellular signaling 
cascades, and (F) the ubiquitination state of DAT. Adapted from 21. 
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DAT internalization, thus playing roles in both the stabilization and destabilization of the DAT 
under varying conditions.34 The stability of DAT expression at the cell surface may have 
powerful implications for disease processes; for example, it has been suggested that PICK1 and 
α-synuclein could promote toxicity from substrate-induced oxidative stress, leading to conditions 
such as Parkinson’s disease.33,35,36  
The DAT is also trafficked to and away from the cell surface in response to substrates 
and inhibitors. The response to substrates is thought to be biphasic in that brief exposure to 
substrate promotes DAT surface expression while prolonged exposure results in DAT 
internalization.22 In heterologous cells and rat striatal synaptosomes, a 30 second to 2 minute 
exposure to DAT substrates DA or amphetamine rapidly increases DAT surface expression as 
well as uptake function.37 Cocaine, a DAT blocker, inhibits this form of substrate-induced 
trafficking to the plasma membrane. Given that the half-life of DA clearance in the rat striatum is 
26-57 seconds,38 this rapid upregulation of DAT fits within a physiologic time frame for 
enhanced clearance.  
The early increase in DAT surface expression and function may be a response to initially 
deal with increased substrate burden. However, prolonged exposure of cells to substrate may 
be toxic, as high levels of cytosolic DA and amphetamine are known to induce oxidative 
stress.39 Amphetamine is also able to deplete intracellular DA stores.40 Thus it is perhaps not 
surprising that DAT surface expression is downregulated in response to prolonged exposure to 
substrates, an effect which is also blocked by cocaine.40,41 Interestingly, cocaine itself increases 
surface DAT when cells are exposed to it for long periods of time.41,42 These findings in vitro 
may be paralleled by human positron emission tomography (PET) studies which show that DAT 
binding is increased in brains from cocaine addicts43 and decreased in chronic 
methamphetamine users.44       
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This process of DAT internalization and recycling is, importantly, regulated by 
posttranslational modifications such that the cell can respond to changing environmental 
conditions requiring more or less reuptake. These posttranslational modifications include 
phosphylation and ubiquitination. Kinases regulating DAT trafficking include protein kinase C-β 
(PKC-β), protein kinase B (PKB, also known as Akt), phosphatidylinositol 3 kinase (PI3K), 
Ca2+/calmodulin kinase (CAMKII), and extracellular signal-regulated kinases (ERK1/2). PKC-β 
has been particularly implicated in constitutive trafficking processes. Protein phosphatase 1 
(PP1) regulates DAT phosphorylation state and trafficking in the opposite direction.45 Major sites 
for DAT regulatory phosphorylation are found on the intracellular face of the transporter, and 
includes five important serine residues on the N-terminal domain.46 However, it should be noted 
that phosphorylation at some of these sites regulate other DAT-mediated processes (e.g. DA 
efflux) rather than DAT trafficking.47  
A change in phosphorylation state that ultimately regulates DAT surface expression and 
function may be induced through signaling cascades initiated by a number of different receptors. 
The D2 autoreceptor has been well-studied in this regard. D2/D3 receptor agonists increase 
DAT surface expression and DA uptake, an effect which is g protein-, PI3K-, and ERK1/2-
dependent.48,49 Interestingly, the D2 receptor may interact directly with the DAT.50 The functional 
significance of this interaction, however, is unclear since downstream signaling cascades 
appear to be necessary to affect trafficking. Other receptors have also been shown to influence 
trafficking. The insulin receptor is a receptor tyrosine kinase expressed throughout the brain, 
including regions expressing the DAT. Insulin signaling increases DAT surface expression by 
activating Akt and PI3K. Of note, insulin impairs amphetamine-induced DAT internalization and 
amphetamine behaviors in hypoinsulinemic rats.51,52  
The DAT also contains several ubiquitination sites. These are lysine residues targeted 
by the protein NEDD4-2 (neural precursor cell expressed, developmentally downregulated 4-2), 
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which contains an E3 ubiquitin ligase.53 Interestingly, ubiquitination sites on three key N-terminal 
lysine residues on the DAT may be necessary for PKC-induced internalization.54 Ubiquitination, 
or polyubiquitination, likely serves to target the DAT for lysosomal degradation, which may be 
an additional source of regulated DAT turnover.   
 
Additional mechanisms regulating DA reuptake 
There are a number of factors regulating DA uptake function for which DAT surface 
expression changes have not yet been identified. These include the molecules arachidonic acid 
(AA) and nitric oxide (NO). AA is a highly diffusible molecule produced through the metabolism 
of lipid membranes in neurons and other cells. It has been shown to inhibit DA transport and 
impair binding of a cocaine analog in heterologous cells.55 Furthermore, inhibitors of AA 
metabolism inhibit DA uptake while compounds that raise levels of endogenous AA inhibit DA 
transport.56 The mechanism behind this effect has been unclear. However, studies have shown 
that AA can induce a novel cation conductance through the DAT (which is blocked by cocaine)57 
and that AA inhibition of DAT is not PKC-dependent.55 NO is another molecule produced by 
neurons that can act as a neurotransmitter. NO exists as a gas and can therefore act across 
membranes and across synapses. It has been shown that inhibition of the production of NO by 
NO synthase (NOS) reduces DA levels in the striatum58 and that NO itself inhibits DAT-
mediated DA uptake.59 These findings support the idea that NO increases tonic DA levels in the 
striatum by exerting inhibitory influence over the DAT. That diffusible compounds like AA and 
NO can affect DAT function further suggests that the DAT is highly susceptible to its local 
microenvironment.  
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The importance of DAT 
The importance of DAT in regulating synaptic DA levels is highlighted by the fact that 
dysfunctional DAT has been strongly linked to a number of human diseases.60 Deficiency of 
functional DAT can be caused by rare mutations at particular sites on the DAT.61 In humans, 
these mutations can lead to a syndrome called DAT deficiency syndrome, also known as 
infantile parkinsonism-dystonia, characterized by generalized muscle dystonia, bradykinesia, 
and postural instability, among other motor deficits.62 DAT mutations have also been linked to 
bipolar disorder, autism, and attention-deficit hyperactivity disorder (ADHD) in humans,63,64 
pointing to DAT’s relevance to a number of diverse neuropsychiatric disorders for which tight DA 
regulation is important.  
Rodent models of DAT dysfunction also clearly demonstrate the importance of DAT and 
its tight regulation under normal conditions. DAT knockout mice, for instance, have reduced DA 
tissue levels but high extracellular DA, reduced DA release, and lower levels of DA receptors 
compared to wild-types.65 This results in increased basal locomotor activity in these mice. 
Interestingly, conditioned place preference (CPP) for psychostimulants directly targeting the 
DAT, including amphetamine and cocaine, remains intact in DAT knockouts. This is widely 
believed to be the result of molecular adaptations due to knockout from birth. However, if the 
DAT is made insensitive to cocaine, cocaine CPP is no longer observed, suggesting that DAT is 
required for cocaine reward and locomotor stimulation.66 Importantly, a number of DAT 
knockdown models have provided additional insights into DAT’s behavioral relevance.67-69 
These models have the advantage of avoiding some of the adaptations that derive from a 
complete deletion of DAT from birth. Some of these models express ~10% of wild-type 
DAT.67,68,70,71 These mice predictably exhibit chronically elevated levels of extracellular DA. 
Behaviorally, they show novelty-induced hyperactivity, impaired response habituation, greater 
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incentive performance for sweet rewards in a runway task, enhanced progressive ratio operant 
responses for food rewards, and enhanced cocaine-induced locomotion and CPP.67,70,71  
Importantly, psychomotor stimulants, or psychostimulants, are a class of reinforcing 
drugs that act on the DAT. This class of drugs includes cocaine, amphetamine, and their 
derivatives. Amphetamine acts as a substrate for the DAT in that it gets taken up by the DAT, 
thus competing with DA for uptake. Amphetamine additionally inhibits function of VMAT2 in the 
brain and promotes reverse transport (i.e. efflux) of DA by the DAT. Cocaine, on the other hand, 
increases extracellular DA by inhibiting reuptake of DA by the DAT.  In rodents, these drugs are 
known for their ability to acutely increase motor activity, reduce food intake, and decrease 
thresholds for intracranial self-stimulation (ICSS).72,73 Importantly, psychostimulants are 
powerful reinforcers; animals will respond in an operant fashion to self-administer them and can 
also be trained to respond to conditioned stimuli associated with psychostimulants.74,75  
 
The DA reward system: historical perspective and new revelations  
DA is the neurotransmitter that allows us to interact with the outside world; it gives us the 
ability to move and motivates us to seek out those things that will keep us moving. If provided 
with all possible resources for survival and procreation before us, we would yet cease to survive 
and procreate without the motivating influence of DA. This underlies the essential nature of DA 
and the brain’s reward system, a system which evolved to compel us to seek out valuable 
resources with survival and reproductive advantage.  
Reward is often defined as pleasure derived from any salient environmental stimulus. 
Reward can be experienced from ingested substances, such as food or certain drugs, but it can 
also be experienced through social interactions with others or activities (e.g. gambling, 
exercise). Reinforcement is any event that increases the probability of a response, and is 
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related to reward because rewarding stimuli typically enhance reward-seeking behaviors.76 Thus 
rewarding stimuli themselves are said to be “reinforcing.”  
That DA is a key neurotransmitter in reward and reinforcement has been well 
recognized. Prior to Arvid Carlsson’s 1957 Nobel Prize-winning discovery that DA is a 
neurotransmitter in the brain, it was believed that DA was simply a precursor to NE.77 Carlsson 
found that rabbits made catatonic through treatment with reserpine could be made mobile and 
active again by treatment with the DA precursor, L-DOPA.78 Further, the brains of these rabbits 
contained high levels of DA - visible by spectrophotofluorimetry - but not NE. We now know that 
reserpine blocks the activity of VMAT leading to DA depletion and induces a Parkinson’s-like 
phenotype in vivo. The discovery that DA could indeed act as a neurotransmitter with important 
biological functions opened the way for further exploration of DA’s roles within the CNS.79  
In the 1960s, a “catecholamine hypothesis” of reward began to gain traction among 
scientists.80 This hypothesis stated that catecholamine-containing neurons drive reward 
behaviors, such as ICSS observed in rodents by Olds and Milner in their classic 1954 study.81 
Prior to the catecholamine hypothesis and the work of Olds and Milner, the prevailing view was 
that reward-seeking was governed by general mechanisms and circuitry related to learning and 
memory, rather than a dedicated system for reward. The catecholamine hypothesis emerged 
from early studies showing that psychostimulant drug actions are impaired by treatment with 
reserpine and restored by L-DOPA82 and was supported somewhat later through studies 
showing that DA receptor blockade reduces ICSS and lever-pressing for food,83,84 among other 
evidence.80 While controversial at first, the idea that catecholamines, particularly DA, drive 
motivated behavior has overwhelmingly dominated the study of reward for the past several 
decades.  
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A number of brain regions have been linked to reward and motivated behavior. Among 
them, the ventral striatum, or NAc, emerged early as a major site of reward, although its 
particular role in reward and reinforcement has been debated and refined over the years. It was 
first noted that rats electrically self-stimulate the NAc, as well as the upstream VTA, a 
phenomenon which could be blocked by accumbal injection of a DA receptor antagonist.85,86 
Furthermore, rats will self-administer drugs that directly or indirectly enhance DA signaling in the 
NAc.87,88  
To understand the NAc’s functional properties, an understanding of its structure and 
circuitry is required. The NAc, like the rest of the striatum, is composed of approximately 95% 
medium spiny neurons (MSNs). These are GABAergic projection neurons. The other 5% of 
neurons are interneurons which employ acetylcholine or GABA as well as NO, somatostatin, 
neuropeptide-Y, and a number of other neurotransmitters. An important property of striatal 
MSNs is their expression of DA receptors. Approximately half of striatal MSNs express D1 DA 
receptors while the other half express D2 DA receptors. These receptors receive input from DA-
producing neurons whose cells bodies are localized to the VTA. D1 receptor-expressing 
neurons are thought to promote reward, while D2 receptor-expressing MSNs promote 
aversion.89-91  
The NAc is further subdivided into NAc shell and core.92 The shell surrounds the core 
and has been implicated in limbic processing and motivational salience.93 Drugs of abuse 
promote a larger release of DA in the shell than the core.94 Neurons in this subregion project to 
the ventral pallidum, amygdala, hypothalamus, and back to the VTA.95 The core, on the other 
hand, is involved in the motor aspects of reward seeking.96 Core neurons contain greater 
dendritic branching and are more susceptible to plastic changes, especially in response to 
rewarding stimuli.97-99 The core projects primarily to the globus pallidus and SN.95  
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Despite near consensus that mesolimbic DA is important for reward, its exact role in 
encoding reward and determining resultant behavioral responses has been surprisingly difficult 
to establish and has been a topic of great debate. Several questions have emerged: Is DA 
responsible for the subjective enjoyment of a reward? Does DA allow us to learn about the 
value of a reward? Is DA simply directing motor patterns in pursuit of reward? Does DA play a 
role in the anticipatory phase or cravings associated with reward? These questions highlight the 
inadequacy of the term “reward” to describe these various phenomena which are likely distinct 
not only in concept but also in biology.  
Defining the role of mesolimbic DA depends first on understanding the stimuli that elicit 
mesolimbic DA and the patterns or modes of DA modulation in response to different stimuli. 
Most importantly, virtually all rewarding stimuli have been shown to increase DA release in the 
NAc. This includes so-called “natural rewards” such as social reinforcers, sex, and palatable 
food, but also includes highly addictive or pleasurable activities (e.g. gambling), direct brain 
stimulation in specific areas, and drugs of abuse. Interestingly, all abused drugs increase 
accumbal DA levels. This is despite the fact that abused drugs may directly target other 
neurotransmitter systems (e.g. opiates target opioid receptors/signaling), suggesting that 
mesolimbic DA makes up a final common pathway for drug reward.100 DA release for rewarding 
stimuli is typically greater upon initial exposure or consumption and lessens with repeated 
exposures.101 On the other hand, secondary reinforcers or cues associated with rewarding 
stimuli can elicit DA release on their own.101,102 Cues can include unconditioned stimuli (e.g. the 
smell of a cheeseburger), or conditioned stimuli from repeated association between the reward 
and cue (e.g. the sight of drug paraphernalia). These cues may even dominate the DA response 
as DA neurons cease to respond the primary rewarding stimulus and fire increasingly in 
response to secondary reinforcers.103  
  18 
 
The context in which a reward is received is extremely important and may affect the 
amount and timing of DA release. These variables likely encode additional information relevant 
to reward processing. One of the most influential theories on DA and reward was proposed by 
Wolfram Schultz in 1997.104 His theory, known as “reward prediction error,” states that DA 
encodes the discrepancy between actual reward received and reward expectancy. A “positive 
prediction error,” for example, means that reward received was unexpected or larger than 
anticipated. This results in an increase in DA release. When a reward occurs as predicted, no 
DA release occurs. Finally, a “negative prediction error” elicits an inhibition of tonic DA release 
when an expected reward is omitted. These different modes of DA signaling were 
experimentally confirmed through high resolution in vivo electrophysiologic recordings of DA 
release when reward-associated stimuli were presented or omitted and the reward itself was 
presented or omitted. More recent work from Schultz and others have refined the reward 
prediction error model.105,106 In the most recent iteration of the model, DA serves to unselectively 
identify potential rewards or reward-predicting stimuli through an initial short-latency, short-
duration phasic response followed by a second slower graded component which signals the 
value of the reward. Thus the process is sequential and serves to alert an animal to the salience 
of a stimulus, as well as a value judgment.  
Whether an individual or animal administers a drug to themselves or is provided with 
drug by an experimenter in a non-response contingent manner also affects DA release 
mechanisms. Indeed, “yoked” rats exhibit substantially smaller increases in DA in response to 
cocaine injection than rats who were able to self-administer the drug.107 This not only 
demonstrates the idea that DA neurotransmission involves contextual information, but also 
shows that even the pharmacology of abused drugs that act on the DA system relies on this 
contextual information.  
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The behavioral responses that are generated from directly manipulating modes of DA 
signaling tell us whether DA signaling is necessary and sufficient to drive different components 
of reward. To this end, early studies revealed that DA receptor agonists and antagonists could 
modulate reward in ways that are unlikely to be accounted for by altered sensorimotor function 
alone.108-110 Additionally, lesions to accumbal DA terminals using the neurotoxin 6-
hydroxydopamine (6-OHDA) reduce the consumption of food, drug, and brain stimulation 
rewards.84,111,112 Rats will fail to consume food to the point of starvation despite sufficient motor 
function to consume readily available foods.113 A similar aphagic phenotype is seen in 
genetically DA-deficient mice which lack the enzyme TH in DA neurons.114 Supplementing with 
L-DOPA or replacement of TH in the striatum is sufficient to rescue feeding behavior. Still, the 
results have been challenging to interpret given that DA is crucial for directing sensorimotor 
function. Supplementing DA-deficient mice with caffeine, however, allows the mice to regain 
some degree of motor function. These mice are, interestingly, able to learn the location of 
rewards and can form a conditioned place preference, but they remain aphagic. This finding 
suggests that DA may not be necessary for reward learning, or the recognition that something is 
indeed rewarding, but rather underlies motivational processes necessary to actually acquire a 
reward.  
The idea that DA supports an anticipatory or motivational component to reward has been 
espoused by the research of Kent Berridge who has supported a model of “incentive 
salience.”110,115 Under this model, DA designates a stimulus as both perceptually salient and 
attractive or motivating. DA thus drives a subjective “wanting” as well as a behavioral response 
in the form of reward seeking. Berridge has been a strong proponent of the separation of this 
“wanting” from “liking” which is the hedonic reaction to a rewarding stimulus, typically during the 
consummatory phase.116 In this manner, a reward can be wanted even if it does not produce a 
subjective state of enjoyment or euphoria. Berridge’s ideas have been supported by studies 
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seeking to distinguish “liking” and “wanting” at neurobiological and behavioral levels. Hedonia or 
“liking” can be observed for food using a taste reactivity assay which relies on evolutionarily 
conserved and observable affective reactions to a sugary solution (e.g. tongue protrusions).117 
Interestingly, blocking mesolimbic DA signaling through DA receptor antagonism or 6-OHDA 
lesions does not impact hedonic reactions to sweet stimuli,118 although such lesions may impair 
seeking behaviors.119,120  
Importantly, DA cannot play any role in reward without post-synaptic receptors and 
neurons to drive responses to DA. The interplay between direct and indirect pathway neurons in 
the striatum and how each drives DA reward responses is a complex topic. This fact derives in 
part from messy DA receptor pharmacology and the measurement of likely non-physiologic 
responses. However, with the emergence of new techniques like optogenetics, researchers 
have been able to better isolate specific signaling through D1- and D2-type neurons. Using 
cocaine as a reinforcer, multiple groups have been able to show that optogenetic activation of 
D1-type neurons promotes drug seeking and reward-context associations while D2-type 
neurons cause aversion to cocaine.89,90 Overexpression of the transcription factor ∆FosB, a 
transcription factor stably upregulated following repeated cocaine administration, in D1 direct 
but not D2 indirect MSNs also increased behavioral responses to cocaine.121 Furthermore, D1-
type populations of MSNs are the primary cell type activated by entry into a cocaine-paired 
environment, as measured by in vivo calcium imaging during a CPP task.91 Despite these 
findings supporting D1-driven responses, there is still a great deal of evidence that D2 receptor 
signaling supports motivated behavior. For instance, Jonathan Javitch and colleagues showed 
that viral overexpression of the D2 receptor in the NAc induces higher levels of operant 
responding when work requirements to achieve a palatable food reward were increased, while 
increased D2 receptor expression did not affect sensitivity to reward devaluation.122  
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Taken together, the literature points toward a role for DA in motivational reward seeking. 
This understanding serves to better inform our interpretation of the alterations in both DA 
homeostasis and behavior following pharmacologic and genetic manipulations. It further allows 
us to interpret changes in DA signaling in relation to pathological states of reward impairment 
(e.g. drug addiction, obesity; described in detail below).  
 
Central reward: beyond mesolimbic DA 
While mesolimbic DA signaling has been at the forefront of the research into reward and 
addiction, several other brain regions and neurotransmitter systems have been implicated in 
both natural and drug-mediated reward. These neurotransmitters and regions deserve 
recognition because they participate in aspects of reward not directly regulated by the 
mesolimbic DA system. Furthermore, many of these regions modulate signaling within the 
mesolimbic system with the ability to shift behavioral responses.  
In addition to the mesolimbic system, both the lateral hypothalamus (LH) and the lateral 
septum (LS) may be “primary” reward centers in that electrical self-stimulation in these regions 
is considered rewarding. In now classic studies, Olds and Milner (1954) discovered that rats 
would press a lever to electrically stimulate sites along the medial forebrain bundle (MFB), a 
bundle of axons which includes projections to and from the LH, VTA, NAc, and LS.81 While less 
attention has been devoted to the LH and LS, these regions nevertheless play important roles in 
reward processes.  
The LH has long been known as both a feeding center and reward center.123 Electrical 
stimulation of the LH appears to be rewarding in itself,81 and also induces an immediate 
hyperphagic response in satiated animals.124 Mechanisms underlying this effect were, until 
somewhat recently, unknown. Interestingly, LH neurons expressing neuropeptides known to be 
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involved in feeding regulation, including melanin-concentrating hormone and orexin, project to 
mesolimbic circuitry.125-127 Based on this anatomical observation, Dileone and colleagues 
proposed that these neuropeptide-expressing LH neurons might support reward processes and 
even addiction.127 Indeed, recent studies support this notion. One study found that activation of 
LH orexin neurons is strongly linked to preferences for cues associated with food and drug 
reward and that direct administration of orexin into the VTA was sufficient to reinstate 
extinguished drug-seeking behavior.128 In addition to neuropeptides, direct GABA and glutamate 
stimulation from the LH onto VTA DA and GABA neurons modulates compulsive sucrose 
consumption.129 Through an elegant set of studies, these authors describe a loop circuit by 
which LH-VTA neuron encode learned reward-seeking behavior while a reciprocal VTA-LH 
circuit encode reward expectancy. Thus the LH appears to regulate important aspects of 
reward-seeking behavior through direct manipulation of the VTA.  
The LS is another region which is highly rewarding by ICSS and may regulate outflow 
from mesolimbic reward circuitry. The LS is a multifunctional brain region; it is most known for 
regulating affective states including mood and fear, and could impact processes related to 
schizophrenia and a number of other neuropsychiatric disorders.130 It is composed primarily of 
GABAergic projection neurons which innervate regions involved in reward and affective state, 
including the VTA, NAc, LH, amygdala, and raphe nuclei. It receives projections from many 
different areas, most notably glutamatergic innervations from the PFC, hippocampus, and 
hypothalamus, and DAergic projections from the VTA. The major LS input and output areas are 
summarized in Figure 4.  
Thus the LS sits at a node where it is poised to regulate a number of neuropsychiatric 
processes. But what about its role in motivation? Is there evidence that it interfaces with the 
mesolimbic DA system? Indeed, exposure to stimuli that have previously been paired with 
positive reinforcers (food, cocaine) increases neuronal activity in the LS.130 Lesioning the MFB 
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axons leading from the LS to the LH and VTA prevents ICSS.131 Moreover, electrical stimulation 
of the LS regulates the firing rates of VTA neurons,132 suggesting that the LS provides top-down 
regulation of the mesolimbic system. In support of this notion, application of tetrodotoxin to the 
LS enhances DA release in the NAc as measured by in vivo voltammetry.133 As the LS receives 
DAergic input from the VTA as well, this interaction is likely reciprocal allowing for circuit-level 
integration and feedback.130 Accordingly, the LS expresses both D1-like and D2-like DA 
receptors. The exact role of DA in the LS is unclear, likely due to varying conditions required to 
activate D1 vs D2 signaling. Like the striatum, the interplay between D1-type and D2-type 
signaling is complex making it difficult to say how DAergic innervation from the VTA influences 
septal function. Nevertheless, it is clear that the LS exhibits behavioral relevance to reward and 
regulates the rewarding properties of the DA-enhancing drug, cocaine. Notably, applying 
baclofen, a GABA receptor agonist, to the LS is able to block cocaine CPP in rats.134 The 
authors of this study suggested that this occurs through inhibiting activation of LH orexin cells 
which, as described above, modulate outputs from mesolimbic circuitry related to reward-
context associations. Another study by this same group used tracers to define a circuit 
connecting the CA3 region of the hippocampus through the LS to the VTA.135 As one might 
expect, this circuit is important for context-reward associations; chemically inactivating 
components of this circuit was sufficient to block context-induced reinstatement of cocaine 
seeking in rats. These results point to a role for the LS in integrating components of reward from 
different areas to be able to account for not only the rewarding effects of the drug itself, but also 
the cues or context associated with it. That cocaine CPP or reinstatement does not exist without 
septal influence highlights the essential nature of the LS.   
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Figure 4. A simplified summary diagram of the afferent and efferent connections of the LS. The 
LS receives strong glutamatergic inputs from the hippocampus and reciprocal inputs from the 
hypothalamus, including LH. It also receives input from the VTA and sends projections to the 
NAc. Amy, amygdala; BNST, bed nucleus of the stria terminalis; EC: entorhinal cortex; LC, 
locus coeruleus; LDT, laterodorsal tegmentum; MS/DBB, medial septum/diagonal band of 
Broca; NA, nucleus accumbens; PAG, periaqueductal gray; PFC, prefrontal cortex; Thal, 
thalamus; VTA, ventral tegmental area. Adapted from 130. 
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While the ventral striatum garners much of the attention in regards to reward, the DS 
also plays a distinct but important role. The DS is typically associated with motor components of 
reward seeking because the DS, with its direct and indirect motor circuits, forms the central 
circuitry of the basal ganglia. Whereas the NAc is implicated in responses to conditioned and 
unconditioned reward stimuli, the DS controls the physical ability to respond to rewarding 
stimuli. Lesions of the DS, thus, affect behaviors such as response initiation and reaction time to 
acquire rewards.136,137 As in the NAc, DA is critical to these functions.138-140 Importantly, the DS 
has been implicated in the compulsive aspects of reward seeking.75 These compulsions develop 
over time as motor patterns of reward seeking become engrained. Thus the DS is often 
associated with “habitual” components of reward seeking.    
The glutamate system also plays a very important role in reward. Glutamate inputs to the 
VTA promote DA neuron firing; moreover, DA would have little effect on its downstream targets 
without a source of excitation as MSNs are quiescent without excitatory input.141 Glutamate 
interacts with the mesolimbic DA system through projections to the VTA from the hippocampus, 
the amygdala and extended amygdala, and the PFC, and a similar set of inputs to NAc 
MSNs.142,143 The hippocampus and amygdala modulate the reward system by providing 
information about context and emotional valence, while the PFC provides top-down regulation of 
the reward system through impulse control and conscious decision-making. Interestingly, in 
degenerative disorders of the PFC such as frontotemporal dementia, patients exhibit 
hyperphagia as they are no longer able to make appropriate decisions regarding palatable food 
consumption.144  
Importantly, afferent glutamatergic projections to the VTA and NAc drive learning 
processes including long-term depression (LTD) and long-term potentiation (LTP). Learning is 
an essential component of reward because it allows the reward system to recognize rewarding 
stimuli it has encountered previously. It is particularly important for establishing associations 
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with conditioned cues. Fast glutamatergic synaptic signaling is mediated by ionotropic glutamate 
receptors, AMPAR and NMDAR. These receptors bind glutamate and, under the right 
conditions, become permeable to cationic currents. These currents are known as excitatory 
postsynaptic currents (EPSCs) and can be measured through slice electrophysiology. Notably, 
AMPAR- and NMDAR-mediated EPSCs have little to do with the acute effects of rewarding 
stimuli. However, the expression of AMPARs and NMDARs and the development of their 
currents are crucial to behavioral adaptation and synaptic adaptations, particularly those that 
develop from prolonged drug use.145 These concepts are discussed further in the next section in 
the context of addiction. 
If DA primarily directs motivation and incentive salience, what neurotransmitter(s) is 
responsible for the hedonic properties of rewards? Opioid peptides and their receptors are one 
clear candidate. Opiates are drugs which target opioid receptors and are known for their pain-
relieving properties as well as for being highly addictive. Interestingly, while DA receptor 
agonists and antagonists do not seem to modify the hedonic properties of sucrose in a taste 
reactivity assay, opioid receptor agonists and antagonists do.146 Furthermore, “hedonic 
hotspots” have been identified within the NAc shell and ventral pallidum which are highly 
responsive to the opioid receptor agonist, DAMGO.147 In regards to drugs of abuse, there may 
be substantial crosstalk between opioid systems and drugs of abuse as opioid receptor 
antagonists (e.g. naltrexone) are able to modify drug-seeking behavior, even for drugs whose 
primary targets are thought to lie outside the opioid system (e.g. alcohol).148  
Another candidate for hedonia is the endocannabinoid system. Endocannabinoids are a 
class of neuroactive lipids which include primarily anandamide and 2-arachidonylglycerol (2-
AG). These molecules are generated upon membrane depolarization by the enzymatic 
remodeling of membrane phospholipids as described in Figure 5. Given their hydrophobic 
composition, endocannabinoids are able to cross neuronal cell membranes easily within a small 
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diffusible area (Figure 6).149 This allows them to interact with presynaptic receptors, primarily 
the CB1 endocannabinoid receptor (CB1R) which is highly expressed in the CNS. They can 
also be degraded into AA and ethanolamine or glycerol within presynaptic neurons or glial cells 
by the enzymes fatty acid amide hydrolase and monoacylglycerol lipase (MAGL). The 
endocannabinoids have been implicated in mood, memory, and appetite. Importantly, 
endocannabinoids have been strongly linked to reward. Endocannabinoid signaling has been 
shown to increase feeding behavior150 and is also the target of tetrahydrocannabinol (THC)-
based drugs which exhibit rewarding properties in humans and other animals.151 Compared to 
some other drugs, THC-based drugs are not thought to be strongly reinforcing. Yet, importantly, 
pharmacological blockade of CB1Rs reduces the seeking for palatable food and drugs of abuse, 
suggesting that endocannabinoids do indeed regulate reward processes in the brain.152 
Furthermore, recent reports have shown that another drug of abuse, namely cocaine, is able to 
mobilize 2-AG within the mesolimbic system,153 while THC and other cannabinoid receptor 
agonists increase DA levels in the striatum.154 Thus there is likely a great deal of cross-talk 
between DA and endocannabinoid systems, although they may possess unique functional 
niches (i.e. hedonia vs motivated behavior).  
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Figure 5. Major biosynthetic and degradative pathway of 2-AG. AA, arachidonic acid; 2-AG, 2-
arachidonoylglycerol; DAG, diacylglycerol; DAGL, diacylglycerol lipase; MAGL, 
monoacylglycerol lipase; PIP2, phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C. 
Adapted from 155. 
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Figure 6. Model of retrograde shuttling and metabolism of 2-AG and AA. 2-AG is generated 
from phospholipids in the postsynaptic neuron. It can bind diffuse and bind to the CB1 
cannabinoid receptor (CB1R), activating a Gi-coupled inhibitory signaling cascade. 2-AG can 
also diffuse into the presynaptic terminal where it is degraded to AA by MAGL. AA, arachidonic 
acid; DAG, diacylglycerol; MAGL, monoacylglycerol lipase; PIP2, phosphatidylinositol 4,5-
bisphosphate. Adapted from 156. 
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An introduction to drugs of abuse and addiction 
  Brain reward systems evolved to compel us to interact with others and our environment 
in a manner which would increase our reproductive fitness, particularly in times of scarcity of 
reproductive partners or food. For example, the reward system encourages consumption of 
energy-dense foods with less need for foraging. These qualities of the reward system conferred 
fitness benefits for the vast majority of evolutionary time. However, with the increased societal 
availability of natural rewards like calorie-dense foods and the emergence of drugs of abuse 
which hijack brain reward systems, pathological states have emerged within the reward system. 
These pathological states include drug addiction, but a number of other addictions may exist 
including addictions to sex, food, gambling, and even the internet.157 Of these, drug addiction is 
likely the best understood and also one of the most problematic in terms of public health 
ramifications.  
 Drug addiction is the compulsive use of a drug despite negative consequences, such as 
health problems, disability, and failure to meet major responsibilities at work, school, or home. In 
the Diagnostic and Statistical Manual of Mental Disorders (DSM V), an individual is considered 
to have a substance use disorder if there is evidence of impaired control, social impairment, 
risky use, and pharmacological criteria specific to a particular drug class. The DSM V 
recognizes substance use disorders for the following classes of drugs: tobacco, alcohol, 
caffeine, stimulants, opioids, hallucinogens, cannabis, hypnotics, anxiolytics, inhalants, 
sedatives, and certain prescription drugs.  
According to the U.S. Department of Health and Human Services, in 2013 an estimated 
21.6 million people aged 12 and older (8.2% of the U.S. population) were classified with 
substance dependence or abuse based on the DSM IV.158 Substance use disorders confer 
wide-ranging societal costs from lost work productivity to crime and healthcare costs. Addiction 
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has an estimated cost burden of $700 billion annually in the U.S. alone.159 Furthermore, the 
large demand for drugs has led to a countless number of deaths and incarcerations associated 
with illegal drug trades.  
 Treatment options for drug addiction are fairly limited and, depending on the drug class, 
range from behavioral therapy only to combined behavioral and pharmacotherapy. Behavioral 
therapy may consist of psychiatric individual or group cognitive behavioral therapy (CBT), 
motivational interviewing, motivational incentives, multidimensional family therapy for youths,160 
as well as community support groups (e.g. Alcoholics Anonymous). CBT has been shown to 
have low to moderate efficacy, depending on the substance.161 Combining CBT with 
pharmacotherapies may have some additional benefit for certain drug classes;162 however the 
benefits do not appear to be additive.161  
Medication-based therapies primarily address withdrawal symptoms, prevent relapse, 
and treat co-occurring diseases (Table 1). Most FDA-approved pharmacotherapies target the 
same proteins acutely targeted by the drugs themselves (Figure 7). For instance, for opiate 
abuse we use opioid receptor agonists (methadone) or partial agonists (buprenorphine) to ease 
the transition into a withdrawal period by lessening withdrawal symptoms, while antagonists 
(naltrexone) block the effects of opioids at the opioid receptor. As is clear from table 1, there are 
very few options for patients with addictions. Indeed, there are no effective pharmacotherapies 
to address addiction to psychostimulants. The lack of options for patients with addiction 
presents a major challenge to their treatment. Furthermore, the treatment of addiction is often 
complicated by comorbid diseases that tend to accompany addiction, including mood and 
anxiety disorders, cardiovascular disease, and chronic viral illnesses (hepatitis C, human 
immunodeficiency virus).159,163  
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Table 1. Pharmacotherapies targeted at several major classes of abused drugs.  
Drug class Pharmacologic treatment options 
Tobacco (nicotine) Nicotine replacement (patch, gum, etc.) 
Bupropion 
Varenicline 
Alcohol Disulfiram 
Naltrexone 
Acamprosate  
Opiates (heroin & pain relievers) Methadone 
Buprenorphine 
Naltrexone 
Psychostimulants (cocaine, amphetamine) None 
Cannabis (marijuana) None 
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Figure 7. Simplified scheme of converging acute actions of drugs of abuse on the VTA-NAc. 
Drugs of abuse promote the elevation of DA in the NAc, despite differing acute targets. 
Proposed sites of action are depicted here. PPT/LDT, peduncular pontine tegmentum/lateral 
dorsal tegmentum. Adapted from 164. 
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Part of developing therapies to address addiction is to understand that addiction 
develops in stages and that each of these stages may require different behavioral or medical 
interventions.103 The first step in the development of an addiction is experimentation, during 
which an individual tries the drug for the first time and may feel some of its euphoric sensations. 
An individual may progress to the binge/intoxication phase in which they take the drug on 
multiple occasions, but the intake remains subchronic and lacks a compulsive nature; rather, 
this early phase tends to rely on impulsive behavior and the positively reinforcing qualities of the 
drug. Over the first few drug administrations, an individual may sensitize to the acutely 
rewarding effects of the drug. However, over longer periods of repeated drug administration, an 
individual will develop tolerance to the drug, leading to dose escalation. Indeed, dose escalation 
is commonly observed in animal models of contingent drug administration.165,166 This effect is 
likely due to potent neuronal adaptations within the brain reward system. For example, DA 
receptors may be downregulated in response to repeated drug administration such that greater 
amounts of drug are necessary to induce a state of internal satisfaction in response to the 
drug.103 Furthermore, these adaptations alter the basal neurochemical balance within the brain, 
which may promote drug cravings and altered affective state. Taken together, these adaptations 
resulting from chronic use are believed to promote greater compulsive intake. The molecular 
bases for adaptations in response to drugs of abuse are discussed in further detail in the next 
section. 
With escalating intake, an individual may begin to experience some of the negative 
consequences of drug abuse such as the deterioration of important relationships, poor work 
performance, and the development of risky behaviors associated with taking or acquiring the 
drug. An individual may attempt to reduce intake following negative consequences, but with 
many drugs of abuse this can produce withdrawal symptoms which can range from intense drug 
cravings to negative affect to physical distress. These immediate adverse consequences of 
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abstaining from drug-taking may, by themselves, support drug-seeking to satisfy drug cravings 
and alleviate withdrawal symptoms. Thus drug-taking shifts from being driven by positive 
reinforcement to negative.  
At this point, the individual is no longer in control of his or her drug use. Herein lays the 
core component of addiction: the inability to stop abusing drugs despite negative life 
consequences. If an individual is able to stop taking the drug for an extended period of time, 
they may be able to get past the initial stage of withdrawal symptoms. However, a common 
finding is that addicts exhibit a high rate of relapse. Relapse tends to occur when an addict 
encounters cues, people, or environments associated with prior drug-taking. Additionally, 
negative life events (e.g. the death of a loved one) or negative affective states (e.g. high stress, 
depression) can trigger a relapse event in which the addict consumes the drug once again. In 
these events, the drug-taking behavior again becomes a chronic situation. 
 
Drug-induced adaptations and predisposing factors to addiction 
Each of these steps in the development of an addiction to drugs comes with molecular 
adaptations in the reward system that drive continued use and relapse. Human imaging studies 
point to some of these chronic adaptations and, in the absence of well-controlled, longitudinal 
interventions in humans, animal models have provided greater information regarding the 
causality of molecular changes in addiction. As DA is clearly an important mediator of at least 
some component of normal reward processes, it comes as little surprise that DA plays a role in 
addiction. As has been previously mentioned, all drugs of abuse acutely elevate mesolimbic DA 
levels, mimicking phasic DA cell firing, despite differing direct mechanisms of action. This 
suggests a final common pathway for addiction which has been espoused by Eric Nestler and 
others (Figure 7).164 In the early stages of addiction, drugs may sensitize the DA system such 
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that DA transmission increases progressively with repeated administration. This effect is thought 
to underlie, at least in part, the increase in ambulatory activity that is observed in rodents 
following repeated administration of many abused drugs. Similarly, DA responses to drug-
associated cues increase with repeated exposures.  
Despite these early increases in DA transmission, a prevailing hypothesis on addiction 
states that chronic drug use leads to a state of DA deficiency.103 This hypothesis suggests that 
chronic drug use characterized by high acute levels of DA promotes chronic DA system fatigue 
and the downregulation of mechanisms of DA neurotransmission. This may include reduced DA 
production and release, altered DA reuptake, and receptor downregulation. Indeed, chronic drug 
administration tends to decrease TH expression in NAc terminals (although it may increase TH 
in the VTA) and reduce D2 receptor expression in striatum.11,164,167 Reduced DA 
neurotransmission in response to a drug may act to paradoxically increase motivation for drugs 
of abuse due to a lack of tonic stimulation. This is thought to contribute, at least in part, to 
escalating drug intake. Interestingly, conditioning triggered by drugs has been shown to promote 
enhanced DA signaling in response to conditioned cues. Thus, while tonic DA stimulation may 
be low in addiction, phasic DA in response to conditioned cues may be higher and drive 
cravings.  
One of the most replicated findings in this regard is a reduction in D2 receptor 
expression in the striatum (including ventral striatum) in addicts. Using human PET imaging 
techniques, Nora Volkow and colleagues found that addicts for virtually any abused drug 
exhibited reduced D2 receptor binding.11 Whether this is an “adaptation” or a pre-existing 
condition is of some debate. Do high levels of DA neurotransmission from chronic drug abuse 
cause a downregulation of DA receptors? Or, are persons vulnerable to addiction more likely to 
have lower D2 receptor expression, thus driving future seeking behavior? These questions have 
not been fully answered yet, but there is evidence to support both scenarios, which are not 
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necessarily mutually exclusive. In support of low pre-existing D2 receptor availability, high D2 
receptor availability in the striatum is linked to resilience against the development of addiction,168 
as well as optimal goal-directed behaviors169 and decision-making based on effort 
expenditure.170 Furthermore, in non-drug-abusing individuals, low levels of D2 expression 
predicted higher self-reports of “drug-liking” in response to the cocaine-like substance, 
methylphenidate.168 In support of drug-mediated D2 receptor changes, non-human primates 
treated chronically with cocaine exhibit long-lasting decreases in D2 receptor availability by 
PET,171 and a response to treatment for cocaine addiction in humans parallels an increase in 
signaling through the D2 receptor.172 Longitudinal studies in humans will be necessary to better 
document whether low D2 receptor availability precedes addiction or is the result of chronic drug 
use.  
The glutamate system has also been strongly implicated in chronic neuroadaptations 
linked to addiction. As reward utilizes mechanisms of synaptic plasticity, so addiction engages 
similar mechanisms to strengthen motivational and motor circuits within the striatum. The types 
of adaptations which occur depend greatly on the length of exposure to drug (acute vs chronic) 
and the time since last exposure.173 Acute exposure to cocaine, for example, has little effect on 
striatal glutamate receptor expression and function. Repeated chronic exposure to cocaine, 
however, engages NMDARs on silent synapses (synapses lacking AMPAR expression). Silent 
synapses are highly plastic and may make the reward system vulnerable to the formation of 
memory traces associated with the drug. Appropriately, these changes in glutamate receptor 
expression coincide with an increased dendritic arborization and spine density in NAc MSNs in 
response to chronic administration of several different classes of drugs.174 The morphological 
changes occurring within the NAc reflect altered electrophysiologic properties of MSNs. These 
include synaptic LTD and LTP. While these are opposing processes, they have both been 
observed following chronic drug administration and they likely both contribute to aspects of 
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drug-seeking behavior. This is a complex topic which is outside the scope of this dissertation; 
however, there are some salient points worth mentioning in regards to neuroadaptations. First, 
repeated cocaine injections in mice result in a long-lasting depression of excitatory synaptic 
transmission in the NAc 24h after a challenge injection.175 In contrast, there is an increase in 
synaptic strength following abstinence that is depotentiated following re-exposure. In contrast, 
LTP is inducible in slices from rats treated repeatedly with cocaine when no withdrawal period is 
given.176 Interestingly, administration of drugs, such as cocaine, can support molecular 
processes associated with changes in LTD and LTP. For example, cocaine interferes with 
endocannabinoid-mediated LTD.177 Cocaine has also been shown to enhance accumbal EPSCs 
through GluA2-lacking AMPARs, particularly after a withdrawal period.178 GluA2-lacking AMPA 
receptors have greater calcium ion permeability and thus enhanced AMPAR synaptic currents, 
which may support cravings and drug-seeking behavior during periods of abstinence.179  
A number of the molecular changes described above may be induced by activation of 
the transcription factor, CREB (cAMP response element binding protein), which is activated in 
the VTA and NAc following repeated administration of cocaine, amphetamine, or opiates.180-182 
CREB activation is thought to drive changes in gene expression related to addiction (e.g. TH, 
GluR1).183  ∆FosB is another transcription factor that gets induced and accumulates in the NAc 
in response to chronic drug exposure and has been implicated in some of the morphological 
changes following chronic drug exposure.184 Importantly, overexpression of ∆FosB increases 
behavioral reactions to cocaine and opiates.185,186  
Later in the course of addiction, other brain regions beyond the ventral striatum may 
affected by pathological adaptations. Indeed, the DS becomes recruited as drug-seeking takes 
on a more compulsive, habitual nature. Similar to the ventral striatum, there is increased spine 
density in the putamens of non-human primates.187 Furthermore, DA neurotransmission in the 
DS appears to be necessary for drug-seeking.7 Interestingly, a number of studies have also 
  39 
 
demonstrated deficits within cortical regions, namely hypofrontality following chronic drug 
exposure. For instance, human imaging studies reveal impaired metabolic function of the 
orbitofrontal cortex, cingulate gyrus, and dorsolateral PFC in addicted subjects.188 These 
changes are believed to underlie impaired decision-making abilities along with increased 
impulsivity and compulsivity observed in addiction.  
It is important here to recognize that the brains of addicts may be different from non-
addicts even before the addict was ever exposed to drug. Indeed some of the aforementioned 
“adaptations” may not be adaptations at all, but rather, predisposing factors (although they are 
not necessarily mutually exclusive). Like many other highly prevalent disorders, addiction is a 
highly multifactorial disease involving a constellation of genetic and environmental factors. We 
know that an individual who tries a drug will not necessarily become addicted. In fact, according 
to the Institute of Medicine of the National Academy of Science, depending on the drug, only 10-
30% of people who try a drug will go on to become addicted. Of course, understanding 
biological underpinnings of vulnerability to drugs may help us discover who is at greatest risk 
and what we can do to prevent addiction or intervene in ongoing addictions.  
Some known risk factors for addiction include a family history of drug problems, male 
sex, impulsive traits, having another mental health disorder, peer pressure (especially in youth), 
and a lack of familial support.189,190 Protective factors include positive social support and role 
modeling, parental controls, traits like high self-esteem, and even a few genetic traits.189 Taken 
together, these factors contribute to an overall susceptibility or resilience to addiction.  
Understanding the genetic factors that contribute to addiction may give us new targets 
for therapy. To that end, family histories and twin studies support substantial heritability of 
addictions (from twin studies, about 50%, of addiction vulnerability that is heritable).191-195 
Unfortunately, finding precise genetic targets through genome-wide association studies has 
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proved challenging. To underscore this point, linkage-based analyses find no single locus 
contributes a substantial fraction of the vulnerability to any addictive substance.191 However, 
some targeted case control studies have defined promising gene loci. As one example, the 
Slc6a3 gene for the DAT contains what is known as a variable number tandem repeat (VNTR) 
sequence. In some individuals, this consists of a 9-repeat allele. This polymorphism has been 
associated with a reduced likelihood to smoke.196 The effect was even greater if an individual 
possessed the DRD2-A2 genotype of the D2 DA receptor. Furthermore, individuals carrying the 
9-repeat allele were more likely to quit smoking and had reduced novelty-seeking traits.197 If we 
can pharmacologically mimic the biology of genes like these which appear to confer some 
resistance to addictive behavior we may be able to affect behavior in addicts.  
 
Crosstalk between food and drug reward 
 Drugs of abuse evolved to utilize a system already in place to respond to natural, 
adaptive rewards. It should therefore come as little surprise that crosstalk between food and 
drug reward systems may be observed in neuronal responses and adaptations, circuits, and 
even hormonal regulators. It is our belief that, by understanding the regulation of behavior 
related to natural rewards such as the consumption of palatable foods, we may be able to 
discover novel therapeutic targets to approach addiction. I begin by describing the evidence for 
food-drug reward crosstalk (shared circuitries and shared pathologies). I finish by discussing 
some emerging evidence that therapies which control feeding and energy metabolism may be 
useful in treating drug addictions.  
Shared circuitries: Feeding is regulated at multiple levels within the CNS (Figure 8). The 
mesolimbic system is thought to control hedonic or non-homeostatic feeding. Hedonic feeding 
generally consists of consuming palatable, calorie-dense foods beyond satiation. Several lines 
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of evidence suggest that the mesolimbic DA system regulates hedonic feeding in ways 
reminiscent of the response to drugs of abuse and may act to suppress homeostatic circuitry 
(i.e. the hypothalamus and brainstem). As a first point in support of this notion, both palatable 
food and drugs of abuse elicit rapid firing by DA neurons and an immediate phasic elevation in 
DA within the NAc.139,198,199 Moreover, increases in DA are observed in anticipation of both 
palatable foods and previously used drugs of abuse,200,201 supporting the idea that accumbal DA 
is a common neurotransmitter mediator of reward and its anticipation for both stimuli. From 
Palmiter’s experiments deleting TH from midbrain DA neurons in mice, we also know that DA is 
essential for feeding.202  The exact role of the post-synaptic DA receptors is less clear. However, 
it is clear that DA receptors do regulate feeding to some degree. It has been shown that chronic 
D2 receptor blockade promotes obesity while D1 receptor blockade has no effect on feeding or 
body weight.203 On the other hand, D2 receptor overexpression increases seeking for a 
palatable food reward.122  
 Notably, in contrast to the literature on drugs of abuse, nigrostriatal and striatopallidal 
circuits – centered around the DS – have been somewhat more strongly implicated in regulating 
feeding behavior than the ventral striatum. In normal-weight humans, palatable food releases 
DA in the DS in proportion to ratings of meal pleasantness.204 In DA-deficient mice, restoration 
of DA signaling selectively to the DS, but not the NAc, rescues food intake as well as motivated 
feeding in an operant task.114,205-207 However, the NAc is likely still important for hedonic feeding 
as ablation of DA neurons projecting to the NAc does attenuate rats’ motivation to work for food 
rewards.208   
Shared pathologies in obesity and drug addiction: Like drug addiction, obesity is a serious public 
health issue which affects primarily developed nations. Obesity in the U.S. has ballooned to 
epidemic proportions, as rates of obesity have increased dramatically over the past 30 years. 
Today, approximately 1/3 of the adult U.S. population is considered obese with a body mass 
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index (BMI) of greater than 30.209 The causes of obesity are multifactorial, to be sure; however, 
it is believed that the recent rise of obesity can be attributed in large part to the availability of 
low-cost calorie-dense foods.210 These foods are highly palatable and, as described above, 
strongly activate the brain’s reward systems in a similar fashion to addictive drugs.211 
Importantly, obese individuals disproportionately consume high energy foods and exhibit 
enhanced motivation to work for rewarding food stimuli.212   
A great deal of literature has shown that obese individuals, like drug addicts, exhibit 
lower D2 receptor availability within the striatum, which is thought to contribute to compensatory 
overeating.213 Indeed, rats which were given extended access to a cafeteria diet gained 
substantial weight and expressed less D2 receptor in the DS.214 These authors further showed 
that the D2 receptor may play a causal role in this process as viral deletion of the D2 receptor 
from the DS made these rats resistant to palatable feeding inhibition by a punishment-paired 
conditioned stimulus. In further support of the notion of DA deficiency in obesity, human imaging 
studies have revealed elevated cue-induced DA elevations but decreased DA responses to 
actual food consumption in obese compared to lean individuals.215,216 Palatable food stimulation 
induces even greater increases in striatal DA release in individuals diagnosed with binge eating 
disorder, a psychiatric disorder that resembles “food addiction”.217  
Interestingly, extended access to palatable food and drugs of abuse, including cocaine 
and heroin, increase LH ICSS reward thresholds to a similar extent compared to chow-fed, drug 
naïve rats.218 This strongly supports shared pathological events within the reward system in 
response to both food and drugs that result in the escalation of ICSS.       
Therapies to control feeding may be useful in drug addictions1: The evidence described so far 
suggests that reward for food and drugs of abuse may possess overlapping substrates within 
                                                          
1
 The work presented in this section is adapted in part from Reddy, I.A., Stanwood, G.D. & Galli, A. Moving beyond energy 
homeostasis: new roles for glucagon-like peptide-1 in food and drug reward. Neurochemistry International 73, 49-55 (2014). 
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the CNS. But are food and drug reward regulated in the same way? If we attempt to target 
feeding behavior, will we also affect circuits regulating addiction? Here, I provide evidence that 
suggests that brain substrates of addiction are susceptible to many of the same components 
regulating feeding behavior. I take this one step further in suggesting that we can use emerging 
therapies to control appetite, body weight, and energy metabolism to treat elements of addictive 
behavior.  
The brain regulates homeostatic feeding behavior via the hypothalamus, hedonic 
feeding behavior through the brain’s reward system, top-down control of feeding through the 
PFC, and modulatory control via regions involved in learning, memory, and emotion (e.g. the 
hippocampus and amygdala) (Figure 8). The brain also receives feedback from peripheral 
hormones which signal the body’s nutritional state and energy supplies. These hormones are 
released from sites within the gut (stomach, pancreas, intestines, etc.) into the bloodstream 
where they circulate and bind to receptors in the periphery as well as the CNS (Figure 9). Some 
of these hormones function in the short-term regulation of feeding (i.e. during a meal) and 
include cholecystokinin (CCK), peptide YY (PYY), glucagon-like peptide 1 (GLP-1), and ghrelin, 
among others. Insulin and leptin regulate long-term feeding patterns and body weight.  
Feeding hormones and their receptors have been major targets for the development of 
drugs to combat obesity. Agonists at the GLP-1 receptor (GLP-1R), for example, have already 
been FDA approved for obesity as they reduce body weight, appetite, and feeding.219,220 
Additionally, bariatric surgeries, or weight loss surgeries, have been shown to substantially 
reduce body weight in patients and alter hormonal systems involved in feeding and 
metabolism.221 Importantly, evidence suggests that changes in hormonal signaling 
accompanying bariatric procedures may be responsible for some of their beneficial effects on 
body weight.221  
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Notably, the receptor targets for many of these hormones are not restricted to the 
homeostatic circuitry. Indeed, receptors for these hormones have been found in a number of 
subcortical regions including the VTA, NAc, LH, and LS.222-225 Hormone receptors have also 
been shown to be expressed on DA neurons.225,226 Their stimulation or inhibition can directly or 
indirectly regulate firing patterns of VTA DA neurons.226-233 Insulin has also been shown to affect 
trafficking and function of the DAT.227,234 Such anatomical and functional findings support 
behavioral studies showing that the acute administration of anorexigenic hormones (or their 
synthetic analogues) reduce the rewarding properties of palatable food as measured by CPP 
and operant tasks.235,236 Additionally, antagonists of the receptor for ghrelin (an orexigenic 
hormone) similarly reduce hedonic feeding behavior.237 Of note, several of these hormones 
have been injected directly into the VTA or NAc to generate a similar increase or attenuation in 
feeding.238,239 Thus it appears that hormones regulating feeding behavior and energy 
metabolism likely do so through homeostatic circuits as well as hedonic regulatory mechanisms. 
Hormone-induced reductions in rewarded feeding behavior prompted the hypothesis that 
such hormones might also modulate reward for drugs of abuse. This hypothesis has now been 
tested for a number of hormones. As will be discussed in great detail in the next section, GLP-1 
has been shown to reduce drug reward behaviors relevant to a number of different drugs of 
abuse.239 Ghrelin receptor antagonists appear to function in a similar fashion.237 Interestingly, 
studies have shown that endogenous ghrelin is necessary for alcohol reward.240 Insulin, as well, 
regulates the psychotropic effects of amphetamine and has been proposed to be required for 
normal reward for food.52,241-244  
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Figure 8. Levels of central regulation of food intake. Food intake is controlled by complex 
neuronal and hormonal systems. Homeostatic regulation of hunger is primarily regulated by the 
hypothalamus. Reward circuitry including the mesolimbic DA system is the major regulatory 
pathway for hedonic feeding and may have the ability to override the homeostatic regulation of 
feeding. Top-down regulation of feeding from the PFC allows us to make informed food choices. 
Additionally, memory, learning, and mood (regulated primarily by the hippocampus and 
amygdala) affect our feeding patterns. Circulating signals of energy availability regulate food 
intake via the hypothalamus, but also via some of these extra-hypothalamic regions.  
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Figure 9. Major routes for the regulation of feeding and energy balance. This schematic 
illustrates routes by which peripheral signals of feeding status and energy balance communicate 
with homeostatic and hedonic circuits within the brain. Certain areas of the brainstem (NTS), 
hypothalamus (VMH, ARH), as well as the VTA can receive direct inputs from circulating 
signaling factors, including hormones (insulin, leptin, ghrelin, PYY, GLP-1, etc.) as well as 
nutrients themselves (glucose, fatty acids, etc.). These factors are capable of crossing the blood 
brain barrier. Additionally, the brain can receive nervous information about feeding status and 
stomach stretch from the vagus nerve which connects the gut to the brainstem NTS. The NTS is 
a major integrator of peripheral feeding signals and can communicate with the hypothalamus, as 
well as extrahypothalamic regions. ARH, arcuate nucleus of the hypothalamus; DMH, 
dorsomedial nucleus of the hypothalamus; LHA, lateral hypothalamic area; PVH, paraventricular 
nucleus of the hypothalamus; VMH, ventromedial nucleus of the hypothalamus. Adapted from 
245. 
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Bariatric surgeries have also been shown to effectively reduce body weight and appetite 
in obese individuals. Patients who undergo the popular roux-en-Y gastric bypass (RYGB) lose 
significant weight, exhibit decreased appetite, and show greater interest in consuming low fat 
than high fat foods.246,247 Studies using rodent models suggest that bariatric surgeries may 
reduce appetite for palatable foods through altered food reward. Following RYGB, rats exhibit 
increased hedonic reactions to a sucrose solution along with reduced consumption of a high-fat 
diet.248 This same group also showed that RYGB rescues motivated feeding behavior in an 
operant task.249 Human functional magnetic resonance imaging (fMRI) studies before and after 
RYGB have also revealed reductions in mesolimbic pathway activation (including the VTA, 
ventral striatum, and dorsomedial PFC) following combined audio and visual energy-dense food 
cues.247 PET studies have also revealed alterations in D2 DA receptor availability and 
extracellular DA following RYGB.250,251 Indeed, Ochner and colleagues have suggested that 20–
45% of post-RYGB weight loss may be unexplained by change in stomach size and increases in 
metabolism.221 Furthermore, weight loss after RYGB may be enhanced by changes in food 
intake behaviors mediated by enteric hormones like GLP-1. This is physiologically plausible 
since RYGB increases both basal and postprandial GLP-1 levels252 and GLP-1 secretion is 
enhanced by faster delivery of food contents to the gut following the procedure.221,253-255 Notably, 
RYGB “good responders” (∼40% weight loss) secreted significantly more GLP-1 in response to 
a postoperative test meal than “poor responders” (<20% weight loss).254,256  
Interestingly, associations have also been made between bariatric surgery and alcohol 
use disorder (AUD). The literature on this subject is mixed in regards to whether bariatric 
surgery promotes or prevents the development of AUD.257-262 There have been two large clinical 
studies of AUD outcomes following RYGB. In one of these studies, 6,165 patients who had 
undergone RYGB surgery were assessed for alcohol intake approximately 6 months after 
surgery. On a 4 point scale, patients who had previously consumed alcohol “occasionally” or 
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“frequently” had significantly decreased their alcohol intake score as a group.262 No changes 
were noted in patients who had not used alcohol before surgery. This same publication also 
studied the effect of RYGB on alcohol consumption in rats selectively bred to consume ethanol. 
Before surgery, sham rats consumed comparable amounts of alcohol to RYGB rats. After 
surgery, the RYGB rats consumed significantly less alcohol than sham-operated rats. In the 
second large clinical study, past year AUD symptoms were assessed using the standard 
Alcohol Use Disorders Identification Test (AUDIT) in patients who had received one of several 
common bariatric surgery procedures (RYGB, laparoscopic adjustable gastric banding, sleeve 
gastrectomy, biliopancreatic diversion with duodenal switch, or banded gastric bypass).261 The 
prevalence of AUD symptoms did not significantly differ from 1 year before to 1 year after 
surgery but was significantly increased in the second postoperative year. Notably, this effect 
was associated with a number of preexisting or preoperative risk factors for the development of 
AUDs, including male sex, younger age, smoking, regular alcohol consumption, prior AUD, 
recreational drug use, and lower interpersonal support. Unfortunately, without a matched control 
group, it is difficult to determine whether these individuals would have been more likely to 
develop an AUD over time independent of their surgical status.  
Alterations in ethanol consumption following RYGB may have be related to changes in 
circulating hormone levels. Indeed, one study revealed that GLP-1 levels increased selectively 
in RYGB rats following oral ethanol gavage.262 Furthermore, intraperitoneal injection of a GLP-
1R agonist reduced ethanol consumption in sham rats but not in RYGB rats, presumably 
because endogenous GLP-1 levels are already elevated in RYGB rats and intake is already low. 
However, treatment with the GLP-1R-specific antagonist, exendin-(9-39) amide (Ex-9), did not 
modulate ethanol consumption in either RYGB or sham rats. The lack of response to a GLP-1R 
antagonist calls into question the hypothesis that elevated endogenous GLP-1 is responsible for 
the decrease in alcohol consumption observed following RYGB. Furthermore, the effect of 
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RYGB on alcohol consumption in rodent models appears to be inconsistent, as two other 
studies found the opposite effect.259,260 Still, these findings suggest potential avenues for future 
study. 
The mechanisms underlying alterations in feeding through targeting different hormonal 
systems are still being investigated. Likely, these hormones act on multiple peripheral and 
central systems to regulate feeding, metabolism, and energy expenditure. However, a common 
theme emerges from studies of these hormonal systems, which is that many of them regulate 
brain reward circuitries. This concept is explored through the original work presented within this 
dissertation.   
Glucagon-like peptide 1:  Here, I present a detailed background on GLP-1’s role in food and 
drug reward. As previously mentioned, GLP-1 is not the only hormone that bridges these two 
domains. However, it will serve as a detailed example and provide the necessary background to 
interpret the original work described within this dissertation.  
Numerous studies in animals and humans have established that GLP-1, a 36 amino acid 
incretin hormone and neuropeptide, acts through both peripheral and central mechanisms to 
regulate energy homeostasis and feeding behavior.263,264 Importantly, central GLP-1 signaling 
has been linked not only to the regulation of energy homeostasis, but also to non-homeostatic 
reinforcing and motivational processes associated with food reward.235,265 Most notably, it was 
recently demonstrated that targeted activation of mesolimbic GLP-1Rs decreases preference for 
palatable foods as well as the motivation to work for such foods.235,265,266 While the exact 
mechanisms underlying the regulation of food reward are still under investigation, these findings 
have inspired the hypothesis that central GLP-1R signaling plays an additional role in the 
hedonic response to drugs of abuse. Several recent behavioral studies in animals have 
provided strong support for this hypothesis. Here I examine the evidence that GLP-1R agonists 
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modulate the rewarding and reinforcing properties of palatable foods and drugs of abuse 
through the regulation of established brain reward circuitries. Furthermore, I discuss potential 
mechanisms of action, with an emphasis on the involvement of the neurotransmitter DA. 
Understanding the effects of GLP-1 on reward circuitries in the brain will allow us to better 
assess its utility as a pharmacotherapeutic for both obesity and substance use disorders. 
  GLP-1 is a peptide hormone produced by L-cells of the intestine in response to nutrient 
absorption within the gastrointestinal tract. While GLP-1’s peripheral effects are many, it is most 
well-known for its glucoregulatory properties.267 As an incretin, GLP-1 promotes glucose-
dependent insulin release by binding to receptors on pancreatic beta cells. The ability to 
potentiate insulin secretion has made long-lasting synthetic GLP-1R agonists powerful drugs for 
the treatment of type 2 diabetes and more recently, obesity.220 FDA-approved drugs in this class 
include exendin-4 (Ex-4) and liraglutide, which are resistant to degradation by the enzyme 
dipeptidyl peptidase-4 (DPP-4). Of interest, a percentage of obese diabetic patients taking these 
drugs lose weight, an effect that occurs primarily through reduced appetite and decreased food 
intake.267,268 
GLP-1 is also a neuropeptide produced by brainstem neurons in the nucleus of the 
tractus solitarius (NTS) which project widely to subcortical areas containing the GLP-1R.269,270 
The NTS, in turn, receives vagal afferents which provide information regarding taste and 
mechanical stretch of the gastrointestinal system.271 
Early studies established that GLP-1’s anorectic effect can be induced by direct central 
administration. GLP-1 reduces appetite and induces weight loss when administered to the 
cerebral ventricles of rats.264,272 Central infusion of GLP-1 also activates c-fos immunoreactivity 
in various nuclei of the brainstem and hypothalamus,273 and injection of GLP-1 directly into the 
paraventricular nucleus of the hypothalamus is sufficient to suppress feeding without inducing 
aversion.274  
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This early research focused on the effects of GLP-1 on the hypothalamus and 
brainstem, regions highly involved in homeostatic metabolic control.267,275 However, the 
homeostatic control of feeding does not fully account for GLP-1-mediated alterations in feeding 
behavior and food preference. For example, peripheral injection of GLP-1 long-lasting 
analogues in rodents reduces preference for sweets,276 while both peripheral and central 
infusions of GLP-1 analogues reduce motivation to work for food reward.235 These findings 
suggest that GLP-1 reduces food intake at least in part through the regulation of food reward in 
non-homeostatic circuits. In fact, various reports indicate that GLP-1Rs are expressed in 
components of the mesolimbic reward circuitry.277 Recently, research exploring the central 
modulation of food intake by GLP-1 has shifted away from homeostatic circuits and toward 
areas associated with reward, motivation, and stimulus salience. This shift in focus is timely, as 
obesity in the U.S. has reached epidemic proportions and homeostatic control is clearly 
insufficient to prevent excessive food intake. In environments in which high fat and sugary foods 
are readily available, brain reward systems may override homeostatic systems.233,243  
The GLP-1R appears to be expressed at low levels in the VTA and the NAc based upon 
autoradiographic binding studies and in situ hybridization; neural tracing also suggests that 
GLP-1-expressing neurons in the NTS project to these areas.265,266,269,270,277,278 Furthermore, 
exogenous intraperitoneal injection with the synthetic GLP-1 analogue, Ex-4, induces Fos 
activation in the NAc.277 The GLP-1R is also highly expressed in the LS, a region which may 
also play a role in modulating mesolimbic reward circuits.  
Direct injection of Ex-4 into the VTA or NAc core has been shown to reduce palatable 
food consumption. In one study, injection of subthreshold doses of Ex-4 into the VTA or NAc 
core, but not the NAc shell, of food-deprived rats resulted in a significant suppression of sucrose 
intake at multiple time points compared to vehicle-injected animals.265 Ex-4 also shifted their 
preference for high fat food to regular chow when injected into the VTA, NAc core, and NAc 
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shell, resulting in a reduced 24 h weight gain. Depending on the time of exposure and location 
of injection, the GLP-1R-specific antagonist, Ex-9,279 increased or had no effect on high fat diet 
intake. This suggests that endogenous GLP-1 signaling maintains a degree of control over food 
intake and preference. 
In another study, it was found that GLP-1 injected into the NAc core reduced 2h regular 
chow intake and induced c-fos expression relative to saline, but no effect was observed in the 
NAc shell. Again, Ex-9 had the opposite effect on chow intake.266 Finally, Ex-4 injected into the 
VTA, but not the NAc shell, reduced 24h chow intake, and the activation of GLP-1Rs in the VTA 
maintained a significant reduction in food intake even 24h after injection.235 The combined 
results of these important studies indicate that (1) the VTA and NAc core are important targets 
for GLP-1-mediated reduction in sucrose and high fat food preference, (2) the NAc shell is likely 
not an important site of action for GLP-1 in regard to food palatability, although it may still play a 
role in motivated behaviors,235 (3) endogenous GLP-1 signaling in mesolimbic reward areas 
may be important for controlling perceived food palatability, and (4) the effects of GLP-1R 
signaling on reward may be relatively long-lived (>24h). 
Motivation to obtain food is an important aspect of feeding behavior and is typically 
assessed through an operant learning paradigm called progressive ratio operant conditioning. In 
this task, the animal must press a lever progressively more times to receive consecutive 
rewards. This test has been used to assess motivational incentive following targeted injection of 
Ex-4 into the VTA or NAc.235 After VTA injection, Ex-4 reduced the number of sucrose rewards 
obtained in a dose responsive manner, but injection into the NAc only resulted in a reduction at 
the highest dose. The effect of Ex-4 on motivated feeding behavior was specific to the GLP-1R, 
as pretreatment of animals with Ex-9 abolished the suppressive effect of intraventricular Ex-4 on 
operant conditioning for sucrose reward. Interestingly, this study also considered the operant 
responsiveness of rats that were “high reward responders” (on vehicle condition, earned 6 or 
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more sucrose rewards in satiated state) versus “low reward responders” (earned 5 or fewer 
rewards). They found that the “high reward responders” earned fewer sucrose rewards when 
given Ex-4 in the VTA, while the “low reward responders” were unaffected. This suggests that 
some animals may be predisposed to the rewarding effects of food and that Ex-4 only 
attenuates motivated behavior in susceptible individuals. Furthermore, these data revealed that, 
at least at the doses used, Ex-4 was unable to reduce the number of rewards earned to the 
level of vehicle-treated animals in the “low responders” group. This finding is striking as it 
illuminates the intrinsic challenges to overcoming reward-seeking behavior in vulnerable 
individuals.280,281 
These collective findings point to a role for central signaling through the GLP-1R not only 
in reducing food intake and palatability, but also the motivation to work for food. It should be 
noted that no aversive behaviors were identified in the aforementioned studies,235,265,266 despite 
reports that aversion may partially account for a reduction in food intake.282 It may be that 
aversion to GLP-1 is mediated by specific brain regions implicated in aversive responses (e.g. 
the central nucleus of the amygdala).235,283 
Excitingly, it was recently discovered that pretreatment with Ex-4 attenuates 
amphetamine- and cocaine-induced locomotion, suggesting that GLP-1R signaling reduces 
extracellular DA in response to psychostimulants.284,285 Moreover, pretreatment with Ex-4 
attenuates the rewarding effects of amphetamine and cocaine in a CPP test,284,286 although 
preference for cocaine is not entirely abolished, suggesting that GLP-1R-independent 
components of cocaine reward exist.286 Ex-4 may possess therapeutic potential in regards to 
psychostimulant abuse as it has been shown to reduce cocaine self-administration in mice by 
reducing the dose-response curve.285 This suggests that the effect of GLP-1R stimulation 
cannot be overcome by administering higher doses of cocaine.  
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Interestingly, the ability of GLP-1R signaling to modulate the rewarding properties of 
drugs extends beyond psychostimulants. Similar effects have been observed for alcohol287,288 
and nicotine.289 Alcohol use disorders, like psychostimulant abuse, are characterized by 
compulsive use and seeking. Alcohol promotes the firing of DA neurons in the VTA by impairing 
GABAergic inhibitory tone. Egecioglu and colleagues found that low doses of intraperitoneal Ex-
4 attenuate alcohol-induced locomotor stimulation in rodents and reduce accumbal DA in 
vivo.287 They also found that Ex-4 reduced alcohol intake in a two-bottle choice model and 
impaired alcohol CPP under both acute and chronic treatment conditions. Finally, Ex-4 
diminished alcohol seeking in a progressive ratio operant conditioning paradigm, suggesting a 
role for Ex-4 in drug motivation. Interestingly, the rats did not exhibit any rebound increases in 
ethanol consumption 48h after Ex-4 administration, implying that withdrawal symptoms may be 
attenuated by Ex-4. A second group also found significant reductions in ethanol CPP and intake 
following peripheral Ex-4 administration.288 Of interest, this study noted that the increased 
ethanol intake of high consumers (top 30%) over low consumers was completely abolished by 
peripheral GLP-1 administration in a 1h intermittent access drinking paradigm. Furthermore, this 
study showed that targeted microinjection of GLP-1 and Ex-4 into the VTA could significantly 
reduce ethanol intake. This is so far the only direct evidence that the VTA is an important site of 
GLP-1R signaling action in drug reward. 
Evidence suggests that DAergic systems are affected by GLP-1R stimulation. Ex-4 
reduces amphetamine-, nicotine-, alcohol-, and cocaine-stimulated striatal DA by microdialysis 
following peripheral Ex-4 injection.284,285,287,289 In all cases, drugs were administered 
systemically; thus this result does not indicate whether this occurs as a direct result of striatal 
GLP-1R stimulation or at the circuit level. Additionally, the contribution of peripheral 
mechanisms cannot be ruled out. Additionally, it is also important to keep in mind that GLP-1 
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stimulates insulin release, which is known to regulate drug reward,52,234 and could potentially 
explain the reward attenuating effects of peripherally-administered GLP-1 and its analogues. 
Alterations in DA homeostasis within the mesolimbic reward system can be mediated by 
postsynaptic and presynaptic mechanisms in the VTA or NAc. Since GLP-1Rs are expressed at 
low levels within the VTA, GLP-1R signaling could alter firing rates of DA neurons, which would 
modulate DA release in the NAc and potentially other projection sites, including the amygdala 
and the PFC. Firing rates of DA cells are an important component of reward and stimulus 
saliency and can be influenced by hormonal signaling.229,233 Currently, we do not know if GLP-
1Rs are located on DA or GABA neurons in the VTA, but alterations in the firing properties of 
either neuronal type could influence DAergic output. Such a mechanism would be similar to that 
observed for the hormone leptin. Leptin significantly reduces DA neuronal firing rate within the 
VTA in vivo and in slice preparations,226 while central leptin infusion attenuates extracellular DA 
by microdialysis.231 An alternative (but not mutually exclusive) mechanism is that GLP-1 alters 
DA signaling and homeostasis directly within the NAc, or in regions that modulate mesolimbic 
output, such as the LS. Again, the existence of GLP-1Rs in the NAc and LS make this a 
plausible hypothesis, although we do not know whether GLP-1Rs are expressed pre- or 
postsynaptically. Presynaptic GLP-1R signaling within the NAc or LS might influence DA 
homeostasis by acting through the DAT. The DAT is normally responsible for clearing DA from 
the intrasynaptic space but its activity can be impaired by the actions of abused 
psychostimulants. It is important to note that other peripherally-generated hormones are 
capable of modulating DAT function. Insulin, for example, has been shown to regulate the 
effects of amphetamine by altering DAT surface expression and amphetamine-induced DA 
efflux in a PI3K-dependent manner.52,244,290 Furthermore, insulin attenuates amphetamine-
induced behaviors.291 This lends credibility to the hypothesis that similar mechanisms of hedonic 
regulation are employed by GLP-1R agonists.  
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In summary, GLP-1 and its analogues attenuate the rewarding properties of food, 
alcohol, nicotine, and psychostimulants in rodents. The literature reviewed herein suggests that 
GLP-1 regulates feeding behavior and drug abuse, in part, through DA circuits. Given that GLP-
1R agonists are already approved for the treatment of diabetes and obesity, barriers to their 
development to treat addiction are low.  
 
Unifying hypothesis 
The overarching hypothesis behind this work is that drugs of abuse, including cocaine, 
will be regulated by hormonal systems which evolved to regulate feeding and metabolism. Thus, 
hormones which reduce the intake of palatable foods will also impair cocaine reward. Moreover, 
manipulations which chronically alter hormonal systems and reduce feeding, such as bariatric 
surgery, will similarly reduce drug reward and provide a proof-of-concept that such chronic 
interventions might provide long-term regulation of reward-related DA homeostasis and reward 
behaviors.   
 
Specific aims 
The aims of this dissertation are as follows:  
1. To determine brain substrates of GLP-1R-mediated alterations in DA homeostasis and 
cocaine behaviors (chapter II). 
2. To determine alterations in striatal DA homeostasis following RYGB surgery (chapter III). 
3. To determine whether biliary diversion surgery alters cocaine-mediated behaviors and 
define novel hormonal targets for the treatment of addiction (chapter IV). 
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CHAPTER II 
 
GLUCAGON-LIKE PEPTIDE 1 RECEPTOR ACTIVATION REGULATES COCAINE ACTIONS 
AND DOPAMINE HOMEOSTASIS IN THE LATERAL SEPTUM BY DECREASING 
ARACHIDONIC ACID LEVELS2 
 
Preface 
Agonism of the GLP-1R has been effective at treating aspects of addictive behavior for a 
number of abused substances, including cocaine. However, the molecular mechanisms and 
brain circuits underlying the therapeutic effects of GLP-1R signaling on cocaine actions remain 
elusive. Recent evidence has revealed that endogenous signaling at the GLP-1R within the 
forebrain LS acts to reduce cocaine-induced locomotion and cocaine CPP, both considered DA-
associated behaviors. DA terminals project from the VTA to the LS and express the DAT. 
Cocaine acts by altering DA bioavailability by targeting the DAT. Therefore, GLP-1R signaling 
might exert effects on DAT to account for its regulation of cocaine-induced behaviors. We show 
that the GLP-1R is highly expressed within the LS. GLP-1, in LS slices, significantly enhances 
DAT surface expression and DAT function. Ex-4, a long-lasting synthetic analogue of GLP-1 
abolished cocaine-induced elevation of DA. Interestingly, acute administration of Ex-4 reduces 
septal expression of the retrograde messenger 2-AG as well as a product of its presynaptic 
degradation, AA. Notably, AA reduces septal DAT function pointing to AA as a novel regulator of 
central DA homeostasis. We further show that AA oxidation product γ-ketoaldehyde (γ-KA) 
forms adducts with the DAT and reduces DAT plasma membrane expression and function. 
These results support a mechanism in which post-synaptic septal GLP-1R activation regulates 
2-AG levels to alter presynaptic DA homeostasis and cocaine actions through AA.  
                                                          
2
 The work presented in this section is adapted from Reddy, I.A., Pino, J.A., et al. Glucagon-like peptide 1 receptor activation 
regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. Translational 
Psychiatry (In Press).  
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Introduction 
Cocaine addiction is a highly prevalent disorder characterized by continued drug use in 
spite of negative consequences. Despite the harmful effects of cocaine, the development of 
pharmacotherapies to treat cocaine addiction has been slow. This is because modulators of 
addictive behavior are limited and we lack a comprehensive understanding of their mechanisms. 
Starting with the discovery that GLP-1 regulates amphetamine-induced locomotion,292 GLP-1R 
agonism has been shown to reduce the rewarding properties of cocaine and other drugs of 
abuse in rodents.239,285,293 
GLP-1 is both a hormone produced by L cells of the intestine and a neuropeptide 
produced by the NTS.265,267 Notably, GLP-1 synthetic analogues are already approved to treat 
type 2 diabetes and obesity in humans.294,295 These synthetic derivatives have a greatly 
extended half-life over endogenous GLP-1.267,294 As such, they remain in circulation long 
enough to cross the blood-brain barrier.296 The importance of the brain bioavailability of GLP-1 
analogues is underscored by the prominent expression of the GLP-1R within the brain.269 Ex-4 
is one such synthetic GLP-1 analogue that has been used extensively to demonstrate that GLP-
1R activation reduces the preference and actions of cocaine, amphetamine, alcohol, and 
nicotine.235,239,284,286-289,292,297 Importantly, the GLP-1R 168Ser allele has been associated with 
increased measures of alcohol self-administration in humans.297 These data suggest that GLP-
1R signaling might regulate common mechanisms within the brain’s reward system. 
The neurotransmitter DA underlies the rewarding properties of drugs of abuse, as well 
as natural rewards.199 It is released at DA terminals during drug intake and in anticipation of the 
consumption of drugs.110,199 We therefore hypothesized that the effects of GLP-1R stimulation 
on cocaine reward would occur at DA nodes exhibiting GLP-1R signaling. One such node is 
found within the forebrain LS. The LS possesses a high concentration of GLP-1Rs and contains 
DA projections.269 Additionally, the LS has historically been linked to reward; it was identified by 
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Olds and Milner (1954) as a potent site of electrical self-stimulation in rats.81 Since then, several 
studies have found that the LS is fundamental to the rewarding properties of drugs of 
abuse.130,134,135,293 Most notably, the Aston-Jones group has found that the LS is an important 
relay center between the hippocampus and the VTA for information about cocaine-context 
associations and that the LS is necessary for the formation of cocaine CPP. 134,135 
Recently, Harasta et al. (2015) found that endogenous signaling through the GLP-1R in 
the LS acts to dampen cocaine-induced locomotion and cocaine CPP, both considered DA-
associated behaviors.293 In the current study, we sought to determine the mechanism by which 
GLP-1R stimulation modulates septal DA homeostasis and the actions of cocaine. Cocaine 
blocks DA reuptake via the DAT, resulting in high levels of synaptic DA. Here we demonstrate 
that GLP-1R stimulation inhibits the ability of cocaine to increase extracellular DA levels. This 
phenomenon is associated with increased DAT surface expression and function mediated by a 
reduction in endocannabinoid and AA levels in the LS. These findings reveal a novel 
mechanism of GLP-1R action in brain and provide a more comprehensive understanding of how 
emerging GLP-1R-targeted therapies affect signaling in the brain.  
 
Methods 
Animals. Male NMRI mice (Taconic, Denmark) were used for microdialysis and c-fos 
experiments.285 Sprague-Dawley rats, weighing 320-345g, were also used for the study 
(Taconic, Lille Skensved, Denmark). All other in vivo experiments used adult male C57BL/6 
mice from Jackson Laboratories or bred internally at Vanderbilt University. All animals were kept 
at room temperature in a 12h light/dark cycle with free access to food and water. All 
experiments were performed during the light cycle. All experiments were in accordance with 
directives of “Principles of Laboratory Animal Care” (NIH publication No.85-23) and approved by 
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either the Danish Experimental Animal Inspectorate and the council of the European 
Communities or the Vanderbilt Institutional Animal Care and Use Committee.  
Drugs and Materials. For in vivo studies Ex-4 was purchased either from Tocris Bioscience, UK 
or from Prospec, Israel. DA used as standards for HPLC was obtained from Sigma (St. Louis, 
MO, USA). Acetonitrile was chromatography grade (Merck, Darmstadt, Germany). All other 
chemicals used for microdialysis/HPLC (Merck or Fluka Chemie AG, Buchs, Switzerland) were 
of analytical grade or better and were used as supplied. GLP-1(7-36)-amide was purchased 
from Phoenix Pharmaceuticals (Burlingame, CA, USA) and Ex-9 was purchased from American 
Peptide Company (Sunnyvale, CA, USA) and was dissolved in artificial cerebrospinal fluid 
(aCSF) on the day of the experiment. Radiolabeled DA, [3H]-DA (3.4-[7-
3H]dihydroxyphenylethylamine), was supplied by PerkinElmer Life Sciences (Waltham, MA, 
USA), and cold DA was obtained from Calbiochem (La Jolla, CA, USA). For in vitro 
experiments, AA, goat anti-γ-ketoaldehyde adduct (neuroketals antibody, C-17, sc-130089), and 
peroxidase (HRP)-goat anti-rat IgG (sc-2006) were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). The rat anti-DAT (MAB369) antibody was obtained from Chemicon 
(Temecula, CA, USA). Bicinchoninic acid, sulfo-NHS-LC-LC-biotin, NeutrAvidin®-Agarose resin, 
HRP-rabbit anti-goat IgG (31402) and HRP-goat anti-rabbit IgG (31460) were obtained from 
Pierce (Rockford, IL, USA). Protein A and protein G Sepharose beads were obtained from GE 
Healthcare (Little Chalfont, UK). Lipofectamine® 2000 and 2.7-dihydrodichlorofluorescein 
diacetate (H2DCFDA) were obtained from Invitrogen (Carlsbad, CA, USA). Salicylamine was 
obtained from Matrix Scientific (Columbia, SC, USA). Anti-dsRed was obtained from Clontech 
Laboratories (632496, Mountain View, CA, USA). Synthetic γ-ketoaldehydes were generously 
provided by Dr. Sean Davies (Vanderbilt University, USA).1 AA used in ex vivo experiments, and 
all other chemicals used in this study were obtained from Sigma-Aldrich Chemical Co (St. Louis, 
MO, USA).  
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Generation of BAC transgenic mice: BAC transgenic mice were created by the Vanderbilt 
Transgenic and Embryonic Stem Cell Core as previously described2 using a BAC clone 
containing the Glp1r gene (34.6 kb), which was flanked by 6 exons of the Dnahc8 gene (27 kb) 
and the first two exons of the Umod1 gene (18 kb) at the 5’ and 3’ ends, respectively; this clone 
was transferred into SW105 cells. An FRT-flanked antibiotic (Kan/Neo) cassette, containing a 
DNA fragment of an mApple fluorescent reporter was electroporated into the normal ATG start 
codon of the Glp1r gene within the BAC clone. Antibiotic-resistant colonies with the correct 
insertion were selected, and the FRT-flanked cassettes were removed via bacterial FLP 
recombination. The final BAC vector construction was confirmed by sequencing of all 
recombination junctions and by pulsed-field and standard fingerprint gels to correspond with 
predicted restriction digests. Validated vectors were injected into B6D2 embryos via pronuclear 
DNA microinjection. Embryos were injected into pseudopregnant B6D2 F1 hybrid females 
(B6D2F1/J; Jackson Laboratories, Bar Harbor, ME). Genotypes were determined via PCR and 
fidelity of transgene expression in the CNS was determined by combined immunohistochemistry 
and ISH. 
Combined immunohistochemistry and ISH validation of GLP-1R BAC transgenic mouse. To 
eliminate the possibility of aberrant mApple expression in our GLP-1R BAC transgenic mouse, 
we tested for co-localization of the mApple protein with GLP-1R mRNA. To accomplish this, we 
obtained brain sections from these mice from cortex through midbrain. Mice were deeply 
anesthetized with Nembutal sodium (120mg/kg; Akorn, Inc., Lake Forest, IL, USA) and 
transcardially perfused with RNAse-free PBS followed by RNAse-free paraformaldehyde (PFA). 
Brains were extracted, post-fixed for approximately 2h in 4% paraformaldehyde (PFA), 
cryoprotected overnight in 30% sucrose, and sectioned by microtome (60 µm). Sections were 
preserved in sucrose at -20°C until use. Selected sections were then processed through an ISH 
assay (RNAscope kit) followed by IHC. All probes, protocols, and RNAscope kit were generated 
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by and obtained from Advanced Cell Diagnostics (Hayward, CA, USA). Following the RNAscope 
assay, sections underwent IHC. Sections were blocked for 15 minutes in 0.1M PB containing 
2% goat serum and 0.1% triton-X then incubated in 1% sodium borohydride in 0.1M PB for 
30sec. Sections were washed and placed in primary antibody. Cells expressing mApple were 
identified with rabbit anti-dsRed (1:1000) and HRP-conjugated goat anti-rabbit (1:200, Perkin 
Elmer, NEF812001EA), and visualized by immunofluorescence with fluorescein-Cy3 
amplification to produce green fluorescence (Perkin Elmer, NEL704A001K). Sections were 
imaged with a confocal microscope (Zeiss LSM 510 Meta).  
Immunohistochemistry for DAT and mApple. Brains from GLP-1R BAC transgenic mice were 
extracted, post-fixed overnight in PFA and sectioned by vibratome (75μm). Sections were 
immunostained and imaged as described for IHC above. Cells expressing mApple were 
identified with rabbit anti-dsRed (1:1000) and HRP-conjugated goat anti-rabbit secondary 
(1:200, Perkin Elmer, NEF812001EA). DAT was identified by staining with anti-DAT (MAB369, 
1:1000) and goat anti-rat secondary (1:5000, Santa Cruz Biotechnology).  
High speed chronoamperometry. Slices containing LS (300µm) were prepared and 
chronoamperometry performed as previously described.298 High KCl aCSF (with 30mM KCl, 
97.5mM NaCl) was applied to the bath for 2 minutes to induce DA release. The oxidative signal 
measured in the slices is attributable to DA as the reduction/oxidation charge ratio is in the 
range 0.6-1.0. 
c-fos expression. The procedure for c-fos IHC is as previously described.299 Briefly, coronal 
brain sections (15μm) were cut through septum using a cryostat. Synthetic oligonucleotide DNA 
probes (DNATechnology, Aarhus, Denmark) were used for visualization of c-fos mRNA by 
autoradiography. The probe sequence was:  5′-CGG-GCA-GTG-GCA-CGT-CTG-GAT-GCC- 
GGC-TGC-CTT-GCC-TTC-TCT-GAC-TGC-3′. 
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In vivo microdialysis in mice. Microdialysis was performed as described previously285 with few 
modifications. The dialysis probe was positioned in LS, AP: 0.5mm, ML: 0.3mm relative to the 
bregma and DV: -2.2mm relative to skull surface.300 The microdialysis probe was perfused at a 
rate of 0.9l/minute with aCSF. The first two 30 minute samples were discarded to obtain stable 
basal values. Hereafter, 30 minute fractions were collected to establish baseline DA levels. 
Subsequently, mice were injected with Ex-4 or vehicle, and three 30min fractions were 
collected. Mice were then subject to local perfusion with cocaine (50M) for 30 minute and five 
30 minute fractions were collected. All fractions were assayed immediately after collection using 
HPLC with electrochemical detection.301  
In vivo microdialysis in rats. Rats were placed in a stereotaxic instrument under servoflurane 
anesthesia (2%) in a mixture of 20% CO2 and 80% oxygen. The anesthesia was maintained 
during surgery and experiment. A small hole was drilled bilaterally to allow probes to be placed 
into right and left LS. Probes (CMA/12, 2mm from CMA/Microdialysis AB, Stockholm, Sweden) 
were gently placed at the following coordinates in mm: AP:+1.0 ML:+ or- 0.4 and DV:-6.2 
(relative to bregma). Rats were habituated 2h before the microdialysis sampling. Sampling (flow 
rate=0.9µl/minute) was at 20 minute intervals for 60 minutes (three fractions) prior to the 
intervention. After the seventh fraction was collected (10 total fractions), the rats were sacrificed 
by rapid decapitation. The brain was extracted and sliced to verify the probe location. Only 
results from rats with probes verified in the LS are reported here. Ex-4 (local or i.p.) or cocaine 
(50µM local) were administered. Local Ex-4 was administered via a plastic-one cannula glue to 
the microdialysis probe, and cocaine was perfused via the 2mm microdialysis probe 
(0.9µl/minute for 20 minutes). All compounds were dissolved in Ringer. 
Ex vivo slice protein biotinylation assay. The procedure for biotinylation of live brain slices has 
been validated and was performed at 28°C as described previously.302  
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Ex vivo slice [3H]DA transport assay. Slices were obtained as described above and allowed to 
recover (≥1h at 28°C) with continuous oxygenation. Following recovery, slices were treated with 
drug (i.e. GLP-1) for 10 minutes followed by application of 50nM [3H]DA for 10 minutes with drug 
still present at 28°C. When Ex-9 was used, slices were pretreated with Ex-9 for 10 minutes prior 
to addition of drug/vehicle. Total protein was taken, and the samples were processed for protein 
concentration using a Bio-Rad protein assay and spectrometry at 595nm. Equivalent volumes of 
sample were added to 3mL of scintillation fluid (Ecoscint H, National Diagnostics, Atlanta, GA, 
USA) and radioactive counts were measured by scintillation counter. [3H]DA was divided by 
protein and normalized to average control uptake from paired vehicle-treated slices from the 
same animal. The uptake protocol and DAT specificity were validated in slices treated with DAT 
blocker GBR-12909 (Sigma-Aldrich), which blocked uptake in LS by 58.2% (t(5)=11.97; 
p<0.0001 by Student’s t test; n=6).  
2-AG and AA measurements. Mice were injected with Ex-4 or vehicle (i.p.) 30 minutes prior to 
sacrifice. Mice were rapidly decapitated and brains were obtained and blocked to obtain DS and 
LS punches. Punches were quickly placed into Eppendorf tubes on dry ice and stored at -80°C 
until use. Samples were homogenized in methanol and centrifuged; water was added to the 
supernatant for a final ratio of 70:30 Methanol:Water. LC/MS was performed as previously 
described.303 Following LC/MS, excess methanol was suctioned off the pellets. Pellets were 
resuspended and processed for protein concentration using a Bio-Rad protein assay and 
spectrometry at 595nm. 
Cell culture. Rat pheochromocytoma cells (PC12) were obtained from the American Type 
Culture Collection (Manassas, VA), and were cultured in DMEM supplemented with 6% fetal 
bovine serum (heat inactivated), 6% horse serum (heat inactivated), 1mM glutamine, 100U/ml 
penicillin and 100μg/mL streptomycin at 37°C in a humidified 5% CO2 incubator.
304 PC12 cells 
overexpressing human DAT fused to GFP (hDAT cells) were stably transfected with the plasmid 
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peGFP-C2-hDAT using Lipofectamine® 2000 and were cultured under the same conditions. 
Krebs-Henseleit (KH) buffer was used (144mM NaCl, 4.2mM KCl, 1.6mM MgCl2, 1.6mM 
KH2PO4, 10mM HEPES, pH7.4) and Fe
+3(197μM)/ascorbate(19.7mM) solutions were prepared 
in KH buffer. In some cases, salicylamine, a γ-KA scavenger, was added to the culture media 
and preincubated with the cells for 1h at 37ºC prior to further treatments. Cell viability was 
measured using trypan blue staining. 
Reactive oxygen/nitrogen species (ROS/RNS) measurements. In order to obtain the necessary 
conditions to induce γ-KAs formation from lipid peroxidation of AA, oxidative stress was 
promoted in hDAT cells. ROS/RNS formation in hDAT cells was measured using the 
fluorescence of H2DCFDA according to previous reports from our laboratory.
3  
PC12 Transport assays. DAT-mediated uptake of DA in PC12 cells overexpressing a GFP-
tagged DAT (hDAT) has been described previously.305  
Cell surface biotinylation in hDAT cells. Cell surface biotinylation was performed as described 
by Egaña et al. (2009) with some modifications.305  
Immunoprecipitations. Immunoprecipitations were performed using 1mg total protein. To 
immunoprecipitate DAT-GFP, cell homogenates were incubated overnight at 4°C with a 
monoclonal anti-GFP antibody (G-6539, 1:100), followed by the addition of 50μl of a mixture of 
protein A and protein G Sepharose beads (2h at 4°C in rotatory shaker). Immunoprecipitated 
proteins were recovered by centrifugation at 14.000xg for 2 minutes (4°C), washed with ice-cold 
buffer D, and resuspended in protein sample buffer containing βME. Proteins were separated by 
SDS-PAGE and transferred to PVDF membranes before incubation with an antibody against γ-
KA-lysil adduct (neuroketals antibody, C-17, 1:400) and anti-DAT (MAB369, 1:1000).  
Analyses. Data are presented as means ± standard error of the mean (SEM). Data were 
examined with Student’s t test for comparisons of only two data sets and one-way or two-way 
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ANOVA for comparisons of multiple groups, followed by Tukey’s- or Bonferroni-corrected 
comparisons. In ex vivo [3H]DA uptake experiments, samples with low protein content 
(<6µg/mL) were excluded from analysis (n=1). Optical density of bands was determined using 
Image J software. Statistical analysis was performed with GraphPad Prism software, version 
5.02 (GraphPad Software, San Diego, CA, USA). A p-value <0.05 defined statistical 
significance. 
 
Results 
GLP-1R expressing neurons are juxtaposed to DA terminals in the LS 
The GLP-1R is highly expressed within the LS,269 a brain region in which DAT-
expressing DA terminals reside.306 Here we first describe their proximity and anatomical 
distribution in this region (Figure 10). To this end, we generated a transgenic mouse expressing 
a bacterial artificial chromosome (BAC) for the protein mApple under the control of the promoter 
for the GLP-1R.  mApple signal was amplified by immunostaining (Figure 10A, C, D, and F) and 
DAT was labeled in parallel (Figure 10B, C, E, and F). Within the rostral LS (Figure 10A-C), DA 
terminals are found medially in the intermediate LS subregion (LSi), directly adjacent to GLP-
1R-expressing cells found mostly in the dorsal LSi. We observed visible overlap between these 
cell bodies/projections and DA terminals. Within the caudal LS (Figure 10D-F), there is similar 
evidence for this anatomical overlap. The DA terminals are labeled as two strips extending 
dorsomedially to ventrolaterally in the LSi. The GLP-1R-expressing cells are also found in the 
caudal LSi, but the cell bodies additionally extend further into the more medial laterodorsal 
tegmental area (Ld). Importantly, we show that DA terminals within this region release DA: 
superfusing LS slices with an artificial cerebrospinal (ACSF) solution containing high [K+] causes 
DA release as recorded by high-speed chronoamperometry (Figure 10G; approximate electrode 
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placement is denoted by * in Figure 10F). The use of mApple for identifying GLP-1R-expressing 
neurons was validated by in situ hybridization (ISH; Figure 11).  
Systemic administration of a GLP-1R agonist reduces cocaine-induced DA elevation and cfos 
expression in the LS 
We next tested whether a therapeutically relevant administration (i.e. systemic 
administration) of Ex-4 was capable of altering neuronal activity in the LS. We first evaluated the 
effect of Ex-4 on the activation of septal neurons by measuring c-fos expression. Ex-4 
administration (i.p.) 30 minutes prior to sacrifice decreased basal c-fos gene expression by ISH 
relative to vehicle-treated mice (Figure 10H and I). This result indicates that systemic 
administration of Ex-4 alters neuronal activity in the LS. 
The psychogenic and addictive properties of cocaine are mediated, at least in part, 
through the blockade of DAT-mediated DA reuptake and an increase in extracellular DA.66,307 
Therefore, signaling pathways able to modulate or diminish this DA increase offer enormous 
therapeutic potential. We determined the effect of systemic Ex-4 on local cocaine-induced 
changes in DA homeostasis in vivo within the LS, as measured by microdialysis in freely moving 
mice. Perfusion of cocaine through the microdialysis probe increased septal DA ~5-fold (Figure 
10J; F(9,49)=2.73, p=0.014 by ANOVA). Systemic pretreatment with Ex-4 (i.p.) 90 minutes prior 
impaired cocaine’s ability to significantly increase extracellular DA. These results were 
paralleled in rats (Figure 12A), demonstrating across species that GLP-1R activation diminishes 
cocaine’s ability to increase extracellular DA in the LS.  
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Figure 10. The GLP-1R is highly expressed in LS where GLP-1R agonists block cocaine-
induced DA in vivo. (A-C) Cells expressing the GLP-1R (white in A, red in C) and terminals 
expressing DAT (white in B, green in C) in rostral LS (GLP-1R in A, DAT in B, merge in C). 
Confocal images in z stack through 13 planes taken with a 10X objective. (D-F) Cells 
expressing the GLP-1R (white in D, red in F) and terminals expressing DAT (white in E, green in 
F) in caudal LS (GLP-1R in D, DAT in E, merge in F). Confocal images in z stack through 14 
planes taken with a 10X objective. (G) DA release induced by 30mM KCl (representative of n=3) 
in section from the caudal LS. Approximate site of recording is demarcated by * in F. 
Ld=laterodorsal tegmental nucleus; LSd=dorsal LS; LSi=intermediate LS; LSv=ventral LS; 
MS=medial septum; SHi=septohippocampal nucleus. Dotted lines delineate region 
boundaries.300 Scale bars=100µm. (H) Representative cfos expression in the LS 30 minutes 
following vehicle (top) or Ex-4 (30µg/kg, i.p., bottom) injection. Dotted box includes the LS. (I) 
Quantification of optical density analysis of cfos autoradiographs in LS (t(14)=3.26; **p<0.01 by 
Student’s t test; n=8). (J) Cocaine (50µM) greatly increased septal DA levels in mice pretreated 
with saline (i.p., solid circles). This cocaine-induced DA increase is significantly diminished in 
mice pretreated with Ex-4 (1µg/kg i.p., solid triangles; 30µg/kg i.p., solid squares). Extracellular 
concentrations of DA are expressed as the percentage of basal levels in two fractions collected 
before the intervention; significant ANOVA. Open symbols indicates significance by post hoc 
test where p<0.001 at 150 minutes and p<0.05 at 120 minutes; n=5-6 per group.  
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Figure 11. GLP-1R mRNA and mApple reporter are highly co-expressed in the LS of GLP-1R 
BAC reporter mice. Mice expressing mApple protein under the GLP-1R promoter (A, green) 
express GLP-1R mRNA (B, white) mApple in the same cell bodies (C, merge). Confocal images 
of a z stack through 23 planes of view taken with a 40X objective. The scale bar in C represents 
25 μm.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Extracellular concentrations of DA measured by microdialysis in the LS in 
anesthetized rats following systemic or local septal application of vehicle or Ex-4 concurrent with 
local cocaine perfusion. (A) Effect of Ex4 0.01µg/kg i.p (solid triangles),  Ex4 1µg/kg i.p. (solid 
squares), and cocaine alone (solid circles, 50µM, 0.9µl/minute in 20 minute). Extracellular 
concentrations of DA are expressed as the percentage of basal levels in three fractions 
collected before the intervention. Significant two-way ANOVA. Open symbols indicate 
significance by post hoc test (p<0.001 for all open symbols compared to cocaine + ringer, n=4). 
(B) Effect of Ex4 0.01µg/µL (solid triangles), cocaine 50µM alone (solid circles). Extracellular 
concentrations of DA are expressed as the percentage of basal levels in three fractions 
collected before the intervention. Significant two-way ANOVA. Open symbols indicate 
significance by post hoc test (p<0.001 at time 20 and 40, p<0.05 at time 60, and p<0.01 at time 
80, n=4-5).   
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Local GLP-1R signaling blocks cocaine-induced elevation in DA, promotes septal DAT 
membrane expression, and increases DA uptake 
We next sought to determine whether local GLP-1R activation could account for 
observed systemic effects of Ex-4 on the LS. Ex-4 or vehicle was perfused through the 
microdialysis probe concurrently with cocaine (Figure 12B). Local administration of Ex-4 
impaired the ability of cocaine to increase extracellular DA levels. This finding further highlights 
the role of septal GLP-1Rs in modulating cocaine’s ability to enhance DA function.  
Multiple mechanisms could explain how local GLP-1R signaling impairs cocaine-induced 
increases in extracellular DA in the LS. However, DAT-mediated DA reuptake is the primary 
mechanism regulating extracellular DA levels,65 a process dynamically regulated by DAT 
plasma membrane expression.241,244,308-310 Notably, DAT expression is inversely proportional to 
the ability of cocaine to cause its behavioural effects.68,69 Therefore, we hypothesized that GLP-
1R signaling regulates DA homeostasis in the LS, as well as cocaine’s ability to increase 
extracellular DA, by controlling DAT surface expression. In support of this mechanism, GLP-1 
application increased surface levels of DAT as measured by LS slice biotinylation311 (Figure 
13A and B). In order to determine whether the elevation of DAT surface expression translated to 
functional changes in DAT activity, we measured uptake of [3H]DA in septal slices treated with 
GLP-1. GLP-1 significantly increased DA uptake (Figure 13C). This increase was specific to 
GLP-1R signaling, as demonstrated by its blockade by the selective GLP-1R antagonist, 
exendin-(9-39)-amide (Ex-9; Figure 13D).279 Ex-9 alone had no significant effect (91% ± 13%; 
t(3)=0.6749; p=0.55 by Student’s t test; n=4). These studies were performed in slices in which 
only the local circuits are intact; therefore, we can assume that our observations were the result 
of local GLP-1R stimulation and not the result of feed-forward circuit-level changes. Together, 
these data demonstrate that GLP-1R signaling increases both DAT expression at the plasma 
membrane and DA uptake, suggesting that GLP-1R signaling might regulate cocaine actions in 
the LS through DAT-dependent mechanisms.  
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Ex-4 reduces levels of the retrograde messenger, 2-AG, and lowers levels of AA in the LS 
Our findings thus far suggest that septal GLP-1R agonism affects DAT expression and 
function locally. However, the GLP-1R is predominantly expressed postsynaptically (Fig. 10 and 
11), while the DAT is located on presynaptic DA terminals (Figure 10). This raised the possibility 
that GLP-1R signaling regulates DAT function through a retrograde signal. 2-AG is a well-
established endogenous cannabinoid retrograde messenger whose signaling has been shown 
to modify reward and feeding.229,312-314 Of note, cannabinoid CB1R antagonists, which decrease 
2-AG signaling, have been shown to decrease cocaine reward.315 2-AG is synthesized post-
synaptically, but degraded into free AA in presynaptic axon terminals. Indeed, 2-AG hydrolysis 
via MAGL is the primary mechanism for free AA generation in the CNS.316 Importantly, AA 
impairs DAT-mediated DA uptake.55,317,318 Thus we sought to determine whether GLP-1R 
activation modulates 2-AG-AA signaling. To this end, mice were injected with Ex-4 (i.p.) 30 
minutes prior to sacrifice, and the LS was punched and analyzed by mass spectrometry for 2-
AG and free AA levels.316 We found that Ex-4 significantly reduced both 2-AG and AA levels in 
the LS (Figure 14A and B), pointing towards reduced endocannabinoid metabolism in the LS. 
This phenomenon was not observed in the DS, where DAT is expressed in high quantities but 
GLP-1R-expressing cells are only sparsely distributed (Figure 15). These data demonstrate 
region-specific regulation by GLP-1R signaling of 2-AG levels and its metabolism.  
AA reduces DA uptake and DAT surface expression 
 Among its functions as a signaling molecule, AA has been previously shown to impair 
DAT-mediated DA uptake.55,317,318 Consistent with findings from heterologous cell lines and 
striatal synaptosomes55,317,318 we first demonstrated that AA application to LS slices significantly 
reduced DA uptake (Figure 14C).  
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Figure 13. Local activation of the GLP-1R promotes septal DAT membrane expression and 
[3H]DA uptake. (A) Representative immunoblot of surface and total DAT following slice 
treatment with vehicle (aCSF) or 1nM GLP-1. (B) Ratio of DAT surface expression in GLP-1-
treated ex vivo septal slices as percentage of average vehicle values (t(3)=10.12; **p<0.01 by 
Student’s t test; n=4). Slices were treated with 1nM GLP-1 for 20 minutes. (C) [3H]DA uptake in 
the LS from ex vivo slice preparation following 20 minute treatment with vehicle (aCSF) or 10nM 
GLP-1. Uptake was significantly elevated (t(4)=2.35; *p<0.05 by Student’s t test; n=5). (D) 
Pretreatment with 100nM Ex-9 for 10 minute blocks the increase in [3H]DA uptake following 
treatment with 10nM GLP-1 (t(3)=1.047; p=0.19 by Student’s t test; n=4).  
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Figure 14. Treatment of mice with Ex-4 reduces septal AA levels and AA is a strong modulator 
of DAT function in LS. (A) Ex-4 (2.4µg/kg, i.p.) administered in vivo 30 minutes prior to sacrifice 
resulted in lower levels of septal 2-AG (t(11)=2.62; *p<0.05 by Student’s t test; n=6-7). (B) Ex-4 
(2.4µg/kg, i.p.) administered 30 minutes prior to sacrifice reduces levels of septal AA 
(t(10)=5.018; ***p<0.001 by Student’s t test; n=6). (C) 80µM AA applied for 20 minutes to slices 
containing the LS reduces [3H]DA uptake to 42% of vehicle- (DMSO) treated slices (t(3)=2.59; 
*p<0.05 by Student’s t test; n=4). (D) [3H]DA uptake kinetics in hDAT cells treated either with 
vehicle (open circles) or Fe+3/Asc (open triangles), or with 40μM AA for 1h at 37°C in absence 
(gray squares) or presence of Fe+3/Asc (gray triangles). The kinetic parameters (E) Vmax and 
(F) Km were obtained from the Michaelis-Menten fit to the influx of [3H]DA. Each value 
represents mean ±S.E.M. of ≥three independent experiments. *p<0.05, ****p<0.001, ##p<0.01, 
and && p<0.01 indicate significant differences between Veh and AA, Veh and Fe+3/Asc+AA, AA 
and Fe+3/Asc+AA, and Fe+3/Asc and Fe+3/Asc+AA, respectively. Significant ANOVA followed by 
post hoc tests. 
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Figure 15. Ex-4 does not alter levels of 2-AG or AA in the DS. (A) Cells expressing the GLP-1R 
(white) are found at low levels in the DS, while the DAT is highly expressed (not shown). Confocal 
images of z stack through 13 planes taken with a 10X objective. (B) Ex-4 (2.4µg/kg, i.p.) 
administered 30 minutes prior to sacrifice does not alter 2-AG levels in the DS (t(12)=0.29; p=0.78 
by Student’s t test; n=5-9). (C) Ex-4 (2.4µg/kg, i.p.) administered 30 minutes prior to sacrifice does 
not alter DS AA content (t(12)=1.33; p=0.21 by Student’s t test; n=5-9). 
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While we have established that AA inhibits DAT function in the LS, the mechanism(s) 
responsible for this effect are unknown. To define these molecular mechanisms we adopted 
PC12 cells stably transfected with the human DAT (hDAT cells). PC12 cells contain vesicles 
capable of neurotransmitter release.319 These vesicles hold catecholamines (mostly DA) and as 
such they were suitable for our molecular studies. Incubation of hDAT cells with AA alone 
decreased DAT maximal velocity (Vmax) to 69% of control condition (Figure 14D and E). 
Notably, psychostimulants are known to induce oxidative stress,320-322 while GLP-1R signaling, 
which reduces AA levels, is known to reduce it.323 Thus we further explored mechanistically the 
interplay between oxidative stress and AA levels in terms of DAT function. Here, we treated 
hDAT cells with AA along with an oxidizing solution containing Fe+3 (197μM) plus ascorbate 
(19.7mM, Fe+3/Asc) (Figure 14D-F). Importantly, Fe+3/Asc induces the lipid peroxidation of AA, a 
process which produces reactive species capable of modifying protein structure and function.324-
327 Notably, DAT is highly susceptible to oxidant injury.328-330 We thus posited that AA might 
exhibit greater inhibitory effects under oxidative conditions. Indeed, a greater decrease in Vmax 
to 34% of control was obtained when AA was applied in the presence of Fe+3/Asc (Figure 14D 
and E; See also Figure 16 for validation of oxidizing conditions and cell viability). However, 
when hDAT cells were incubated with Fe+3/Asc alone, there were no significant changes in DAT 
activity (Figure 14D and E). These results show that in the presence of AA there is a significant 
reduction in DAT function under both oxidizing and non-oxidizing conditions. Notably, a greater 
loss of function was observed under oxidizing conditions which also affects DAT’s apparent 
affinity for DA (Figure 14F). 
DAT plasma membrane trafficking is a key regulator of DA transport capacity.35,331 
Therefore, the effect of AA on DAT function could be explained by changes in cell surface 
expression. Our results indicate that in hDAT cells, AA, under both oxidative and non-oxidative 
conditions, decreases significantly and to the same extent plasma membrane DAT (Figure 17A 
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and B) as determined by biotinylation. Therefore, the decrease in DAT function induced by AA 
alone parallels the decreased transport capacity induced by AA (Figure 14). These data also 
point to additional mechanisms promoted in terms of DAT function by oxidative stress.  
AA oxidative product, γ-KA, forms a complex with DAT and regulates its function 
Oxidation of AA (mediated by free radicals and other reactive oxygen/nitrogen species) 
yields a series of prostaglandin H2 isomers that rearrange to their corresponding γ-KAs, also 
named isoketals. These γ-KAs react rapidly with lysine residues forming stable adducts, which 
can modulate the activity of proteins.324-327 At the plasma membrane DAT localizes to 
microdomains including lipid rafts. Lipid rafts are regions highly enriched in phospholipids 
containing AA, and DAT localization to lipid rafts has been associated with regulation of DAT 
function and trafficking.34,332,333 Therefore we determined whether post-translational 
modifications of DAT by γ-KAs are associated with changes in DAT function.  
To determine if DAT is a target of AA oxidative products (e.g. γ-KAs) and whether this 
interaction is relevant for its function, we conducted experiments using synthetic isoketals 
(IsoK). hDAT cells were incubated with IsoK or vehicle for 1h at 37°C and cell extracts were 
used for immunoprecipitation experiments. We observed a significant increase (78%) in the 
amount of isoketal adducts that co-immunoprecipitated with DAT compared to the control 
condition (Figure 18A and B). Importantly, incubation with IsoK resulted in a 59% decrease in 
function compared to vehicle control (Figure 18C and D), with no change in Km (Figure 18E). 
Furthermore, we evaluated the effects of salicylamine, a selective scavenger of γ-KA, on DA 
uptake (Figure 18F). In the presence of salicylamine, there were no significant changes in Vmax 
(Figure 18G) or Km (Figure 18H) when cells were treated with AA under non-oxidative or 
oxidative conditions with respect to the control condition. This is in contrast to our earlier results 
in the absence of salicylamine (Figure 14D and E), suggesting that the ability to form γ-KA-DAT 
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adducts is necessary for AA to impair DAT function. Importantly, our findings demonstrate that 
DAT is a target of AA oxidative products, and that this interaction has profound functional 
implications. 
 
Discussion 
Since the discovery that the LS is a potent site of electrical self-stimulation in both 
rodents and humans,81,334 it has historically received relatively little attention as a reward center. 
Recent studies, however, suggest that it integrates output from traditional reward areas 
including the VTA and lateral hypothalamus. 134,135 In this context, the LS has been described as 
a relay node from the hippocampus (area CA3) to the VTA, and has been suggested to play a 
pivotal role in encoding context-reward associations for cocaine.135 Notably, functional 
inactivation of the rostral LS abolished cocaine CPP. 134 These reports and others 130,335,336 
characterize the LS as a brain region critically involved in coordinating the activity of multiple 
reward centers and reinforce its importance in cocaine reward.  
GLP-1Rs are highly expressed in the LS and their signaling has been shown to 
attenuate the locomotor response to the psychostimulant d-amphetamine,292 to reduce cocaine 
CPP,284,286 and to block self-administration for cocaine in rodents.285 Therefore it is conceivable 
that their signaling within the LS may modulate cocaine CPP and reward. To support this 
hypothesis, a recent study shows that GLP-1R expression in the LS controls cocaine CPP and 
locomotion.293 However, the mechanism by which GLP-1R signaling fine tunes DA homeostasis 
and cocaine reward in the LS remains elusive.  
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Figure 16. Fe+3/Ascorbate solution induces reactive oxygen species/reactive nitrogen species 
formation in PC12 cells without changes in cell viability.  (A) Time course of reactive oxygen 
species/reactive nitrogen species (ROS/RNS) production in PC12 cells in absence (buffer, black 
squares) or presence of Fe+3/Asc (open squares) at 37°C, evaluated with the fluorescent probe 
H2DCFDA (2.5μM). Control experiments without cells in absence (buffer: gray circles) or presence 
of Fe+3/Asc (open circles) were also performed. (B) Data are expressed as ROS/RNS production 
(in nmol of ONOO-) in the first 6 minutes of incubation with the Fe+3/Asc solution. Each value 
represents the mean ±S.E.M. of at least three different experiments. *** indicates significant 
differences between KH buffer and Fe+3/Asc conditions (t(5)=8.49; ***p=0.0004 by Student’s t test; 
n=5-9). (C) Cell viability of PC12 cells treated with AA (40μM) for 1h at 37 °C in absence or 
presence of Fe+3/Asc. As positive control of cellular death cells were incubated with 2.2mM H2O2 
(1h at 37°C). Each value represents the mean ±S.E.M. of at least three independent 
experiments.*** indicates significant difference (***p <0.0001) with respect to control condition 
(Veh: 0.1% ethanol in KH buffer). ANOVA followed by post hoc test. 
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Figure 17. AA decreases DAT cell surface expression in hDAT cells. (A) Cell surface 
biotinylation and immunoblots for DAT using anti-DAT in extracts from hDAT cells treated with 
AA (40μM) for 1h at 37°C in absence or presence of Fe+3/Asc. (B) Results expressed as the 
ratio of optical density between biotinylated (surface) and total DAT signals for each 
experimental condition. Each value represents mean ±S.E.M. of ≥three independent 
experiments. *p<0.05 indicates significant differences with respect to vehicle condition (0.1% 
ethanol in KH buffer). Significant ANOVA followed by post hoc tests. 
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Figure 18. Synthetic isoketals form adducts with hDAT and decrease its function. (A) 
Immunoblots with anti-γ-KA protein adduct and anti-DAT antibodies using GFP-DAT 
immunoprecipitates from hDAT cells treated with synthetic isoketals (1μM) for 1h at 37°C. (B) 
Quantitation of immunoprecipitates as a ratio of γ-KA:DAT. Each value represents mean 
±S.E.M. of ≥four independent experiments (t(6)=3.94; **p<0.01 by Student’s t test; n=4). (C) 
Uptake of [3H]DA in hDAT cells treated with vehicle (open circles) or with 1μM synthetic 
isoketals (gray triangles) for 1h at 37°C. The kinetic parameters (D) Vmax and (E) Km were 
obtained from the Michaelis-Menten fit to [3H]DA uptake. Each value represents mean ±S.E.M. 
of three independent experiments (Vmax: t(4)=4.21; *p<0.05 by Student’s t test; n=3; Km: 
t(4)=0.88; *p=0.43 by Student’s t test). (F) Influx of [3H]DA in hDAT cells pretreated with 
salicylamine (0.5mM) and then treated with vehicle (open circles, 0.1% ethanol in KH buffer), 
Fe+3/Asc (open triangles) or with 40μM AA for 1h at 37 °C in absence (gray squares) or 
presence of Fe+3/Asc (gray triangles). The kinetic parameters (G) Vmax and (H) Km were 
obtained from the Michaelis-Menten fit to the influx of [3H]DA. Each value represents mean 
±S.E.M. of ≥three independent experiments. No significant differences were observed between 
groups. Statistical analysis was performed with ANOVA. 
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Cocaine, by targeting the DAT, increases extracellular DA levels which leads to 
cocaine’s behavioral actions. DAT expression level is an important factor in determining the 
effects of cocaine, likely through effects on basal DA tone. For example, extended access to 
cocaine, which results in escalating cocaine intake, causes lower expression of striatal DAT and 
reduced DA clearance in rats.337-341 The involvement of DAT expression in cocaine’s behavioral 
actions is further supported by the finding that hyperlocomotor responsiveness to cocaine is 
significantly enhanced in two different mouse models expressing low levels of DAT,68,69 likely 
resulting from reduced basal DAT-mediated DA uptake 69. Additionally, experiments from 
heterologous cell lines show that cocaine is more potent in inhibiting DA uptake in cells 
expressing lower amounts of DAT.342 Notably, a high percentage of striatal DAT (at least 47%) 
needs to be occupied by cocaine in addicts before they report subjective effects of the drug,343 
implying that modulating DAT surface expression alters the reinforcing effects of cocaine in 
humans. However, it is clear to us that other mechanisms in addition to DAT occupancy 
participate in the behavioral actions of cocaine. These include altered firing activity of DAergic 
neurons and/or other mechanisms that modify DA release. These kinds of mechanisms have 
been defined for other drugs of abuse, such as morphine, and may be contributing in parallel to 
altered cocaine reward.344  
In this study, we hypothesized that GLP-1R signaling controls, at least in part, cocaine 
actions by regulating DAT expression/function in the LS. We find that GLP-1R agonism 
enhances membrane expression of DAT. This increase translates into an increase in transport 
capacity, and is paralleled by reduced ability of cocaine to increase extracellular DA levels. Our 
data suggest that increasing the amount of DAT expressed at the cell surface may reduce the 
extent to which cocaine is effective at increasing extracellular DA within the LS. These data offer 
an additional mechanism for GLP-1R signaling regulation of the reinforcing and rewarding 
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properties of cocaine without precluding the possibility that GLP-1R signaling may also affect 
DA release and firing properties of VTA neurons. 
Here we find that stimulating the GLP-1R through administration of Ex-4 in a 
therapeutically relevant manner (systemic administration) reduces septal 2-AG levels. One 
possibility is that the decrease in 2-AG is due to GLP-1R-mediated stimulation of PI3K,345 or 
inhibition of PTEN346 which will decrease the levels of plasma membrane PIP2, one of the 
precursors for 2-AG synthesis.347 We show that in the LS GLP-1R is located postsynaptically. 
Indeed, 2-AG diffuses across synapses. Therefore, we believe that this loss of 2-AG is causal 
for the observed decrease in LS AA content as AA is primarily produced in the brain through the 
presynaptic conversion from 2-AG.316 This reduction is important since AA has been shown to 
inhibit DA uptake in ex vivo and in vitro preparations,55,317,318 and that psychostimulants such as 
amphetamine cause release of AA by activation of PLA2.
348 Consistent with AA-mediated 
inhibition of septal DA uptake, we show that GLP-1R-mediated reduction in AA signaling is 
associated with an increase in DA uptake in LS slices. This increase in DAT function stems at 
least in part from augmented DAT surface expression, pointing to DAT trafficking as the 
underlying mechanism by which GLP-1R signaling and AA levels controls DA homeostasis in 
the LS, as depicted by our schematic model (Figure 19).  
Of note, AA is known to facilitate a pro-inflammatory state in the brain;349 GLP-1 
analogues, on the other hand, possess both anti-inflammatory and neuroprotective 
effects.323,350,351 GLP-1R stimulation has demonstrated positive effects in rodent models of 
Alzheimer’s disease as well as Parkinson’s disease (a degenerative disorder of DAergic 
neurons).351-353 Furthermore, psychostimulants themselves enhance AA levels and may 
exacerbate oxidative stress in the brain,320-322,348 possibly increasing levels of harmful AA 
metabolites. Based on our findings, GLP-1R signaling may oppose the effects of 
psychostimulants by affecting levels of AA as well as oxidative stress.   
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In this study, we provide biochemical and functional evidence supporting the notion that 
AA regulates DAT function by regulating DAT trafficking. We believe that the increase in DAT 
surface expression promoted by GLP-1R signaling represents a mechanism by which this 
neuropeptide controls both cocaine-induced increase in LS DA as well as cocaine actions. This 
AA-mediated mechanism is enhanced by peroxidation of AA leading to the formation of AA 
metabolites such as γ-KA. Treatment of hDAT cells with AA under conditions favoring lipid 
peroxidation significantly decreased DAT surface expression and transport capacity; the latter 
effect was also demonstrated with synthetic isoketals. These results are consistent with the 
known ability of isoketals to impair the function of plasma membrane proteins.354 Interestingly, 
AA alone was also able to significantly reduce DAT function. However, this reduction was 
smaller than that obtained under conditions favoring lipid peroxidation or in the presence of 
isoketals. These results provide a mechanism for the results reported by Chen et al. (2003) and 
Zhang and Reith (1996), wherein the activity of DAT expressed in heterologous systems was 
reduced by AA.55,318 They also mechanistically support the notion that GLP-1R signaling 
regulates DA homeostasis in the LS by decreasing AA levels. How exactly AA and its 
metabolites control DAT function and trafficking remains elusive. However, we hypothesize that 
covalent interactions of AA metabolites with specific lysine residues on the DAT support these 
actions.324 Notably, we were able to demonstrate a physical interaction between γ-KA and DAT 
by immunoprecipitation.  
 In summary, we have shown that GLP-1R agonism increases DAT function and 
membrane expression, decreases cocaine-induced increases in extracellular DA, and reduces 
endocannabinoid and AA signaling in the LS. This decrease is important since cocaine has 
been shown to increase 2-AG tone in brain.355 This suggests that other brain centers targeted 
by cocaine and expressing the GLP-1R, albeit at lower levels, may exhibit a similar mechanism 
of reward modulation. These brain regions include the NAc and VTA which have been identified 
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as targets of Ex-4 actions on brain reward.235,288,289,356,357 Nevertheless, this mechanism has still 
to be validated outside the LS. Our study points to septal GLP-1R as a potential novel target for 
the treatment of drug abuse. Targeting GLP-1R signaling represents an enormous translational 
opportunity since GLP-1 analogues are already available for clinical use. 
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Figure 19. Schematic depicting model for GLP-1R-mediated retrograde regulation of DA 
uptake. 2-AG, 2-arachidonylglycerol; DA, dopamine; DAT, dopamine transporter; Ex-4, exendin-
4; GLP-1, glucagon-like peptide 1; GLP-1R, GLP-1 receptor; MAGL, monoacylglycerol lipase; 
VTA, ventral tegmental area. 
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CHAPTER III 
 
STRIATAL DOPAMINE HOMEOSTASIS IS ALTERED IN MICE FOLLOWING  
ROUX-EN-Y GASTRIC BYPASS SURGERY3 
 
 
Preface 
RYGB is an effective treatment for obesity. Importantly, weight loss following RYGB is 
thought to result in part from changes in brain-mediated regulation of appetite and food intake. 
DA within the DS plays an important role in feeding behavior; we therefore hypothesized that 
RYGB alters DA homeostasis in this subcortical region. In the current study, obese RYGB-
operated mice consumed significantly less of a high-fat diet, weighed less by the end of the 
study, and exhibited lower adiposity than obese sham-operated mice. Interestingly, both RYGB 
and caloric restriction (pair feeding) resulted in elevated DA and reduced NE tissue levels 
compared with ad libitum-fed sham animals. Consequently, the ratio of NE to DA, a measure of 
DA turnover, was significantly reduced in both of these groups. The RYGB mice additionally 
exhibited a significant increase in phosphorylation of TH at position Ser31, a key regulatory site 
of DA synthesis. This increase was associated with augmented expression of ERK1/2, kinases 
targeting TH Ser31. Additionally, RYGB has been shown in animal models and humans to 
improve insulin sensitivity and glycemic control. Curiously, we noted a significant increase in the 
expression of insulin receptor-β in RYGB animals in striatum (a glucosensing brain region) 
compared to sham ad libitum-fed mice. These data demonstrate that RYGB surgery is 
associated with altered monoamine homeostasis at the level of the DS, thus providing a critical 
foundation for future studies exploring central mechanisms of weight loss in RYGB. 
 
 
                                                          
3
 The work presented in this chapter is modified from Reddy, I.A., et al. Striatal dopamine homeostasis is altered in mice following 
Roux-en-Y gastric bypass surgery. ACS Chemical Neuroscience 5, 943-951 (2014). 
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Introduction 
Obesity is a growing health epidemic in both youth and adult populations. Over 15% of 
American children and over 30% of adults are obese.358 The associated comorbidities of 
obesity, including type 2 diabetes and heart disease, are a major source of mortality.359 Notably, 
bariatric surgery has been an effective means of weight loss for obese individuals who are able 
to undergo surgery.360 RYGB is the most widely used bariatric surgical procedure performed in 
the USA, which results in sustained weight loss and improved metabolic parameters.361,362 The 
procedure reroutes the upper stomach to a more distal portion of the small intestine (proximal 
jejunum), thus bypassing the major portion (~90%) of the distal stomach, the duodenum and the 
proximal jejunum (Figure 20).363  
A number of non-mutually exclusive mechanisms have been suggested to account for 
weight loss following RYGB. Ochner et al. (2011) estimated that restrictive effects of limiting 
stomach size and malabsorptive effects of bypassing a portion of the proximal gut account for 
approximately 55-80% of observed weight loss, while the additional weight loss must be 
explained by alternative mechanisms.364 One of the more striking consequences of RYGB is a 
sustained loss of appetite associated with a reduction in food intake, likely mediated by 
adaptations within the central nervous system to post-operative changes in levels of circulating 
hormones, including insulin.239,256,365-367 The brain plays an important role in regulating appetite 
and feeding, which requires the integration of information about nutritional requirements, energy 
stores, the availability and desirability of foods, and the motivation to work for palatable 
foods.4,368,369 The latter may be particularly relevant to the etiology of the contemporary obesity 
epidemic in which the evolutionarily adaptive drive to consume energy-dense foods becomes 
maladaptive in the setting of abundance.  
Functional brain imaging studies in humans have demonstrated significantly blunted MRI 
responses to the consumption of palatable food in obese individuals compared with healthy- 
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Figure 20. RYGB in mice. The RYGB procedure in our mice consisted of ligation of the stomach 
between the glandular portion and the gastric fundus. A portion of the jejunum, 4 cm from the 
Ligament of Treitz and 6 cm from the site of gastroenterostomy, was transected. The distal 
segment was anastomosed to the stomach in a side-to-side fashion. GI continuity was 
established by performing a side-to-side jejuno-jejunostomy. The sham procedure involved 
mobilization of the forestomach and proximal and distal jejunum and ileum without any 
intersection. Adapted from 370. 
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weight controls,371 suggesting a model by which deficits in the experience of foods promotes 
compensatory overconsumption. Under this model, weight loss in RYGB might be explained, in 
part, by amelioration of central dysfunction. The aim of the current study was to begin to define 
the central neurochemical and molecular candidates by which RYGB may regulate feeding 
behavior in the setting of obesity.  
In this study, we focused on the nigrostriatal DA axis. This pathway has been strongly 
implicated in the motivation to seek food.140,233 Importantly, impairments in striatal DA signaling 
have been repeatedly associated with obesity.213,214,372 In this context it is important to point out 
that circulating hormones which are altered in states of obesity and diabetes, such as insulin 
and GLP-1, promote changes in DA homeostasis within the striatum.234,239 Further, it has been 
previously shown that appropriate insulin signaling at the level of the striatum prevents 
excessive high fat feeding.234,373 These findings provide a theoretical framework in which 
DAergic tone is impaired under the state of altered hormonal signaling in obesity and, 
importantly, that RYGB would enhance striatal DA neurotransmission in the setting of obesity. 
 
 
Methods 
Mice: Male C57BL/6J mice arrived from Jackson Laboratory (Bar Harbor, ME) at 6 weeks of age 
and were initially group-housed at the Vanderbilt Mouse Metabolic Phenotyping Center 
(Nashville, TN, USA) with a 12h light/dark cycle (lights on at 6:00 a.m.). Mice were given one 
week to acclimate to the facility before being switched from a standard chow diet to a 60% kcal 
fat diet (Research Diets, Inc., New Brunswick, NJ, USA) for seven weeks prior to surgery to 
establish diet-induced obesity (Figure 21). Mice were kept on this diet for the remainder of the 
study. Animals which had undergone sham surgery were split into pair-fed and ad libitum-fed 
groups. On day 7 following surgery, all animals were moved from group housing to single 
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housing. Feeding from this point on was measured every 2-4 days (grams of food given minus 
grams of food remaining). Mice which were noticeably crumbling food were excluded from food 
intake analysis (n=1). Pair feeding was started on day 9 post-surgery; this consisted of providing 
animals with a measured amount of food each morning and evening, which matched food 
consumed per half day in the RYGB animals from the same cohort in the prior 2-4 days. Body 
weight throughout the study was measured on a weekly basis. All experiments, procedures, and 
surgeries involving mice were performed in compliance with and were approved by the 
Institutional Animal Care and Use Committee of Vanderbilt University. 
RYGB surgical preparations: RYGB and sham surgeries were performed under inhaled 3-5% 
isoflurane anesthesia as previously described (“RYGB” procedure).370 Mice which did not 
achieve a body weight of at least 33g on the day before surgery were excluded from the study. 
Prior to surgery, mice were fasted for approximately 12h. On the morning of surgery, the mice 
received 0.03 mg of buprenorphine analgesic (Patterson Veterinary via Hospira Inc., Nashville, 
TN, USA) and 0.1 mL 0.9% saline (intraperitoneal). Animals were administered 0.017 mg 
ketoprofen (Cayman Chemical, Ann Arbor, MI, USA) once/day as needed for 1-2 days following 
surgery and weekly iron dextran injections (10 mg/kg; Durvet, Inc., Blue Springs, MO, USA) to 
prevent anemia.  
Whole body composition: Body composition was measured in conscious mice using the mq10 
NMR analyzer (Bruker Optics Inc., Billerica, MA, USA) at the Vanderbilt University Mouse 
Metabolic Phenotyping Center as described previously.370 Measurements were made one week 
prior to surgery (+/- 1 day) and each week thereafter.  
Monoamine content: Mice were sacrificed four weeks following surgery under inhaled isoflurane 
anesthesia. A section of brain including the striatum was blocked. A small portion of the DS was 
taken by punch microdissection for determination of monoamine content, while the rest of the 
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striatum was dissected and saved for western blotting. Tissue saved for both monoamine 
determination and western blotting was immediately placed in tubes on dry ice. Tissue punches 
were analyzed at the Vanderbilt University Neurochemistry Core by high performance liquid 
chromatography (HPLC) with amperometric detection as described previously.302  
Tissue preparation and immunoblotting: Tissue punches from DS were collected and 
homogenized on ice in buffer containing 22 mM HEPES, 133 nM NaCl, 1% triton, 0.1% each of 
leupeptin, pepstatin, and aprotinin, 1% phosphatase inhibitor cocktail 3 (Sigma Aldrich, St. 
Louis, MO, USA), and 0.5 mM PMSF, then spun at 13,000×g for 30 minutes at 4°C. The 
supernatant was taken and combined with pulldown buffer containing 24 mM HEPES, 146 nM 
NaCl, 0,1% triton, 0.1% each of leupeptin, pepstatin, and aprotinin, 1% phosphatase inhibitor 
cocktail 3 (Sigma Aldrich), and 0.5 mM PMSF. The protein content was then assessed, 
compensated so that each sample contained the same amount of total protein, and analysis 
performed. Protein was eluted with 2X sample buffer for 5 minutes at 95°C, cooled, and 
separated by 10% SDS-PAGE. Resolved proteins were then transferred to polyvinylidene 
difluoride (PVDF) membrane and blocked in either 5% milk or 2.5% BSA in 0.1% Tween20 in 
Tris-buffered saline. Blots were then incubated in primary antibody rocking either at room 
temperature for 1h or overnight at 4°C. The primary antibodies used in this study included: 
tyrosine hydroxylase (1:1000; Cell Signaling Technology; Danvers, MA, USA), phospho-tyrosine 
hydroxylase serine 31 (1:500; Cell Signaling Technology), DAT (1:10,000; Dr. Roxanne 
Vaughan, University of North Dakota School of Medicine), ERK 1/2 (1:1000; Promega; Madison, 
WI, USA), phospho-ERK 1/2 (3:2000; Promega; Madison, WI, USA), and insulin receptor-β 
(1:300; Santa Cruz Biotechnology, Santa Cruz, CA, USA). All proteins were detected using HRP 
conjugated secondary antibodies (1:5000; Santa Cruz Biotechnology). After chemiluminescent 
visualization (Amersham ECL-Plus; Piscataway, NJ, USA) on Hyblot CL film (Denville Scientific, 
South Plainfield, NJ, USA), protein band densities were quantified using ImageJ software 
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(ImageJ, National Institutes of Health, Bethesda, MD, USA). All measures of protein were 
normalized to measures of β-actin from the same samples and expressed as a percentage of 
the average optical density of the sham control group.  
Statistics: Results are presented as mean ± standard error of the mean (SEM). All statistical 
analyses were performed using GraphPad Prism version 6.00 for Windows (San Diego, CA, 
USA). Comparisons between sham, sham pair-fed, and RYGB groups were made by one-way 
ANOVA with Dunnett’s post test against the sham group unless otherwise noted. For all 
measures, data points which fell ≥ an interquartile range outside the first and third quartiles for 
the surgical/feeding group were excluded from analysis as outliers. Correlation analyses were 
performed by linear regression in GraphPad Prism. Significance was defined as a p value 
<0.05. 
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Figure 21. RYGB study design. Mice were acclimated to the mouse metabolic phenotyping core 
facility for one week. They were then placed on a 60% high-fat diet for 7 weeks. At week 7, the 
mice underwent surgery, either RYGB or sham. They were given one week for recovery, after 
which they were singly housed and the sham group was split into pair-fed animals and ad-
libitum-fed animals. At week 11 after starting the high fat diet, all mice were sacrificed and 
striatal tissue was collected for analysis (n=6-8 per group).  
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Results 
RYGB reduces body weight, food intake, and adiposity in mice:  
After 7 weeks on a high fat diet, mice were randomly assigned to receive sham or RYGB 
surgery (Figures 20 and 21). All mice were allowed to feed on a high-fat diet ad libitum for one 
week following surgery, after which the sham group was randomly assigned to either continue 
ad libitum feeding, or to be pair-fed to the RYGB group (see methods for details). Body weights 
for animals in each of these three groups were monitored for the duration of the study (n=6-8 
per group). Following the initial seven weeks on the high-fat diet, the average weight of the 
animals was 38.4 ±0.8g with no significant differences among animals (Figure 22A; p>0.05). At 
the end of the study (4 weeks after surgery), the RYGB group weighed significantly less than 
the sham animals (Figure 22A; 27.5 ±0.9g vs. 40.0 ±1.7g; ####p<0.0001 by two-way ANOVA 
and Bonferroni’s multiple comparison test), with an average weight loss of 26.9 ±1.4% from 
peak weight immediately before surgery to four weeks post-surgery. In contrast, the sham pair-
fed group only lost 11.1 ±2.4% of their peak body weight, which was significantly different from 
the ad libitum sham group at week 11 (*p<0.05). Importantly, the RYGB group also weighed 
significantly less than the pair-fed group (††p<0.01). 
The RYGB animals consumed significantly less food by weight compared to the shams 
(Figure 22B; **p<0.01 in last 4 days of intake measurement by two-way ANOVA and 
Bonferroni’s multiple comparison test). At four weeks post-surgery, the body fat in the RYGB 
group was 10.25 ±0.55% and 31.05 ±3.5% in the sham group (Figure 23A; ***p<0.001). In 
contrast, the adiposity of the pair-fed group (28.08 ±2.3%) was no different than that of ad 
libitum-fed shams (p>0.05). RYGB also resulted in greater lean mass composition by the end of 
the study with respect to sham ad libitum mice, our control group for the remainder of the study 
(Figure 23B; ****p<0.0001).  
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Figure 22. RYGB decreases body weight and food intake. (A) Body weights of sham, sham 
pair-fed, and RYGB mice over the course of the study. There were no significant differences in 
body weight prior to surgery. # represents significant differences between sham and RYGB 
groups. * indicates significant differences between sham and sham pair-fed groups. † 
represents significant differences between RYGB and sham pair-fed groups (n=6-8). (B) 
Cumulative intake of a 60% high-fat diet was measured starting at day 9 (start of pair-feeding) 
through day 27 post-surgery. * indicates a significant difference between the sham-operated ad-
libitum-fed group and the RYGB-operated group (n=5-8).  
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Figure 23. RYGB decreases fat mass and increases lean mass. (A) Fat mass and (B) lean 
mass in each of the surgical/feeding groups quantified as percent of total body weight at week 
11 (n=5-8). Together, fat mass and lean mass compose the entirety of body weight with the 
exception of free fluid mass. Significant differences were noted between the sham and RYGB 
groups for both fat (***p<0.001) and lean mass (****p<0.0001). Data are represented as mean ± 
SEM. 
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Mice that have undergone RYGB or caloric restriction exhibit higher levels of DA and reduced 
levels of NE in the striatum:  
Four weeks post-surgery, all groups were sacrificed and DS tissue was collected. Levels 
of monoamines and their metabolites were determined by HPLC. DA levels were significantly 
elevated in both the RYGB and sham pair-fed groups with respect to shams fed ad libitum 
(Figure 24, top; **p<0.01 and *p<0.05 for DA in RYGB and sham PF animals, respectively; 
mean HPLC values were 120.9 ±9.7 ng/mg protein, 148.9 ±4.1, and 168.8 ±8.9 for sham, sham 
PF, and RYGB groups, respectively; n=5-8 per group). On the other hand, NE levels were 
significantly reduced in the RYGB and sham PF mice (Figure 24, middle; *p<0.05 in RYGB and 
sham PF mice; mean HPLC values were 3.1 ±0.1 ng/mg protein, 2.0 ±0.2, and 2.0 ±0.4, 
respectively; n=5-7 per group), while there were no significant differences in the levels of the 
non-catecholaminergic monoamine, serotonin (5-HT; Figure 24, bottom; p>0.05).  
DA levels within terminals are highly regulated by a number of homeostatic mechanisms, 
including metabolism, synthesis, and synaptic reuptake.374 In relation to DA metabolism, there 
were no significant differences between groups in terms of levels of DA metabolites (Figure 25). 
However, a small proportion of DA is also converted to NE in the striatum by the enzyme DA β-
hydroxylase.375 Thus, it was important to determine whether the conversion of DA to NE was 
affected by RYGB by measuring changes in the ratio of NE to DA. This ratio was significantly 
reduced both in the pair-fed and RYGB animals relative to sham ad libitum-fed animals (Figure 
24B; **p<0.01). These findings demonstrate that, in the setting of high-fat feeding, both food 
restriction and RYGB act to increase striatal DA content and that this effect is potentially 
mediated in small part by reduced conversion of DA to NE.  
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Figure 24. DA levels are elevated in the DS of sham PF and RYGB-operated mice. (A) Striatal 
DA measured by HPLC was significantly elevated in both sham pair-fed (*p<0.05) and RYGB 
mice (**p<0.01) compared to sham-operated animals (top; n=5-8). In contrast, NE was 
significantly decreased in both sham pair-fed and RYGB mice compared to sham-operated 
animals (middle; *p<0.05; n=5-7) while 5-HT was not significantly different between groups 
(bottom; n=6-7). (B) Conversion of DA to NE was significantly impaired in the pair-fed and 
RYGB mice, as noted by the ratio of NE to DA (**p<0.01; n=5-6). Data are represented as mean 
± SEM. 
A B 
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Figure 25. Striatal content of DA metabolites is not altered by RYGB or pair-feeding. Levels of 
DA metabolites (A) DOPAC (n=5-8), (B) 3-MT (n=5-8), and (C) HVA (n=6-8) normalized to total 
DA were the same across surgical and feeding groups (p>0.05). Data are represented as mean 
± SEM. 
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Figure 26. TH phosphorylation at Ser31 and expression of ERK 1/2 are elevated in RYGB-
operated mice. (A) Phosphorylation of tyrosine hydroxylase at residue Ser31 (pTH-Ser31) was 
significantly elevated in the RYGB group compared to the sham ad-libitum-fed animals 
(*p<0.05; n=6-8). Data were normalized to β-actin. (B) Representative immunoblots. (C) 
Expression of ERK 1/2 was elevated in the RYGB mice compared to shams (**p<0.01; n=5-6). 
Data were normalized to β-actin and (D) a representative immunoblot is shown. Data are 
represented as mean ± SEM. 
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RYGB but not caloric restriction increases TH phosphorylation at residue Ser31: 
In addition to DA metabolism, DA levels in neurons are also homeostatically regulated 
by reuptake and synthesis. Given that altered conversion of DA to NE can only explain partially 
the increase in DA in the RYGB animals, we thus asked whether these other components of DA 
homeostasis were altered by either RYGB or caloric restriction (pair-feeding). First, we 
determined whether expression of the DAT is altered by either intervention. The DAT acts to 
clear DA from the synapse by active uptake into the terminals. Total expression of DAT was not 
significantly different across the three different experimental groups (100.0 ±9.1%, 115.2 ±9.4%, 
and 140.5 ±35.4% in sham, sham PF, and RYGB, respectively; n=6). Similarly, total expression 
of TH, the rate-limiting enzyme in DA synthesis, was unchanged across groups (100 ±24.7%, 
104.9 ±10.7%, and 124.9 ±32.8% in sham, sham PF, and RYGB, respectively; n=4-6).  
The activity of TH in relation to DA synthesis is regulated, in part, by phosphorylation of 
the residues Ser31 and Ser40. Phosphorylation at either of these residues results in increased 
activity of TH and increased DA synthesis.376 Due to the low stoichiometric presence of Ser40 in 
striatum,377 we focused on measuring striatal changes in phosphorylation of TH at Ser31. 
Interestingly, RYGB animals showed increased expression of phospho-TH Ser31 compared 
with sham animals (Figure 26A and 4B; *p<0.05), while there was no significant difference 
between sham pair-fed animals and shams fed ad libitum.  
The phosphorylation of TH at Ser31 is known to be regulated by ERK1/2.376,378 Although 
we did not observe an increase in ERK1/2 phosphorylation (100 ±18.7%, 127.7 ±30.5%, and 
98.6 ±14.1% in sham, sham PF, and RYGB, respectively; n=6-8) a significant increase in 
ERK1/2 expression in the RYGB animals was noted, which may account for the observed 
increase in phospho-TH Ser31 (Figure 26C and D; **p<0.01). Individually, both ERK 1 and ERK 
2 were significantly increased in the RYGB group (100 ±12.5%, 91.3 ±9.9%, and 167.8 ±9.9% 
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for ERK1 in sham, sham PF, and RYGB, respectively; p<0.001; 100 ±10.5%, 125.7 ±11.1%, 
and 177.3 ±25.1% for ERK2 in sham, sham PF, and RYGB, respectively; p<0.01; n=6-8 per 
group). 
RYGB promotes expression of the insulin receptor β subunit in striatum:  
It is well documented that levels of circulating hormones are altered by RYGB surgery.221 
The brain receives constant information about the body’s nutritional status via these circulating 
hormones including, but not limited to, insulin, leptin, GLP-1, orexin, and ghrelin. Receptors for 
each of these hormones have been found in brain regions involved in energy homeostasis and 
feeding behavior, including striatum.379-381 These enteroendocrine signaling factors have been 
shown to regulate feeding and body weight through central mechanisms.382 In particular, within 
the central nervous system, insulin signaling has previously been linked to changes in DA 
homeostasis and food reward.290,308,383 Given that circulating insulin levels are proportional to 
adiposity,384 that RYGB improves insulin sensitivity,385 and that in our study the RYGB group 
exhibited lower levels of adiposity than the pair-fed animals, possible changes in striatal insulin 
signaling were determined in our experimental groups. Here, expression of the β subunit of the 
insulin receptor was elevated in the striatum of animals that underwent RYGB, but not in the 
pair-fed group (Figure 27A and B; *p<0.05).  
After uncovering a number of molecular changes associated with RYGB, we were 
interested to know whether any of these changes correlated with reductions in body weight. 
Such an analysis might provide insight into the contribution of body weight and associated 
metabolic changes toward adaptations in the brain DAergic system. Incorporating all animals 
from all groups, we measured the correlation between body weight and striatal DA, DAT, 
pERK1/2, ERK1/2, TH, pTH-Ser31, and the insulin receptor β subunit (Table 2). Significant 
inverse correlations were found between body weight and DA, ERK1/2 expression, pTH-Ser31 
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expression, and expression of the insulin receptor β subunit. Given that the RYGB group lost 
more weight than the pair-fed group, it is difficult from this study to determine whether the 
changes were caused primarily by a reduction in body weight/adiposity or through a more 
surgery-dependent, weight-independent mechanism. 
 
Discussion 
Both human and rodent studies indicate that RYGB alters the rewarding properties of 
palatable foods.366,386-389 People who undergo bariatric surgery self-report less desire to 
consume palatable foods than before surgery366,386-388 and reduce their intake.390 Shin et al. 
(2010) performed RYGB in rats and found that, compared with sham animals, they exhibited 
more positive orofacial responses to a low concentration sucrose solution and a lower rate of 
licking of a high concentration sucrose solution.248 Importantly, RYGB resulted in reduced 
consumption of a high-fat diet. This same group also noted that RYGB rescued food motivation 
to the level of lean controls in both an incentive runway paradigm and a progressive ratio 
operant paradigm.248,249 These results promote a model by which RYGB reduces the need to 
consume large quantities of palatable food by restoring appropriate levels of hedonic 
stimulation. These behavioral correlates implicate adaptations within brain reward circuitry; yet 
the neural mechanisms driving changes in feeding behavior in bariatric surgery are unclear.  
Dysregulated DA signaling within the striatum has been strongly associated to high-fat feeding, 
obesity, and reward.4,213,214,244,391,392 PET studies point to altered DA signaling in the DS of obese 
individuals.213,393 Similarly, rodent models of obesity, including diet-induced obesity 
models,214,244,391,394 and obesity-prone genetic lines,395 have all exhibited deficits in striatal DA 
homeostasis. Importantly, viral-mediated knockdown of the striatal D2 receptor suggest that 
impaired DA signaling may be a causal factor in the etiology of obesity.214 Of note, 
amphetamine as well as other DA-targeting drugs possess potent anorectic properties,396,397 
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supporting our hypothesis that RYGB reduces intake of obesogenic food by enhancing DA 
neurotransmission. Of course, these drugs possess addictive properties; thus, defining other 
targets of regulation within this system through the study of RYGB has the potential to reveal 
novel and safer pharmacological targets for the treatment of obesity.   
Although the literature makes strong reference to differences in levels of appetite-
regulating gut hormones following bariatric surgery,239,256,364,367,398 few attempts have been made 
to define the neurobiological adaptations that result from this altered neuro-hormonal 
milieu.250,399,400 The aim of the current study was to define the neurochemical and molecular 
phenotype of RYGB within the striatum in a well-controlled preclinical mouse model. 
Furthermore, we sought to determine which of these phenotypes resulted from a simple 
reduction in caloric intake versus an effect of the surgical procedure. We focused our study on 
monoamine signaling within the DS, as DA within this region plays a critical role in the 
consummatory drive for food.140,233 We observed altered catecholamine (DA and NE) levels in 
the DS of both RYGB and pair-fed (chronically food-restricted) animals, but not the non-
catecholaminergic neurotransmitter 5-HT. This finding is consistent with the idea that DA 
signaling within the DS supports the rewarding properties of palatable food,204 and that food is 
more rewarding under conditions of restriction.236 A potential explanation for a small component 
of this effect may lie in alterations in DA conversion to NE, as observed in the current study. As 
this process occurs within vesicles and without changes to DA metabolism, we would expect a 
reduction in DA processing to NE to result in an increase in DA accumulation in vesicles with 
enhanced DA release in both chronically food-restricted and RYGB mice. In fact, it has 
previously been reported that electrically-evoked DA release in the DS and NAc is attenuated in 
slices taken from rats fed a cafeteria diet for 15 weeks versus rats on a regular chow diet.395 
Future studies will determine whether evoked DA release is corrected in the RYGB model.  
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Figure 27. Expression of the insulin receptor β subunit is elevated in RYGB-operated mice. (A) 
Expression of the insulin receptor β was higher in the RYGB mice compared to shams (*p<0.05; 
n=6-7). Data were normalized to β-actin and (B) a representative immunoblot is shown. Data 
are represented as mean ± SEM. 
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Table 2. Correlation between body weight and studied molecular markers of DA homeostasis.  
 
Body weight was significantly inversely correlated with DA levels, ERK1/2 expression, 
phosphorylation of TH at residue Ser31, and IR-β expression. R2  = coefficient of determination; 
df = degrees of freedom.  
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To further explain this increase in striatal DA content, we next focused on determining 
possible changes in the function of key regulators of the DA synthetic pathway. We determined 
that animals which underwent RYGB had significantly greater levels of TH phosphorylation at 
Ser31. This phenotype was not observed in either the sham or the sham pair-fed groups, 
suggesting that the increased DA levels in the sham pair-fed group stems from a mechanism 
independent of changes in TH function. Consistent with the increase in phospho-TH, the 
expression of ERK1/2 was elevated in the RYGB mice. Since phosphorylation of Ser31 is 
targeted by ERK1/2, the increase in expression of ERK1/2 may suggest a possible mechanism 
by which TH activity is upregulated.378 Finally, given the extensive literature on altered neuro-
hormonal levels following RYGB, we explored markers of differential hormonal signaling in the 
RYGB group which could connect changes in gut anatomy with the changes DA homeostasis 
observed in the DS. Our group and others have previously found that insulin signaling in the DS 
acts to regulate DA homeostasis,52,290 and that this signaling is dysregulated in rodents fed a 
high-fat diet.244 Importantly, insulin resistance and type 2 diabetes often develop in the setting of 
obesity and are corrected by RYGB.385,401 We found that expression of the insulin receptor β 
subunit was significantly upregulated in mice that underwent RYGB surgery, but not in either of 
the sham groups. The relevance of these data is enhanced considering that the striatum has 
been described as glucosensing brain region402,403 and that increased brain glucose availability 
(i.e. hyperglycemia) and glucose oxidation disrupt both nigrostriatal neurotransmission and 
striatal DA turnover.404,405  
Here, we report for the first time neurochemical changes at the level of the striatum in a 
preclinical model of RYGB. These changes include an elevation of DA levels with reduced 
conversion to NE, increased phosphorylation of TH, increased expression of the regulatory 
kinase ERK1/2, and increased insulin receptor-β expression. RYGB, while generally effective as 
a treatment for obesity, is not equally effective for all individuals.406 Here, we have speculated 
that neural mechanisms may be an important factor mediating weight loss in RYGB. 
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Understanding these neural contributions to weight loss may allow for the development of 
pharmacotherapeutic interventions to improve clinical outcomes in patients undergoing bariatric 
surgery. Of course, pharmacological weight loss approaches, or so-called “knifeless surgery,” if 
sufficiently effective would be beneficial as a means to avoid surgery altogether and bring relief 
to a larger patient population.407,408 
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CHAPTER IV 
 
BILIARY DIVERSION SURGERY ENHANCES BILE ACID SIGNALING AND IMPAIRS 
COCAINE REWARD IN MICE 
 
Preface 
The gut-to-brain axis regulates diverse behavioral phenotypes; however, mechanisms 
supporting this communication are poorly understood. We reveal that a gut-based bariatric 
surgical approach chronically elevates systemic bile acids and attenuates cocaine-induced 
elevations in accumbal DA. Notably, this surgery reduces cocaine reward and sensitization. 
These findings define bile acid signaling and bile acid analogues as a pharmacological target for 
the treatment of cocaine abuse and reveal a mechanism of gut-to-brain communication.  
 
Introduction 
Traditionally, bile acids have been seen as simple detergents participating in the 
emulsification of ingested fats. However, it is increasingly apparent that bile acids also function 
as steroid hormones with targets in the intestine, liver, and brain.409-411 Bile acids produced from 
cholesterol in the liver enter the proximal small intestine at the duodenum and are taken back up 
into portal circulation at the distal ileum, a segment of the small intestine densely populated by 
bile acid receptors and reuptake transporters. Biliary diversion - a newly developed bariatric 
surgical procedure in mice - is capable of chronically elevating circulating bile acids through 
ligation of the common bile duct and anastomosis of the gallbladder to the ileum (Figure 28A; 
GB-IL).412 In the control surgery, the gallbladder is anastomosed to the duodenum (Figure 28A; 
GB-D), restoring normal bile flow independent of the sphincter of Oddi.   
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Biliary diversion was recently developed in mice to treat high fat diet-induced obesity.412 
GB-IL mice exhibited reduced high fat food consumption and weight loss. This reduction in the 
intake of rewarding, calorically-dense food could stem at least in part from altered reward for 
palatable food. Dysregulated mesolimbic DA circuitry has been linked to high fat, high calorie 
food consumption.214,413,414 Psychostimulants such as cocaine hijack these circuits to cause 
addiction. We thus hypothesized that bile diversion to the ileum, which reduces high fat intake, 
might also reduce the rewarding properties of cocaine.    
 
Methods 
Mice:  Male wild-type C57BL/6J mice used for surgeries or for OCA treatment were acquired 
from Jackson Laboratories (Bar Harbor, ME, USA) at 5 weeks of age. Mice were acclimated to a 
Vanderbilt University housing facility for one week prior to surgery. Surgery (GB-D or GB-IL) 
occurred at 6 weeks of age. Mice were given at least 2 weeks to recover from surgery and were 
handled for 3 days prior to the start of the CPP paradigm. At this point, mice either underwent 
behavioral testing (beginning with CPP) or were sensitized to cocaine without behavioral testing. 
Mice from the surgical model were sacrificed at either 4-5 or 7-8 weeks post-surgery. Gpbar1 
(TGR5) knockout heterozygous breeder mice were obtained from Dr. David Wasserman at the 
Vanderbilt University School of Medicine and their generation is described in Vassileva et al.415 
These mice were maintained on a C57BL/6J background. Heterozygous mice were mated to 
generate male and female knockout mice and wild-type mice used in behavioral experiments. 
These mice were handled for 3 days prior to the start of the CPP paradigm, which began at 8 
weeks of age. All mice were group housed at a Vanderbilt University housing facility with ad 
libitum access to standard chow and water. The temperature- and humidity-controlled facility is 
maintained on a 12:12 h light:dark cycle (lights on 07:00-19:00 h) and all experiments were 
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performed during the light phase. All protocols were approved by the Vanderbilt University 
Institutional Animal Care and Use Committee. 
Surgery: The control surgery (GB-D) and experimental surgery (GB-IL) were performed as 
previously described.412 Body weights were measured immediately prior to surgery and 
following surgery up until sacrifice. Body weights for each mouse were averaged within 4 day 
bins and are represented as such in the group averages.  
Amperometry in ex vivo slice preparation: Following recovery from surgery as described above, 
GB-D and GB-IL mice were treated with saline or cocaine along the same schedule as used for 
cocaine CPP using 20 mg/kg cocaine (see below; briefly, i.p. injections of saline every other day 
for 8 days and injections of cocaine on alternate days). After each injection, mice were placed 
back in their home cages. Mice were sacrificed by rapid decapitation under isoflurane 
anesthesia 1-2 days following their final cocaine injection. Slices were prepared as previously 
described302 and electrically-evoked DA release in the NAc was measured by standard 
methods.416 DA release was stimulated with a bipolar electrode placed on the surface of the 
slice and recorded with a carbon fiber electrode. 
HPLC: Mice were sacrificed by decapitation under isoflurane anesthesia at 4-5 weeks following 
GB-D or GB-IL surgery. The brain was quickly dissected, blocked, and the NAc was punched 
bilaterally. Punches were placed into tubes on dry ice and stored at -80°C until processing. 
HPLC to measure monoamines from tissue was performed as previously described.417  
CPP and locomotor sensitization: CPP was performed as previously described, with 
modifications.286 Briefly, 2-chamber CPP apparati (MED-CPP2-MS; Med Associates, St. Albans, 
VT, USA) with distinct rod and mesh floor inserts were used. The associated software allowed 
for automated measurement of beam breaks on X-Y-Z axes (16 infrared beams, 50 ms 
intervals). Mice were weighed and then acclimated to the testing room for 20 minutes prior to 
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testing each day. During the first phase (pre-conditioning, day 1), mice were placed on the grid 
floor side of the 2 chamber apparatus. For 30 minutes, the mice had free access to both sides of 
the apparatus. During the second phase (conditioning, days 2-9), on alternate days mice were 
restricted to one side or the other of the apparatus for 30 minutes by use of a dividing door. Just 
prior to being placed in the chamber, each mouse was given an injection of either cocaine (20 
mg/kg, i.p.) or saline (i.p.). Cocaine was paired with the side of the apparatus less preferred 
during pre-conditioning. Approximately half of the mice were started on cocaine, while the other 
half were started on saline. During this time, each mouse’s locomotor activity was measured 
and used to determine cocaine-induced locomotor sensitization. The final phase of CPP (post-
conditioning, day 10) consisted of placing the mouse on the cocaine-paired side initially with the 
dividing door removed; however, no drug was given on this day. Thus, mice were given full 
access to both compartments and their time spent on each side was measured. %CPP was 
calculated as the time spent on the cocaine-paired side during post-conditioning minus the time 
spent on the cocaine-paired side during pre-conditioning divided by the time spent on the saline-
paired side during pre-conditioning. The first 20 minutes of pre-conditioning and post-
conditioning were used in the calculation of %CPP. Locomotor sensitization to cocaine was 
determined by the ambulatory distance on days when mice received cocaine during the 
conditioning phase of CPP (4 exposures). All CPP was performed during the first phase of the 
light cycle. Activity Monitor v5.10 (MED Associates) was used to analyze CPP activity. 
Open field (OF) locomotion: 4-7 days following CPP, GB-D and GB-IL mice from selected 
cohorts were tested for OF locomotion. Mice were initially weighed. Following 20 minutes of 
acclimation to the testing room, mice were placed in clean automated OF chambers (28x28 cm; 
MED-OFA-510; MED Associates) under constant illumination for 60 minutes and ambulatory 
distance was recorded. Time spent in the center of the chamber relative to the outer edges was 
calculated using the default center-surround analysis in the accompanying software. Mice were 
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then removed from the chamber, injected with saline (i.p., equivalent volume to a 20 mg/kg dose 
of cocaine at 1.2 mg/mL) and placed back in the chamber for 90 minutes. Finally, mice were 
removed again and injected with cocaine (20 mg/kg, i.p.) before being placed back in the 
chamber for an additional 120 minutes. Activity Monitor v5.10 (MED Associates) was used to 
analyze OF activity. AUC was calculated from the cocaine phase of testing. 
Morris water maze – Hidden Platform (HWM): Following CPP and OF locomotion, GB-D and 
GB-IL mice from selected cohorts were tested on the HWM. The water maze protocol here was 
modified from a protocol previously described.418 A round tub measuring 92x92 cm was filled 
with clean water the day before the first day of behavioral testing. On each morning of testing, 
mice were acclimated to the testing room for at least 10 minutes after which behavioral testing 
began. For the first 5 days, a platform was placed just under the water in the northeast corner of 
the maze such that mice could not see it. Each day for 4 trials per day, mice were placed into 
the pool facing the wall and were given 60 seconds to find and stand on the platform. If they 
found it, they were allowed to stand on it for 10 seconds before being removed by the 
experimenter. If they did not find the platform in the 60 seconds, they were placed on the 
platform by the experimenter for 20 seconds. After each trial, mice were allowed to dry in a 
clean cage on top of a warming pad, with at least 10 minutes in between each trial. On the final 
day of testing, the platform was removed. The mice were placed in the pool for a single trial and 
% time in the target quadrant was measured. All sessions were recorded by video and analyses 
of behavioral performance on the water maze were made using ANY-maze software (Stoelting 
Co., Wood Dale, IL, USA).  
Tail Suspension Test (TST): Following CPP and OF locomotion, GB-D and GB-IL mice from 
selected cohorts were tested on the TST. This involved individually suspending each mouse by 
the tail using adhesive tape to a flat, stainless steel force sensor connected to a computerized 
monitoring system (v3.30, MED Associates). The force sensor measured the amount of time 
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each mouse spent struggling to right itself. The mouse was suspended from the sensor for a 
total 6 minutes. The last 4 minutes of the trial were used to calculate time immobile, which was 
defined as the total time during which the mouse movement did not exceed a preset threshold 
of seven for 200 ms. A single trial was performed for each mouse.  
Rotarod: Following CPP and OF locomotion, GB-D and GB-IL mice from selected cohorts were 
tested on the rotarod. The rotarod consisted of a rotating, grooved rubber cylinder (approx. 3 cm 
in diameter) with dividers so that multiple mice could be placed on the machine at once. Mice 
were placed on the cylinder, which rotated for 5 minutes gradually increasing from 4 to 40 rpm. 
The amount of time spent on the cylinder before safely falling was recorded. Three trials were 
performed each day for 4 days, with 5 minutes in between trials.  
Bile acid determination: Serum bile acids were measured by mass spectrometry via the 
Vanderbilt Mass Spectrometry Core facility using methods previously described.412 Bile acids 
were measured from trunk blood taken immediately following decapitation at sacrifice at 4-5 
weeks and 7-8 weeks post-surgery.  
OCA administration: To allow for gut bioavailability of OCA without the stress of oral gavage, 
OCA was administered to mice by voluntary oral administration.419 OCA (Adipogen, San Diego, 
CA, USA) was initially dissolved in beta cyclodextrin (20% w/v) and then dissolved within 
palatable drug-laced jellies. Jellies were composed of gelatin (10% w/v), sucralose (18.5% w/v), 
artificial strawberry flavoring (8% v/v); beta cyclodextrin (2% w/v) in water. Jellies containing 
OCA were made to contain 10 mg/kg based on each mouse’s original weight on the first day of 
drug or vehicle administration. Jellies containing vehicle were identical to drug-laced jellies 
except that they contained beta cyclodextrin without dissolved drug. Mice were given jellies by 
voluntary oral administration on six consecutive days per week for 4 weeks. They were given 
the jellies between 3pm and 6pm by placing each mouse into an OF chamber containing the 
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jelly for 20 minutes. To ensure that mice consumed the jellies consistently, all mice were initially 
trained to eat jellies without drug for 5 days prior to drug/vehicle jelly administration. Mice in this 
group underwent behavioral testing for cocaine CPP as described above 2 weeks into chronic 
drug administration. Drug administrations were continued until sacrifice at 4 weeks following the 
start of drug/vehicle administration.  
Whole-cell electrophysiology: Ex vivo mouse sagittal brain slices were prepared as previously 
described.177 Briefly, mice were acutely anesthetized using isoflurane and sacrificed by rapid 
decapitation. Brains were submerged in ice-cold sucrose dissecting solution (80 mM NaCl, 2.5 
mM KCl, 7 mM MgCl2, 0.5 mM CaCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, 75 mM sucrose, 
and 25 mM glucose) and 250 µm thick slices were cut using the Leica 200VT Vibratome. Slices 
were allowed to recover for 10-15 minutes at 35°C in an N-methyl D-glucamine (NMDG) based 
recovery solution (2.5 mM KCl, 20 mM HEPES, 1.2 mM NaH2PO4, 25 mM glucose, 93 mM 
NMDG, 30 mM NaHCO3, 5 mM sodium ascorbate, 3 mM sodium pyruvate, 10 mM MgSO4, and 
0.5 mM CaCl2) before being transferred to a room temperature ACSF holding chamber for 1h 
prior to use. ASCF used for holding chamber and recordings contained 120 mM NaCl, 2.5 mM 
KCL, 1.5 mM MgCl2, 2.5 mM CaCl2, 1 mM NaH2PO4, 25 mM NaHCO3, and 10 mM glucose. The 
nucleus accumbens shell was identified by the shape of the anterior commissure, the corpus 
callosum, and the absence of stria in the brain slice. Accumbens shell medium spiny neurons 
were patched using the Scientifica Patch Star system and 4-7 MΩ glass micropipettes made 
using the Sutter Brown/Fleming P1000 Micropipette Puller. Patch pipettes were filled with a 
cesium-based internal solution (120 mM CsMeSO3, 15 mM CsCl, 8 mM NaCl, 10 mM HEPES, 
0.2 mM EGTA, 10 mM TEA-Cl, 4 mM ATP, 0.3 mM GTP, 0.1 mM spermine, and 5 mM QX-314 
bromide). Evoked responses were elicited by electrical stimulation via the Iso-flex stimulation 
isolator and recorded using the Axopatch Multiclamp 700B amplifier and Axon Digidata 1550 
low-noise data acquisition digitizer (Molecular Devices, Sunnyvale, CA, USA). All recordings 
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were performed in 50 µM picrotoxin to isolate excitatory events and cells with an access 
resistance greater than 20 MΩ or those in which the access resistance changed greater than 
20% during recording of a single experiment were excluded from analysis. For measurements of 
EPSC amplitude in the presence of OCA, OCA (Adipogen) stock aliquots in DMSO were diluted 
1:1000 in ACSF (final concentration: 10 µM). OCA-containing ACSF was perfused into the 
recording chamber for 10 minutes following baseline acquisition while holding at -70 mV. Peak 
EPSC amplitude was measured for the duration of the experiment and normalized to the first 10 
minutes. Analysis was performed by averaging six sweeps of identical interstimulus intervals 
and dividing the mean amplitude of the second event by the initial. 
Cecal content sampling and microbiota analysis: Cecal content samples were collected from 
GB-D and GB-IL mice at sacrifice 4-5 weeks after surgery and stored at -80°C. The DNA 
extractions, amplification, library prep, and sequencing were done by the Gut Microbiome Core, 
at the University of California at Davis. The 16S universal Eubacteria primers (PCR primers 
515/806) were used to amplify the V4 variable region. A single-step 30 cycle PCR using 
HotStarTaq Plus Master Mix Kit (Qiagen, Valencia, CA, USA) were used under the following 
conditions: 94°C for 3 min, followed by 28 cycles of 94°C for 30 seconds; 53°C for 40 seconds 
and 72°C for 1 min; after which a final elongation step at 72°C for 5 minutes was performed. 
Following PCR, all amplicon products from different samples were mixed in equal 
concentrations and purified using Agencourt Ampure beads (Agencourt Bioscience Corporation, 
MA). Microbial sequencing was analyzed by bacterial tag encoded FLX amplicon 
pyrosequencing (bTEFAP) using a Roche 454 pyrosequencer and titanium reagents and 3-5K 
nominal sequences per sample of high quality extracted DNA. Sequences were depleted of 
barcodes and primers, then short sequences <200 base pairs are removed, sequences with >1 
ambiguous base calls removed, and sequences with homopolymer runs exceeding 6 base pairs 
removed using the statistical software package Quantitative Insights Into Microbial Ecology 
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(QIIME). A total number of 491,009 sequences passed a quality filter with a minimum score of 
25 and an average length of 460 base pairs. Operational taxonomic units were defined after 
removal of chimeric and singleton sequences, clustering at 3% divergence (97% similarity).420 
OTUs were then taxonomically classified using BLASTn against a curated GreenGenes 
database. 
Statistical analysis: Data are presented as means ± standard error of the mean. Statistical 
analysis was performed with GraphPad Prism software, version 5.02 (GraphPad Software, San 
Diego, CA, USA). Data were analyzed by statistical tests noted in figure legends, which included 
Student’s t test, multiple t test, two-way RM ANOVA, and linear regression functions through 
Prism as appropriate. Outliers were defined as having values outside of quartile1 – 
1.5×interquartile range (IQR) and quartile3 + 1.5×IQR and were excluded. A p-value <0.05 
defined statistical significance for all tests except for multiple t test analysis which determined 
significance using the Holm-Sidak method for correction of multiple comparisons, with 
alpha=5%. 
 
Results 
Cocaine directly alters DA neurotransmission and produces its rewarding effects by 
increasing available extracellular DA in specific brain regions, including the NAc.413,421 We first 
studied the effect of the surgery on cocaine’s ability to enhance DA availability in NAc. We 
performed our experiments in animals fed a chow diet. In GB-IL mice, there were no significant 
differences in body weight as compared to GB-D as early as day 12 post-surgery (Figure 28B). 
This strongly suggests that, on a chow diet, the long-term homeostatic regulation of body weight 
in GB-IL parallels that of the GB-D mice. Here, we measured the effect of cocaine on 
electrically- evoked DA release in NAc slices. Three stable baseline recordings were taken at 
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five minute stimulation intervals and no differences were noted between GB-D (Figure 28C, 
baseline) and GB-IL (Figure 28D, baseline) in terms of peak amperometric current (Figure 28E). 
However, the increase in electrically-evoked DA release promoted by 10 µM cocaine was 
significantly reduced in the GB-IL mice (Figure 28C-D, cocaine; quantitation in 28F, as area 
under the curve). Quantitation of the area under the curve (AUC) of the amperometric trace in 
the presence of cocaine expressed as a percentage of average AUC for the three baseline 
recordings is shown in figure 28F. Importantly, GB-IL mice do not exhibit an overt 
neurochemical phenotype, as total accumbal tissue levels of DA and its related monoamines, 
NE and serotonin (5-HT), were not significantly altered with respect to GB-D (Figure 28G). 
We next determined whether GB-IL mice display reduced behavioral responses to 
cocaine. Mice were tested for cocaine conditioned place preference (CPP; 20 mg/kg, i.p.) in a 
dual compartment apparatus (Figure 29A). During conditioning sessions, locomotor behavior 
was measured. On first exposure to cocaine, cocaine-induced hyperlocomotion was 
indistinguishable between the two groups, suggesting that GB-D and GB-IL mice experienced 
similar levels of cocaine centrally. Notably, while control mice exhibited significant locomotor 
sensitization to cocaine over multiple exposures (*p<0.05), the GB-IL mice did not (Figure 29B; 
Figure 30). Prior work strongly suggests that psychomotor sensitization is associated with the 
development of molecular adaptations within the mesocorticolimbic system in the development 
of an addiction.422 The lack of locomotor sensitization in our biliary diversion model may thus 
support impairments in the central encoding of cocaine reward. Importantly, while both groups 
formed a place preference for cocaine, the preference of GB-IL mice for the cocaine-paired side 
was significantly less than that observed for GB-D mice (Figure 29C). In an open field, neither 
spontaneous nor saline-induced locomotion in GB-IL mice significantly differed from GB-D mice; 
however cocaine-induced locomotion (20 mg/kg, i.p.) was significantly attenuated between 10 
and 30 minutes post-injection (Figure 29D and inset).  
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Figure 28. Biliary diversion blocks cocaine’s ability to increase DA levels in the NAc. (A) 
Schematic representation of GB-D (black arrow) surgery and GB-IL (blue arrow) surgery. Dotted 
boxes outline incision sites in gallbladder and intestine. (B) Body weight following GB-D or GB-
IL surgery (n=17-21; *p<0.001 by multiple t test comparison). (C) Amperometric recordings of 
DA from the NAc in GB-D (top) and GB-IL (bottom) mice. Electrically-evoked DA responses are 
stable at 5 minute  intervals. Cocaine robustly enhanced the evoked DA response in the GB-D 
mice (n=4). This effect is blunted in GB-IL with respect to GB-D mice (n=5). (D) Quantitation of 
the peak amplitude of amperometric recordings under baseline (dotted bar) or cocaine 
(checkered bar) conditions in GB-D (black) or GB-IL (blue) animals (p>0.05 comparing baseline 
to cocaine for each surgical group). (E) AUC of the evoked DA response normalized to the 
average of the pre-cocaine baseline values from each slice (n=4-5; *p<0.05, Student’s t test). 
(F) Levels of DA, NE, and 5-HT in NAc tissue punches from GB-D and GB-IL mice. No 
significant differences were noted (n=4-6; p>0.05 by Student’s t test). 
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Figure 29. Bile diversion to the ileum blocks cocaine locomotor sensitization and reduces CPP. 
(A) Mice underwent surgery (GB-D or GB-IL), recovered for 2 weeks, and began the cocaine 
CPP paradigm. (B) Average group locomotor activity in CPP chambers during four cocaine 
exposures (20 mg/kg, i.p.) with linear regression of activity over the four exposures (n=12-15; 
*p<0.05 indicates significant regression from zero slope; F(1,46)=6.280). (C) Cocaine CPP 
expressed as %CPP normalized to GB-D average (n=13-14; *p<0.05 by Student’s t test). (D) 
Open field locomotion. GB-IL mice exhibit a reduced response to cocaine with no difference in 
basal locomotion (n=8-10; p<0.05 by two way RM ANOVA for cocaine administration, F(1, 
16)=6.544; ***p<0.001 between 10 and 30 minutes following cocaine injection by multiple t test 
comparison). (inset) Area under the curve for cocaine locomotor responses in GB-D and GB-IL 
mice (**p<0.01 by Student’s t test).    
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Figure 30. Biliary diversion reduces locomotor sensitization to cocaine. Each dot indicates the 
slope of the linear regression of the ambulatory distance induced by the four cocaine exposures 
in each individual mouse (n=12-15; *p<0.05 by Student’s t test).  
 
 
 
 
 
 
 
  124 
 
The reduction in conditioning to cocaine cannot be attributed to impaired spatial learning 
or memory capabilities, as we did not observe any significant impairment in performance on a 
hidden water maze task (Figure 31A-C). Moreover, no generalized impairments in motor 
abilities (Figure 31D) or motivated behavior/affective state in a tail suspension test (Figure 31E) 
were observed. However, in the open field, we did observe a small but significant increase in 
center time in the GB-IL group (Figure 31F), suggesting that the surgery may also affect 
systems regulating exploratory behavior or anxiety.   
GB-IL mice exhibit greatly increased levels of total and conjugated circulating bile acids 
relative to GB-D, while levels of primary, secondary, and unconjugated bile acids remain 
unchanged (Figure 32A). This finding, in conjunction with our behavioral data, points to a potent 
and previously unexplored role for conjugated bile acids as regulators of cocaine reward. 
However, whether bile acids signal directly within the brain is unknown. Prior work suggests that 
AMPAR signaling in the NAc participates in molecular mechanisms underlying cocaine-seeking 
behavior.173,423 Here we show that the synthetic bile acid obeticholic acid (OCA) induces a 
robust depression of AMPAR-mediated EPSCs in the NAc (Figure 32B). This result indicates 
that bile acid signaling acutely regulates excitatory neurotransmission in the NAc, an important 
component of the development of reward-context associations in the CPP test.91,173 Using an in 
vivo pharmacologic model, we further demonstrate that chronic OCA administration is sufficient 
to reduce cocaine CPP (Figure 32). For two weeks prior to the initiation of cocaine CPP, mice 
were treated with OCA (10 mg/kg, p.o.) or vehicle (Figure 32C). The treatment continued until 
sacrifice 4 weeks following drug initiation. Mice treated with OCA, compared with vehicle 
treatment, exhibited decreased cocaine CPP (Figure 32D).  
In addition to their canonical role as fat emulsifiers, bile acids signal in a hormonal 
fashion mainly through two bile acid receptors, the farnesoid x receptor (FXR) and g protein-
coupled bile acid receptor 1 (TGR5);424 only TGR5 is expressed in the brain.410,425 To test 
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whether TGR5 receptor signaling contributes to reduced susceptibility to the rewarding 
properties of cocaine, we measured cocaine CPP in TGR5 knockout mice. We found that 
deletion of the TGR5 receptor results in significantly increased preference for the cocaine-paired 
chamber relative to wild-type littermates (Figure 32E). This enhancement in cocaine reward 
identifies a role for the TGR5 receptor in reward processes and supports basal signaling 
through TGR5 as a contributor to resilience to cocaine reward.  
 
Discussion 
Our findings support a pivotal role for bile acid signaling in neuronal function as well as 
in reward behaviors. This was first revealed by a novel surgery where bile acids were diverted to 
the ileum to increase reabsorption and augment levels of circulating bile acids. We demonstrate 
that this surgery was able to modify reward acquisition for cocaine. GB-IL blocks both 
sensitization and the rewarding properties of cocaine, which relies on increases in extracellular 
DA levels. Notably, the surgery alters cocaine’s ability to increase DA levels in the NAc. These 
results thus reveal that a surgery designed for weight loss also regulates psychostimulant 
reward. We also show that bile acid signaling may be critical to this process. This notion is 
supported by the finding that chronic OCA treatment impairs cocaine reward. Conversely, TGR5 
knockout mice exhibit enhanced cocaine preference compared to their wild-type counterparts. 
Together, these results point to a role for bile acid signaling in susceptibility or resilience to 
cocaine reward. Of note, we did not find any differences in the gut microbiome composition in 
our surgical model (Figure 33), suggesting that potential alterations to the gut microflora are 
unlikely to mediate altered gut-to-brain communication in this setting.  
Interestingly, both DAergic and glutamatergic systems in the NAc appear to be affected 
by alterations in bile acid signaling as we were able to alter cocaine-induced increases in 
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extracellular DA in our surgical model and acutely induce a long-lasting depression of EPSCs 
pharmacologically. Notably, both of these actions contribute to the rewarding and reinforcing 
effects of cocaine.426 Thus, further studies exploring whether pharmacologic, or even surgical, 
enhancement of bile acid signaling could intervene in established addictions are warranted. 
Importantly, the bile acid receptor agonist used in the current study (OCA) has already 
completed a phase III clinical trial to treat hepatic steatosis.427 This drug showed clinical efficacy 
in this setting with an excellent safety profile, thereby reducing barriers to its development for 
addiction.    
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Figure 31. Biliary diversion does not alter learning, memory, motor function, or affective 
behavior. (A) There were no significant differences between GB-D and GB-IL mice in a Morris 
Water Maze acquisition task (n=7-8; p>0.05 by two-way RM ANOVA). (B) There were no 
significant differences between groups in a Morris Water Maze recall task (p>0.05 by Student’s t 
test). (C) Mean swimming speed in GB-D and GB-IL mice (p>0.05 by Student’s t test). (D) There 
were no significant differences in latency to fall from a rotarod (n=5-8; p>0.05 by two-way RM 
ANOVA). (E) Time immobile on a tail suspension task was similar between groups (n=7-8; 
p>0.05 by Student’s t test). (F) Open field locomotion revealed a significant increase in center 
time in the GB-IL mice (n=11-14; *p<0.05 by Student’s t test). 
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Figure 32. Bile acid signaling regulates cocaine reward. (A) GB-IL mice exhibit elevated levels 
of serum total and conjugated bile acids with respect to GB-D (n=7-8; *p<0.05 by Student’s t 
test). (B) 10 µM OCA reduced EPSC amplitude in NAc medium spiny neurons (n=4; *p<0.05 by 
Student’s t test). (C) Mice were treated orally with either vehicle or 10 mg/kg OCA six days a 
week for four weeks. After 2 weeks the mice were started on the cocaine CPP paradigm. (D) 
OCA-treated mice showed reduced preference for the cocaine-paired chamber (n =7-8; *p<0.05 
by Student’s t test) expressed as %CPP normalized to GB-D average. (E) Constitutive deletion 
of the TGR5 receptor (-/-) results in increased preference for the cocaine-paired chamber, 
expressed as %CPP normalized to TGR5 (+/+) littermate average (n=11-14; *p<0.05 by 
Student’s t test). 
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Figure 33. GB-IL mice do not exhibit altered gut microbiota compared to GB-D controls. 
Stacked column bar graph depicting the relative abundances and distributions of the most highly 
abundant resolved bacterial phyla across the 12 fecal samples analyzed. Cecal contents from 
mice subject to GB-D (n=6) or GB-IL (n=6) were subjected to 16S RNA sequencing. 
Bacteroidetes are colored in shades of red, proteobacteria in shades of blue, tenericutes in 
purple and verrucomicrobes in pink. Each column represents a single mouse. No significant 
differences in bacterial abundances were noted.  
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CHAPTER V 
 
SYNTHESIS, GENERAL DISCUSSION, AND FUTURE DIRECTIONS 
 
 In summary, we have shown that the hormone GLP-1 regulates DA homeostasis and 
cocaine actions through a novel retrograde mechanism in the LS (Chapter II), that RYGB 
surgery alters striatal DA homeostasis (Chapter III), and that a surgery designed for weight loss 
increases systemic bile acids which appear to play a role in regulating reward for cocaine 
(Chapter IV). These findings are bound together by the concept that the gut and the hormones 
produced by it to regulate feeding and energy metabolism can modify DA homeostasis and 
behavioral manifestations of cocaine action.  
While we are far from understanding the complete mechanisms by which the gut 
communicates with the brain to regulate reward, we believe that we have helped to expand a 
new frontier in neuroscience. More and more we learn that the periphery plays an important role 
in shaping central function. The gut and its associated signaling systems have garnered much 
attention recently in this regard. We now know – from our work and that of others – that 
alterations to the gut or gut-generated hormones can affect complex behaviors related to stress, 
affective state, and reward.389,428,429 These studies reveal that the gut should not be viewed as a 
simple feedback system, but a system that plays an integral part in shaping our day-to-day 
moods and desires. Furthermore, a better understanding of the gut-to-brain axis may allow us to 
probe its role in the development of serious neuropsychiatric disorders and harness newly 
defined mechanisms of central regulation towards the generation of novel therapies.  
We believe that substance use disorders, highly-prevalent disorders caused at least in 
part by reward system dysfunction, could benefit from this enhanced understanding of gut-to-
brain regulation. Currently, the individual and public health impact of substance use disorders, 
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particularly for psychostimulants, is compounded by the fact that we have very few effective 
therapies to combat them. Behavioral therapies, although effective for some patients, have not 
provided a systemic solution.  
Movement through the translational pipeline for pharmacotherapies to fight addiction has 
been slow in part, I believe, because we have traditionally sought to intervene at direct sites of 
drug action. This is problematic because this type of intervention interferes with normal reward 
processes, which may lead to anhedonia (e.g. CB1R antagonists) or prolonged withdrawal 
symptoms (e.g. opioid receptor antagonists).430,431 Furthermore, directly impairing DA or opioid 
systems can lead to severe side effects (e.g. antipsychotics which block D2 receptors; opioid 
receptor antagonists),432-434 limiting the utility of such drugs. I believe that we need to find 
modulators of reward systems which may not affect reward processes quite so directly or 
dramatically but which have the potential to reduce drug intake without serious side effects. 
Understanding how hormones and other gut-to-brain signaling mechanisms regulate 
neurotransmission, reward, and drug use may provide some of the modulatory regulation 
necessary to fight addiction.  
In this vein, long-lasting synthetic analogues of GLP-1 have been shown to reduce the 
rewarding and reinforcing properties of food, psychostimulants, alcohol, and nicotine, and are 
now approved as weight-loss therapy in obese individuals.220,235,284-289 Given their strong safety 
profile in patients, GLP-1 analogues have great potential to be developed as therapy for 
substance use disorders. However, a few questions should first be addressed: At what stages of 
addiction can GLP-1 analogues be effectively used? What are the targets of GLP-1 analogues 
in the brain and how are they working? 
Regarding the first question, it is important to remember that the development of 
substance use disorders involves at least (1) susceptibility to the drug in naïve individuals, (2) 
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the potentially damaging physiologic effects of the drug, (3) the enjoyment of the drug, (4) the 
motivation to work to obtain more of the drug, (5) learning to associate the drug with 
environmental cues, (6) withdrawal effects from the drug, and (7) susceptibility to relapse in 
prior users. In designing novel therapies against substance use disorders, it is important to 
characterize the intervention at each of these levels. For example, it would be inappropriate to 
prescribe a therapy that decreases the hedonic properties of a drug but increases the motivation 
to consume it. The animal literature has primarily shown that GLP-1 analogues reduce acute 
effects of drugs (in locomotor assays),284,287,289,292 drug intake (in choice tests and self-
administration),285,287 and drug reward (as measured by CPP)284,286,287,289,435 through acute pre-
administration of GLP-1 analogues. Unfortunately, these results don’t tell us much about how 
GLP-1 analogues might function in the context of an individual who has been taking drugs for a 
long time (and has potentially developed some of the central adaptations to the drug described 
in Chapter I). They also fail to inform how GLP-1 analogues might work if administered 
chronically and out of sync with drug administrations. Indeed, central resistance is thought to 
develop in response to chronic insulin and leptin administration.436-438 There is little evidence to 
suggest that this happens at the GLP-1R;439 however, this possibility should be explicitly tested. 
Additionally, one of the most important tests of the utility of GLP-1 analogues would be in a 
reinstatement model of drug-seeking. Reinstatement models are a way for us to test in animals 
how a therapy might be able to block or attenuate drug-seeking following an abstinence period. 
This is thought to model the very relevant condition of relapse drug-seeking in humans. To our 
knowledge, no experiments have been performed to determine whether GLP-1 analogues might 
prevent reinstatement, but such tests will be crucial going forward. Finally, there is some 
evidence that signaling through the GLP-1R may play a role in the susceptibility or resilience to 
drug reward. GLP-1R knockout mice exhibit augmented cocaine-induced locomotor responses 
and CPP compared with wild-type controls.293 This effect relies, of course, on endogenous GLP-
1R-mediated signaling. It will thus be interesting to determine whether polymorphisms in the 
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GLP-1R or differences in endogenous GLP-1 signaling contribute to drug reward vulnerability. In 
fact, there are common variants within the GLP-1R,297,440 and at least one is associated with 
alcohol dependence in males.297 Taken together, it seems that signaling through the GLP-1R 
plays a definitive role in modifying drug reward. Nevertheless, additional work will be required to 
determine how to effectively implement GLP-1-based therapies in the treatment of human 
addictions.    
In our study of GLP-1R signaling in the LS, we attempted to address the second key 
question regarding the targets of GLP-1 analogues in the brain and mechanism of action. One 
of the goals of neuroscience is not just to find therapies that work, but also to understand how 
they work in order to refine our use of them as new technologies and targeted approaches 
become available. In doing so, we first showed that administration of Ex-4 reduces septal levels 
of the endocannabinoid 2-AG. This finding is interesting on its own because 2-AG promotes 
hedonic reactions and feeding behavior, processes opposed by Ex-4. Furthermore, a recent 
study showed that cocaine is able to mobilize 2-AG;153 thus Ex-4 may act to oppose the hedonic 
properties of cocaine in this manner. Future work will be required to determine the exact 
mechanisms by which increased stimulation of GLP-1Rs leads to the downregulation of 2-AG. A 
lipidomics analysis of precursors to 2-AG may suggest where a bottleneck may be occurring 
and point to potential enzymes inhibited by GLP-1R signaling. It would also be reasonable to 
determine whether the effect on 2-AG alone contributes to altered reward mechanisms. 
Behavioral and molecular studies of Ex-4 action using the drug rimonabant to block CB1Rs will 
determine whether any of Ex-4’s effects on reward are CB1R-dependent. This may be important 
as reduced CB1R signaling has been associated with anhedonia and suicidal ideation. While 
there is no evidence of these symptoms in patients taking GLP-1R agonists for the treatment of 
diabetes,441 this may be a consideration in patients suffering from addiction.    
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In this same study we also showed that AA levels are reduced by treatment with Ex-4, 
likely an effect of a processing bottleneck upstream of 2-AG. Focusing our studies in a cell 
model, we further show that AA reduces DAT function – consistent with prior literature – and 
likely does so through reduced surface expression. Given that AA generates γ-KA species 
capable of covalently binding the DAT and reducing its function, we suggest that the DAT is 
permanently altered by this interaction. In this scenario, the DAT is likely tagged for degradation, 
perhaps by ubiquitination, and trafficked into the lysosomal degradation pathway. Recovery of 
DAT expression would require trafficking from a reserve pool of DAT and increased de novo 
DAT production. This is in contrast to much of the DAT trafficking literature which has focused 
on the role of signaling kinases in trafficking DAT to recycling endosomes. Additional work will 
be necessary to test the hypothesis that γ-KA-DAT is targeted for degradation and clarify which 
of these two internalization pathways dominates in response to AA.  
Based off of this work, we further hypothesize that the γ-KA scavenger, salicylamine, 
may modify reward processes related to cocaine. Interestingly, one study revealed that 
salicylamine prevents working memory deficits in a mouse model of Alzheimer’s disease and 
could be safely administered in vivo.442 Future studies will explore whether salicylamine alters 
reward in behavioral assays. 
We might also consider the therapeutic possibilities that arise from the biliary diversion 
model. This surgical manipulation of the gut allowed us to reduce the development of cocaine 
reward in mice as measured by CPP. Biliary diversion (GB-IL) surgery, which chronically 
elevates systemic bile acid levels, reduced the formation of cocaine CPP as well as the 
sensitization to cocaine over time. Chronic oral treatment with a synthetic bile acid leading up to 
and throughout the CPP protocol also impaired the development of a preference for cocaine. On 
the other hand, genetic deletion of a major bile acid receptor involved in hormonal signaling was 
able to enhance preference for cocaine. All of these interventions altered bile acid signaling well 
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before the mice were ever exposed to cocaine. Therefore, these results suggest that bile acid 
signaling may play a role in the resilience or susceptibility to the rewarding effects of cocaine. 
While it is currently difficult to imagine a way to prevent addictive behavior clinically, we believe 
that a better understanding of the possible modulators of the reward system will inform future 
work regarding therapeutic targets. Furthermore, the things that make us susceptible to disease 
are of interest, particularly in the age of increasingly affordable genetic testing. It is possible that 
components of bile acid processing may be polymorphic or dysregulated from one individual to 
another and thus contribute to disease potential. This is plausible, as endogenous signaling 
through the TGR5 bile acid receptor appears to be an important contributor to cocaine CPP. In 
the future it will be also interesting to determine whether biliary diversion is able to affect drug-
seeking behavior in animals with prior experience with cocaine. We believe that biliary diversion 
may have an effect on already established cocaine responses as the surgery has been shown 
to reduce high fat feeding in mice which had been fed such a diet for 12 weeks prior to surgery.  
The mechanism(s) by which biliary diversion or bile acids affect reward is still, 
admittedly, poorly understood. First and foremost, experiments will be required to determine 
whether the effect of increased bile acid signaling relies on a direct central effect. To determine 
whether the effect of biliary diversion or bile acid signaling on cocaine CPP relies on central 
mechanisms, bile acids could be perfused directly into the brain or into specific brain regions. 
Additionally, the TGR5 bile acid receptor could be genetically deleted from the brain or specific 
brain regions using conditional mouse lines, viral approaches, or RNA silencing. Secondly, 
describing the distribution of bile acid receptors in the brain will also be important. Several 
studies have suggested that TGR5 receptors are expressed at low levels in the brain,410,425 but 
their distribution and co-expression profiles are unknown. This information may help fuel future 
mechanistic studies. For instance, it would be helpful to know if the TGR5 receptor is expressed 
on accumbal MSNs and, if so, whether it is expressed on the D1 or D2 subtype MSNs. Such 
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information might inform, for example, the interaction with DAergic and glutamatergic systems 
that we observed in our study. Beyond TGR5, there is also the possibility that there may be 
alternative bile acid targets within the CNS. These include neurosteroid receptors as well as the 
pregnane X receptor,443,444 which have been shown to bind bile acids or structurally related 
species.  
Finally, a behavioral study to follow-up our findings of altered striatal DA homeostasis in 
RYGB is likely warranted. As was reviewed in the introductory chapter, there is evidence that 
RYGB alters food and alcohol intake and reward; however, its effect on psychostimulants has 
not been tested. It should be noted that food and alcohol are ingested, caloric substances and 
may therefore be absorbed and processed differently following RYGB than a drug that is not 
taken by oral administration. Therefore we might expect a different result for a drug like cocaine. 
If RYGB does show effects on cocaine reward, this might open up the possibility of surgical 
interventions in humans as RYGB is already commonly performed on obese individuals. Of 
course, this would be a very extreme treatment for addiction, but the benefits might outweigh 
the risks for cases of intractable addiction. Moreover, a number of different hormonal systems 
are affected by RYGB,252 and there are likely many changes that we are yet unaware of. Further 
study of the RYGB model and its effects on reward could therefore uncover novel mechanistic 
or therapeutic targets related to reward and addiction. 
 In conclusion, through our studies we have revealed, as proof of principle, that 
hormonal systems and gut-based interventions can have profound effects on brain DA 
homeostasis and behavioral responses to cocaine. As described above, these interventions 
may have therapeutic potential or inspire the discovery of novel therapeutic targets. In the face 
of an addiction crisis and a failing pharmaceutical pipeline, such inspiration is sorely needed.   
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